<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD004439.pub3" GROUP_ID="MUSKINJ" ID="770802100216513332" MERGED_FROM="" MODIFIED="2013-12-17 14:28:30 +0000" MODIFIED_BY="Laura MacDonald" NOTES="&lt;p&gt;Exported from Review Manager 4.2.9&lt;br&gt;Exported from Review Manager 4.3&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.3&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.2.3&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.3 Beta&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.2.7&lt;br&gt;Exported from Review Manager 4.2.1&lt;br&gt;Exported from Review Manager 4.2.2&lt;br&gt;Exported from Review Manager 4.2.1&lt;br&gt;Exported from Review Manager 4.2&lt;/p&gt;&lt;p&gt;Old Title: Interventions for treating chronic osteomyelitis&lt;/p&gt;&lt;p&gt;Date last edited when imported: 14/08/20003 - from Lesley&lt;/p&gt;" NOTES_MODIFIED="2013-09-23 16:47:36 +0100" NOTES_MODIFIED_BY="Laura MacDonald" REVIEW_NO="091" REVMAN_SUB_VERSION="5.2.6 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="7.0">
<COVER_SHEET MODIFIED="2013-12-17 14:28:30 +0000" MODIFIED_BY="Laura MacDonald">
<TITLE>Antibiotics for treating chronic osteomyelitis in adults</TITLE>
<CONTACT MODIFIED="2013-12-17 14:28:30 +0000" MODIFIED_BY="Laura MacDonald"><PERSON ID="15042" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Lucieni</FIRST_NAME><MIDDLE_INITIALS>O</MIDDLE_INITIALS><LAST_NAME>Conterno</LAST_NAME><POSITION>Co-ordinator of Infectious Diseases Discipline and Clinical Epidemiology Unit</POSITION><EMAIL_1>lucieni@famema.br</EMAIL_1><MOBILE_PHONE>+55 14 81216011</MOBILE_PHONE><ADDRESS><DEPARTMENT>Department of General Internal Medicine and Clinical Epidemiology Unit</DEPARTMENT><ORGANISATION>Marilia Medical School</ORGANISATION><ADDRESS_1>Avenida Monte Carmelo 800</ADDRESS_1><ADDRESS_2>Fragata</ADDRESS_2><CITY>Marilia</CITY><ZIP>17519-030</ZIP><REGION>São Paulo</REGION><COUNTRY CODE="BR">Brazil</COUNTRY><PHONE_1>+55 14 34021831</PHONE_1><PHONE_2>+55 14 34021750</PHONE_2><FAX_1>+55 14 34335036</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2013-12-17 14:28:30 +0000" MODIFIED_BY="Laura MacDonald"><PERSON ID="15042" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Lucieni</FIRST_NAME><MIDDLE_INITIALS>O</MIDDLE_INITIALS><LAST_NAME>Conterno</LAST_NAME><POSITION>Co-ordinator of Infectious Diseases Discipline and Clinical Epidemiology Unit</POSITION><EMAIL_1>lucieni@famema.br</EMAIL_1><MOBILE_PHONE>+55 14 81216011</MOBILE_PHONE><ADDRESS><DEPARTMENT>Department of General Internal Medicine and Clinical Epidemiology Unit</DEPARTMENT><ORGANISATION>Marilia Medical School</ORGANISATION><ADDRESS_1>Avenida Monte Carmelo 800</ADDRESS_1><ADDRESS_2>Fragata</ADDRESS_2><CITY>Marilia</CITY><ZIP>17519-030</ZIP><REGION>São Paulo</REGION><COUNTRY CODE="BR">Brazil</COUNTRY><PHONE_1>+55 14 34021831</PHONE_1><PHONE_2>+55 14 34021750</PHONE_2><FAX_1>+55 14 34335036</FAX_1></ADDRESS></PERSON><PERSON ID="23955150760667508693111202124448" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Marilia</FIRST_NAME><MIDDLE_INITIALS>D</MIDDLE_INITIALS><LAST_NAME>Turchi</LAST_NAME><SUFFIX>MD, PhD</SUFFIX><POSITION>Professor</POSITION><EMAIL_1>marilia.turchi@gmail.com</EMAIL_1><EMAIL_2>marilia.turchi@pq.cnpq.br</EMAIL_2><MOBILE_PHONE>+55 62 84239241</MOBILE_PHONE><ADDRESS><DEPARTMENT>Department of Public Health, Institute of Tropical Pathology and Public Health</DEPARTMENT><ORGANISATION>Federal University of Goias</ORGANISATION><ADDRESS_1>Rua Amorinopolis QdR2 Lt13 Residencial Goias</ADDRESS_1><ADDRESS_2>Alphaville Flamboyant</ADDRESS_2><CITY>Goiania</CITY><ZIP>74884-540</ZIP><REGION>Goias</REGION><COUNTRY CODE="BR">Brazil</COUNTRY><PHONE_1>+55 62 32460184</PHONE_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2013-09-23 16:40:07 +0100" MODIFIED_BY="Laura MacDonald">
<UP_TO_DATE>
<DATE DAY="9" MONTH="4" YEAR="2013"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="9" MONTH="10" YEAR="2012"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="9" MONTH="4" YEAR="2015"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="4" YEAR="2003"/>
<REVIEW_PUBLISHED ISSUE="3" YEAR="2009"/>
<LAST_CITATION_ISSUE ISSUE="9" YEAR="2013"/>
</DATES>
<WHATS_NEW MODIFIED="2013-09-23 16:47:36 +0100" MODIFIED_BY="Lindsey Elstub">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2013-09-23 16:46:02 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="23" MONTH="9" YEAR="2013"/>
<DESCRIPTION>
<P>Source of support added</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2013-09-23 16:47:36 +0100" MODIFIED_BY="Lindsey Elstub">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2013-09-23 16:47:36 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="6" MONTH="9" YEAR="2013"/>
<DESCRIPTION>
<P>We added one new author (MDT) and included one new study.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2013-09-23 16:47:32 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="21" MONTH="5" YEAR="2013"/>
<DESCRIPTION>
<P>For this review update, published in Issue 9, 2013, we made the following changes.<BR/>1. We updated the search to October 2012.<BR/>2. We included one new trial (<LINK REF="STD-Euba-2009" TYPE="STUDY">Euba 2009</LINK>).<BR/>3. We excluded one trial that was included in the previous version (<LINK REF="STD-Greenberg-1987" TYPE="STUDY">Greenberg 1987</LINK>).<BR/>4. In accordance with Collaboration policy, we updated the review to include new methodology, including risk of bias assessment.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-03-10 13:44:22 +0000" MODIFIED_BY="Lindsey Elstub">
<DATE DAY="23" MONTH="10" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2013-09-06 15:02:45 +0100" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES MODIFIED="2013-09-03 15:05:03 +0100" MODIFIED_BY="[Empty name]">
<SOURCE>
<NAME>Marilia Medical School</NAME>
<COUNTRY CODE="BR">Brazil</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE MODIFIED="2013-09-03 15:05:03 +0100" MODIFIED_BY="[Empty name]">
<NAME>Institute of Tropical Pathology and Public Health, Federal University of Goias</NAME>
<COUNTRY CODE="BR">Brazil</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES MODIFIED="2013-09-06 15:02:45 +0100" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2013-09-06 15:02:33 +0100" MODIFIED_BY="[Empty name]">
<NAME>MDT has a scholarship from the Brazilian National Research Council (Bolsa de Produtividade CNPq)</NAME>
<COUNTRY CODE="BR">Brazil</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE MODIFIED="2013-09-06 15:02:45 +0100" MODIFIED_BY="[Empty name]">
<NAME>MDT is a research member of the National Institute of Science and Technology for Health Technology Assessment (IATS)</NAME>
<COUNTRY CODE="BR">Brazil</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2013-09-06 11:08:33 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2013-09-04 10:03:23 +0100" MODIFIED_BY="Lindsey Elstub">
<TITLE MODIFIED="2013-03-01 20:30:58 +0000" MODIFIED_BY="[Empty name]">Antibiotics for treating chronic bone infection in adults</TITLE>
<SUMMARY_BODY MODIFIED="2013-09-04 10:03:23 +0100" MODIFIED_BY="Lindsey Elstub">
<P>Osteomyelitis is an inflammation of the bone and bone marrow caused by pus-forming bacteria, mycobacteria or fungi. All bone infection that is long-standing is called chronic osteomyelitis. People with this condition are treated with systemic antibiotics, which can be given by mouth or parenterally (i.e. by injection into the muscle or vein). This review is an update of our previous 2009 publication.</P>
<P>We included eight small randomised trials involving 282 people. The trials presented results for a total of 248 people with chronic osteomyelitis. Post-traumatic bone infections were the most frequent type. Surgical removal of the infected tissue (debridement) before starting on antibiotic therapy was mentioned as part of treatment in all trials, but in four trials it was unclear whether all participants underwent surgery. There were five comparisons of different treatments but we could only pool results for the comparison of antibiotic given by mouth with antibiotic given parenterally.</P>
<P>The pooled results (which included data from 150 people) did not show any difference between people given antibiotics by mouth or parenterally in terms of the number of people who did not have symptoms (in 'remission') at the end of treatment (four trials) or 12 months later (or more) (three trials); nor in the number of people that had negative side effects or had a superinfection (another infection that is not sensitive to antibiotic treatment). This evidence suggests that the way antibiotics are given does not impact on the disease remission rate if the bacteria causing the infection are sensitive to the antibiotic used. However, confirmation is needed. There was either no or insufficient evidence on which to base judgements about the optimum length of antibiotic treatment or the best antibiotics to use.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2013-09-04 10:11:47 +0100" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2013-09-03 14:12:38 +0100" MODIFIED_BY="Lindsey Elstub">
<P>Chronic osteomyelitis is generally treated with antibiotics and surgical debridement but can persist intermittently for years with frequent therapeutic failure or relapse. Despite advances in both antibiotic and surgical treatment, the long-term recurrence rate remains around 20%. This is an update of a Cochrane review first published in 2009.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2008-11-27 13:20:34 +0000" MODIFIED_BY="[Empty name]">
<P>To determine the effects of different systemic antibiotic treatment regimens for treating chronic osteomyelitis in adults.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2013-08-27 14:12:03 +0100" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Bone, Joint and Muscle Trauma Group Specialised Register (October 2012), the Cochrane Central Register of Controlled Trials (<I>The Cochrane Library</I> 2012, Issue 9), MEDLINE (January 1948 to September Week 4 2012), EMBASE (January 1980 to 2012 Week 40), LILACS (October 2012), the WHO International Clinical Trials Registry Platform (June 2012) and reference lists of relevant articles.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2013-09-03 12:18:29 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trials (RCTs) or quasi-RCTs addressing the effects of different antibiotic treatments given after surgical debridement for chronic osteomyelitis in adults.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2013-09-03 12:18:35 +0100" MODIFIED_BY="Helen HG Handoll">
<P>Two review authors independently screened papers for inclusion, extracted data and appraised risk of bias in the included trials. Where appropriate, we pooled data using the fixed-effect model.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2013-09-04 10:11:47 +0100" MODIFIED_BY="Lindsey Elstub">
<P>We included eight small trials involving a total of 282 participants with chronic osteomyelitis. Data were available from 248 participants. Most participants were male with post-traumatic osteomyelitis, usually affecting the tibia and femur, where recorded. The antibiotic regimens, duration of treatment and follow-up varied between trials. All trials mentioned surgical debridement before starting on antibiotic therapy as part of treatment, but it was unclear in four trials whether all participants underwent surgical debridement.</P>
<P>We found that study quality and reporting were often inadequate. In particular, we judged almost all trials to be at moderate to high risk of bias due to failure to conceal allocation and inadequate follow-up.</P>
<P>Four trials compared oral versus parenteral route for administration of antibiotics. There was no statistically significant difference between the two groups in the remission at the end of treatment (70/80 versus 58/70; risk ratio (RR) 1.04, 95% confidence interval (CI) 0.92 to 1.18; four trials, 150 participants). There was no statistically significant difference between the two groups in the remission rate 12 or more months after treatment (49/64 versus 44/54; RR 0.94, 95% CI 0.78 to 1.13; three trials, 118 participants). There was also no significant difference between the two groups in the occurrence of mild adverse events (11/64 versus 8/54; RR 1.08, 95% CI 0.49 to 2.42; three trials, 118 participants) or moderate and severe adverse events (3/49 versus 4/42; RR 0.69, 95% CI 0.19 to 2.57; three trials, 91 participants). Superinfection occurred in participants of both groups (5/66 in the oral group versus 4/58 in the parenteral group; RR 1.08, 95% CI 0.33 to 3.60; three trials, 124 participants).</P>
<P>Single trials with few participants found no statistical significant differences for remission or adverse events for the following four comparisons: oral only versus parenteral plus oral administration; parenteral plus oral versus parenteral only administration; two different parenteral antibiotic regimens; and two different oral antibiotic regimens. No trials compared different durations of antibiotic treatment for chronic osteomyelitis, or adjusted the remission rate for bacteria species or severity of disease.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2013-09-03 12:20:01 +0100" MODIFIED_BY="[Empty name]">
<P>Limited and low quality evidence suggests that the route of antibiotic administration (oral versus parenteral) does not affect the rate of disease remission if the bacteria are susceptible to the antibiotic used. However, this and the lack of statistically significant differences in adverse effects need confirmation. No or insufficient evidence exists for other aspects of antibiotic therapy for chronic osteomyelitis.</P>
<P>The majority of the included trials were conducted over 20 years ago and currently we are faced with a far higher prevalence of bacteria that are resistant to many of the available antibiotics used for healthcare. This continuously evolving bacterial resistance represents another challenge in the choice of antibiotics for treating chronic osteomyelitis.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2013-09-06 11:08:33 +0100" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2013-09-05 17:22:06 +0100" MODIFIED_BY="Lindsey Elstub">
<CONDITION MODIFIED="2013-09-03 14:22:59 +0100" MODIFIED_BY="Lindsey Elstub">
<P>Chronic osteomyelitis is a long-lasting infection of the bone and bone marrow, caused by pyogenic bacteria, mycobacteria or fungi, which can progress to bone necrosis and sequestrum formation. Usually long-lasting symptoms are vague and can include chronic pain, chills and low grade fever. Physical examination can reveal erythema, or swelling, sometimes in association with a draining sinus tract.</P>
<P>Osteomyelitis can be classified as either exogenous or hematogenous, based on its pathogenesis. Exogenous osteomyelitis results from a direct inoculation of bacteria into the bone at the time of trauma, during surgical reduction and internal fixation of fractures, or from an adjacent focus of infection (e.g. decubitus ulcer, soft tissue trauma) (<LINK REF="REF-Cunha-2002" TYPE="REFERENCE">Cunha 2002</LINK>; <LINK REF="REF-Lew-2004" TYPE="REFERENCE">Lew 2004</LINK>; <LINK REF="REF-Mader-1997a" TYPE="REFERENCE">Mader 1997a</LINK>; <LINK REF="REF-Mader-1999a" TYPE="REFERENCE">Mader 1999a</LINK>; <LINK REF="REF-Mader-1999b" TYPE="REFERENCE">Mader 1999b</LINK>; <LINK REF="REF-Waldvogel-1970" TYPE="REFERENCE">Waldvogel 1970</LINK>; <LINK REF="REF-Walenkamp-1997" TYPE="REFERENCE">Walenkamp 1997</LINK>). Thus, exogenous osteomyelitis includes post-traumatic and post-operative osteomyelitis, as well as osteomyelitis that is secondary to a contiguous focus (adjacent areas that are in contact) of infection or associated with peripheral vascular disease. In hematogenous osteomyelitis, blood-borne bacteria reach bone from a remote portal of entry. This type is predominantly encountered in paediatric populations.</P>
<P>Regardless of the route of access, the microorganism (for example <I>Staphylococcus aureus</I>) adheres to fibronectin receptors or other membrane proteins of the bone marrow to establish an infection. Subsequently, biofilm development occurs whereby bacteria are covered by a layer of fibrinogen (slimy coat) and protected from host defence mechanism and antibiotics. The local inflammation elicited by the bacteria or by trauma contributes to destruction of bone trabeculae and bone matrix. The devitalised bone and tissue provide an inert matrix upon which microorganisms thrive. This biofilm can act as a barrier that retards the penetration of nutrients and antimicrobial agents, and together with impaired vascularisation, favours infection persistence. In the biofilm, the bacteria hide intracellularly and achieve a slow metabolic rate. The metabolically-inactive bacteria are largely insensitive to antibiotics. Fragments of dead bone (sequestra) or metal implants can perpetuate the infection by exposing sites to which pathogenic bacteria can bind (<LINK REF="REF-Ciampolini-2000" TYPE="REFERENCE">Ciampolini 2000</LINK>; <LINK REF="REF-Gristina-1990" TYPE="REFERENCE">Gristina 1990</LINK>; <LINK REF="REF-Haas-1996" TYPE="REFERENCE">Haas 1996</LINK>; <LINK REF="REF-Lew-2004" TYPE="REFERENCE">Lew 2004</LINK>; <LINK REF="REF-Mader-1997a" TYPE="REFERENCE">Mader 1997a</LINK>; <LINK REF="REF-Waldvogel-1970" TYPE="REFERENCE">Waldvogel 1970</LINK>; <LINK REF="REF-Walter-2012" TYPE="REFERENCE">Walter 2012</LINK>).</P>
<P>Another classification of osteomyelitis is based on the anatomical stage of disease and is related to prognosis: medullary (confined to medullary cavity), superficial (involves just cortical bone), localised (involves both the cortical and medullary bone, but not the entire bone diameter) or diffuse (involves the entire thickness of the bone). Under this classification system, patients are classified as A, B or C according to the presence and severity of underlying diseases (<LINK REF="REF-Cierny-1985" TYPE="REFERENCE">Cierny 1985</LINK>; <LINK REF="REF-Cierny-2003" TYPE="REFERENCE">Cierny 2003</LINK>).</P>
<P>All aetiological classes of osteomyelitis may progress to a chronic process and it is not possible to define a time threshold after which an acute infection becomes chronic. The infection can persist intermittently for years with frequent therapeutic failure (<LINK REF="REF-Huber-2002" TYPE="REFERENCE">Huber 2002</LINK>; <LINK REF="REF-Mader-1993" TYPE="REFERENCE">Mader 1993</LINK>).</P>
<P>In recent years, chronic osteomyelitis incidence has apparently increased probably due to population aging, increasing prevalence of diabetes and trauma, and diagnosis improvement (<LINK REF="REF-Pollard-2006" TYPE="REFERENCE">Pollard 2006</LINK>; <LINK REF="REF-Trampuz-2006" TYPE="REFERENCE">Trampuz 2006</LINK>). Osteomyelitis usually occurs in adults, secondary to an open injury to the bone, or after surgery for reconstruction of the bone (<LINK REF="REF-Darouiche-2004" TYPE="REFERENCE">Darouiche 2004</LINK>; <LINK REF="REF-Holtom-1999" TYPE="REFERENCE">Holtom 1999</LINK>; <LINK REF="REF-Lazzarini-2002" TYPE="REFERENCE">Lazzarini 2002</LINK>; <LINK REF="REF-Mader-1999b" TYPE="REFERENCE">Mader 1999b</LINK>). Infections associated with prostheses are also common (<LINK REF="REF-Carek-2001" TYPE="REFERENCE">Carek 2001</LINK>; <LINK REF="REF-Haas-1996" TYPE="REFERENCE">Haas 1996</LINK>; <LINK REF="REF-Lew-2004" TYPE="REFERENCE">Lew 2004</LINK>). Chronic osteomyelitis may present as a recurrent or intermittent disease, with periods of quiescence of variable duration. These tend to relapse, after apparently successful therapy, with a major impact on the quality of life and a substantial financial burden to health system (<LINK REF="REF-Huber-2002" TYPE="REFERENCE">Huber 2002</LINK>).</P>
<P>Based on bacterial cultures of operative specimens, <I>S. aureus </I>is the main causative agent of chronic osteomyelitis. However, gram negative bacilli (<I>Pseudomonas</I> <I>spp</I> and <I>Enterobacteriaceae) </I>have been more frequently reported, as well as a high proportion of polymicrobial aetiology cases (<LINK REF="REF-Carek-2001" TYPE="REFERENCE">Carek 2001</LINK>; <LINK REF="REF-Mader-1992" TYPE="REFERENCE">Mader 1992</LINK>; <LINK REF="REF-Sheehy-2010" TYPE="REFERENCE">Sheehy 2010</LINK>; <LINK REF="REF-Waldvogel-1980" TYPE="REFERENCE">Waldvogel 1980</LINK>).</P>
<P>The microbiological aetiology of chronic osteomyelitis can be difficult to establish. Bone culture should guide the antimicrobial choice. Superficial samples or swabs from fistulas should not be used for pathogen identification since they present low accuracy when compared with bone biopsy culture (<LINK REF="REF-Senneville-2006" TYPE="REFERENCE">Senneville 2006;</LINK> <LINK REF="REF-Zuluaga-2002" TYPE="REFERENCE">Zuluaga 2002</LINK>)</P>
<P>Non-specific blood tests, such as erythrocyte sedimentation rate, C-reactive protein and alpha-1 acid glycoprotein, are widely employed in assessing chronic osteomyelitis. They are usually elevated but have low sensitivity and specificity. Some authors suggest that they can be helpful to assist the early diagnosis of postoperative bone infection, and to assess the effectiveness during the course of antibiotic therapy (<LINK REF="REF-Bourguignat-1996" TYPE="REFERENCE">Bourguignat 1996</LINK>; <LINK REF="REF-Ferard-2002" TYPE="REFERENCE">Ferard 2002</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2013-09-03 14:23:39 +0100" MODIFIED_BY="Lindsey Elstub">
<P>In general, chronic osteomyelitis is treated with antibiotics and surgical debridement to remove all the dead bone tissue (<LINK REF="REF-Parsons-2004" TYPE="REFERENCE">Parsons 2004</LINK>). Microorganisms residing in the dead bone, if not removed along with sequestra (dead bone), can cause flare-ups many years after the initial attack. The goal of debridement is to reach healthy, viable tissue and to remove the biofilm. Adequate debridement may leave a large bone defect known as dead space. The dead space is usually filled with local tissue flaps, or free flaps, bone graft, calcium hydroxyapatite implants or temporarily with polymethylmethacrylate beads with or without antibiotic. The goal of dead space management is to replace dead bone and scar tissue with durable vascularised tissue. If necessary, measures must be taken to achieve permanent stability of the bone. Skin grafting is used to cover wound sites involving bone that has undergone surgery, or to cover muscle flaps or graft of cancellous bone (bone that has a spongy structure) (<LINK REF="REF-Ciampolini-2000" TYPE="REFERENCE">Ciampolini 2000</LINK>; <LINK REF="REF-Eckardt-1994" TYPE="REFERENCE">Eckardt 1994</LINK>; <LINK REF="REF-Haidar-2010" TYPE="REFERENCE">Haidar 2010</LINK>; <LINK REF="REF-Lew-2004" TYPE="REFERENCE">Lew 2004</LINK>; <LINK REF="REF-Mader-1997a" TYPE="REFERENCE">Mader 1997a</LINK>; <LINK REF="REF-Mader-1999b" TYPE="REFERENCE">Mader 1999b</LINK>; <LINK REF="REF-Parsons-2004" TYPE="REFERENCE">Parsons 2004</LINK>; <LINK REF="REF-Waldvogel-1980" TYPE="REFERENCE">Waldvogel 1980</LINK>; <LINK REF="REF-Walter-2012" TYPE="REFERENCE">Walter 2012</LINK>).</P>
<P>Given the importance of biofilm in the pathophysiology and relapses of chronic osteomyelitis, some experts suggest the use of an antibiotic (e.g. rifampin) with activity against micro-organisms in biofilm as a combination drug in both parenteral and oral regimens. However, there is insufficient evidence for choosing antibiotics based on biofilm antimicrobial susceptibility testing rather than the conventional antimicrobial susceptibility test (<LINK REF="REF-Saginur-2006" TYPE="REFERENCE">Saginur 2006</LINK>; <LINK REF="REF-Walter-2012" TYPE="REFERENCE">Walter 2012</LINK>).</P>
<P>Four to six weeks of parenteral (non-oral administration such as an intravenous injection) antibiotic therapy after surgery has become the standard treatment for chronic osteomyelitis. The rationale for this regimen is that three to four weeks are required for the bone to revascularise, and is based on experience of treating children with acute osteomyelitis (<LINK REF="REF-Carek-2001" TYPE="REFERENCE">Carek 2001</LINK>; <LINK REF="STD-Gentry-1990" TYPE="STUDY">Gentry 1990</LINK>; <LINK REF="REF-Lazzarini-2002" TYPE="REFERENCE">Lazzarini 2002</LINK>; <LINK REF="REF-Lazarini-2005" TYPE="REFERENCE">Lazarini 2005</LINK>; <LINK REF="REF-Mader-1992" TYPE="REFERENCE">Mader 1992</LINK>; <LINK REF="REF-Mader-1999a" TYPE="REFERENCE">Mader 1999a</LINK>). However, different centres can vary regarding antibiotic use and duration of treatment, depending on the disease stage, pathogen identified or surgical intervention performed (<LINK REF="REF-Walter-2012" TYPE="REFERENCE">Walter 2012</LINK>; <LINK REF="REF-Spellberg-2012" TYPE="REFERENCE">Spellberg 2012</LINK>).</P>
</INTERVENTION>
<THEORY MODIFIED="2013-09-03 14:24:18 +0100" MODIFIED_BY="Lindsey Elstub">
<P>Despite advances in both antibiotics and surgical treatment, the long-term recurrence rate of chronic osteomyelitis remains at around 20% (<LINK REF="STD-Gentry-1990" TYPE="STUDY">Gentry 1990</LINK>; <LINK REF="STD-Mader-1990" TYPE="STUDY">Mader 1990</LINK>; <LINK REF="REF-Spellberg-2012" TYPE="REFERENCE">Spellberg 2012</LINK>; <LINK REF="REF-Rissing-1997" TYPE="REFERENCE">Rissing 1997</LINK>). Evaluating the success of treatment is difficult as many studies show promising initial results but frequently lack long-term follow-up data (<LINK REF="REF-Mader-1992" TYPE="REFERENCE">Mader 1992</LINK>).</P>
<P>The optimal duration of antibiotic therapy has not been well-defined. Due to failure rates in clinical studies, some authors advocate longer treatment with six to eight weeks of high doses of intravenous therapy followed by a course of three months or longer of oral therapy (<LINK REF="REF-Johnston-2007" TYPE="REFERENCE">Johnston 2007</LINK>; <LINK REF="REF-Spellberg-2012" TYPE="REFERENCE">Spellberg 2012</LINK>). Apart from the doubts related to the duration of chronic osteomyelitis treatment, there are some controversies about the best route of antibiotic administration. Some reports suggest that short-term parenteral therapy followed by oral antibiotic therapy for six weeks or oral antibiotic alone may be an effective strategy with more economic benefits than parenteral therapy alone (<LINK REF="STD-Gentry-1990" TYPE="STUDY">Gentry 1990</LINK>; <LINK REF="REF-Mader-2001" TYPE="REFERENCE">Mader 2001</LINK>; <LINK REF="REF-Rissing-1997" TYPE="REFERENCE">Rissing 1997</LINK>; <LINK REF="REF-Spellberg-2012" TYPE="REFERENCE">Spellberg 2012</LINK>; <LINK REF="REF-Swiontkowski-1999" TYPE="REFERENCE">Swiontkowski 1999</LINK>).</P>
<P>Short-term oral antibiotics for treating chronic osteomyelitis, if as effective as the parenteral route, would be more convenient for patients, with no risk of vascular line infection, and would probably cost less.</P>
</THEORY>
<IMPORTANCE MODIFIED="2013-09-05 17:22:06 +0100" MODIFIED_BY="Lindsey Elstub">
<P>The epidemiology of chronic osteomyelitis has changed in recent years. There has been a significant increase in post-traumatic and post surgical osteomyelitis, especially in developed countries (<LINK REF="REF-Trampuz-2006" TYPE="REFERENCE">Trampuz 2006</LINK>).</P>
<P>Surgical debridement is a mainstay of chronic osteomyelitis treatment (<LINK REF="REF-Parsons-2004" TYPE="REFERENCE">Parsons 2004</LINK>). However, in current practice, additional treatment with antibiotics is frequently recommended for infection eradication (<LINK REF="REF-Spellberg-2012" TYPE="REFERENCE">Spellberg 2012</LINK>; <LINK REF="REF-Walter-2012" TYPE="REFERENCE">Walter 2012</LINK>). Various antibiotic regimens are in use (<LINK REF="REF-Lazarini-2005" TYPE="REFERENCE">Lazarini 2005</LINK>; <LINK REF="REF-Walter-2012" TYPE="REFERENCE">Walter 2012</LINK>) and there are many questions regarding the ideal route of antibiotic administration (oral or parenteral). If oral therapy is proven to be similarly or more effective for treating chronic osteomyelitis, it will be preferred because it is generally more comfortable for the patient and less expensive (<LINK REF="REF-Johnston-2007" TYPE="REFERENCE">Johnston 2007</LINK>; <LINK REF="REF-Spellberg-2012" TYPE="REFERENCE">Spellberg 2012</LINK>; <LINK REF="REF-Stengel-2001" TYPE="REFERENCE">Stengel 2001</LINK>; <LINK REF="REF-Walter-2012" TYPE="REFERENCE">Walter 2012</LINK>).</P>
<P>Currently, increasing antibiotic resistance, due in part to the inappropriate use of antimicrobials, is of great concern worldwide. Many <I>S. aureus </I>acquired infections in<I> </I>the<I> </I>community or in hospital are now resistant to beta-lactamic antibiotics, and the gram negative bacilli have become resistant to beta-lactamic and fluoroquinolones (<LINK REF="REF-Lew-2004" TYPE="REFERENCE">Lew 2004</LINK>; <LINK REF="REF-Murphy-2011" TYPE="REFERENCE">Murphy 2011</LINK>; <LINK REF="REF-Sheehy-2010" TYPE="REFERENCE">Sheehy 2010</LINK>). Therefore, the duration and type of antibiotic regimen to treat chronic osteomyelitis needs to be defined based on good quality research. This is an update of a Cochrane review first published in 2009 (<LINK REF="REF-Conterno-2009" TYPE="REFERENCE">Conterno 2009</LINK>).</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2013-09-04 10:13:37 +0100" MODIFIED_BY="[Empty name]">
<P>To determine the effects of systemic antibiotics for treating chronic osteomyelitis in adults.</P>
<P>We aimed to compare different antimicrobial regimens, in terms of choice of drug and route of administration, to treat bacterial chronic osteomyelitis in adults.</P>
</OBJECTIVES>
<METHODS MODIFIED="2013-09-06 11:07:03 +0100" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2013-09-04 10:18:25 +0100" MODIFIED_BY="Lindsey Elstub">
<CRIT_STUDIES MODIFIED="2013-09-03 14:26:30 +0100" MODIFIED_BY="[Empty name]">
<P>We included randomised controlled trials (RCTs) and quasi-RCTs (i.e. a method of allocation that is not strictly speaking random, such as date of birth or alternation) irrespective of publication status or blinding.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2013-09-04 10:18:25 +0100" MODIFIED_BY="[Empty name]">
<P>We included adults with chronic osteomyelitis.</P>
<P>The diagnosis of chronic osteomyelitis could be defined in the included studies as: clinical pattern evolved over months or years and characterised by low-grade inflammation, presence of pus, microorganisms or presence of dead bone (sequestra), demonstrated by plain film, computed tomography or magnetic resonance imaging, or isolation of bacteria from the bone lesion (<LINK REF="REF-Lew-2004" TYPE="REFERENCE">Lew 2004</LINK>). Trial participants should have undergone surgical management of infection with the debridement of necrotic tissue. However, we did not exclude studies based on failure to describe prior treatment. </P>
<P>We excluded trials that focused specifically on the treatment of diabetic foot osteomyelitis, implant-associated osteomyelitis, sternal or vertebral osteomyelitis. We included mixed population trials primarily focusing on chronic osteomyelitis only if the proportion of participants with otherwise excluded conditions was low or separate data were available.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2013-09-03 14:27:51 +0100" MODIFIED_BY="[Empty name]">
<P>Comparative studies of systemic antibiotic treatment of chronic osteomyelitis. We included trials comparing different antibiotics, different antibiotic routes of administration (oral, parenteral or a combination of parenteral and oral) or different treatment durations.</P>
<P>We defined parenteral route of administration as any route other than the mouth or bowel. We did not include studies addressing local antibiotic treatment. The bacteria should have had documented sensitivity to the antibiotics used. Participants should have had surgical management of infection with debridement of all necrotic tissue and obliteration of dead space; stabilisation of the bone and adequate soft tissue coverage should have been done if necessary.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2013-09-03 14:28:09 +0100" MODIFIED_BY="Lindsey Elstub">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2013-09-03 14:28:04 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Remission of infection, where we defined remission as the resolution of all signs and symptoms of active infection at the end of therapy and after a minimal post-treatment observation period of one year (<LINK REF="REF-Carek-2001" TYPE="REFERENCE">Carek 2001</LINK>; <LINK REF="STD-Gentry-1990" TYPE="STUDY">Gentry 1990</LINK>; <LINK REF="REF-Mader-1992" TYPE="REFERENCE">Mader 1992</LINK>).</LI>
<LI>Number of participants who presented remission of infection at the end of therapy.</LI>
<LI>Number of participants who presented remission of infection at least one year after therapy.</LI>
</UL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2013-09-03 14:28:09 +0100" MODIFIED_BY="Lindsey Elstub">
<UL>
<LI>Number of participants with failure (defined as a lack of apparent response to therapy as evidenced by one or more of the following: persistence of drainage, recurrence of sinus tract or failure of sinus tract to close, persistence of systemic signs of infection (chills, fever, weight loss, bone pain), or progression of bone infection shown by imaging methods) (<LINK REF="STD-Gentry-1990" TYPE="STUDY">Gentry 1990</LINK>; <LINK REF="REF-Mader-1992" TYPE="REFERENCE">Mader 1992</LINK>). Treatment failure also included early interruption of treatment, such as for adverse effects or disease complications such as amputation.</LI>
<LI>Number of participants with early relapse (defined as recurrence of signs and symptoms plus isolation of the same pathogen(s) within four to six weeks after discontinuation of antibacterial therapy) (<LINK REF="STD-Gentry-1990" TYPE="STUDY">Gentry 1990</LINK>; <LINK REF="REF-Mader-1992" TYPE="REFERENCE">Mader 1992</LINK>).</LI>
<LI>Number of participants with late relapse (defined as recurrence occurring after six weeks and up to 12 months after the end of therapy) (<LINK REF="STD-Gentry-1990" TYPE="STUDY">Gentry 1990</LINK>; <LINK REF="REF-Mader-1992" TYPE="REFERENCE">Mader 1992</LINK>).</LI>
<LI>Adverse events:</LI>
<UL>
<LI>Adverse events related to antibiotic use</LI>
<LI>Orthopaedic sequels such as residual pain and non-union</LI>
<LI>Superinfection (defined as the isolation of new pathogens from infected bone during therapy)</LI>
<LI>Number of amputations</LI>
<LI>Death</LI>
</UL>
</UL>
<SUBSECTION>
<HEADING LEVEL="5">Resource use (all settings)</HEADING>
<P>Such as:</P>
<UL>
<LI>Cost of antibiotics</LI>
<LI>Days of hospitalisation</LI>
</UL>
</SUBSECTION>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2013-09-06 11:07:03 +0100" MODIFIED_BY="[Empty name]">
<ELECTRONIC_SEARCHES MODIFIED="2013-09-06 11:07:03 +0100" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Bone, Joint and Muscle Trauma Group Specialised Register (October 2012), the Cochrane Central Register of Controlled Trials (<I>The Cochrane Library</I> 2012, Issue 9), MEDLINE (January 1948 to September Week 4 2012), EMBASE (January 1980 to 2012 Week 40) and LILACS (Latin America and Caribbean Health Sciences - October 2012). We also searched the <A HREF="http://apps.who.int/trialsearch/">World Health Organization International Clinical Trials Registry platform</A> (June 2012) for ongoing trials. We did not apply any language restrictions.</P>
<P>In MEDLINE (OVID WEB), we combined the search strategy with the revised optimal trial search strategy (<LINK REF="REF-Higgins-2006" TYPE="REFERENCE">Higgins 2006</LINK>). We modified the strategy for use in the other databases (see <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>).</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2009-05-11 15:59:11 +0100" MODIFIED_BY="[Empty name]">
<P>We searched reference lists of relevant articles.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2013-09-04 10:20:54 +0100" MODIFIED_BY="Lindsey Elstub">
<STUDY_SELECTION MODIFIED="2013-09-03 14:28:58 +0100" MODIFIED_BY="Lindsey Elstub">
<P>Two review authors (LOC and MDT) independently inspected each reference produced by the search and identified potentially eligible studies, for which we obtained full text articles where possible. The same two authors independently performed study selection. We resolved any disagreements by consensus.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2013-09-03 14:29:07 +0100" MODIFIED_BY="[Empty name]">
<P>Two review authors (LOC and MDT) independently extracted the data from trial reports. We used a tool based on the generic data extraction tool developed by the Cochrane Bone, Joint and Muscle Trauma Group. We resolved any disagreements by consensus.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2013-09-04 10:19:27 +0100" MODIFIED_BY="Lindsey Elstub">
<P>In this review update, two authors independently assessed the risk of bias in newly included trials, without masking the source and authorship of the trial reports. At least one author assessed risk of bias in trials that we included in previous versions of the review. We performed a pilot trial of the assessment form using two trials. One author checked data extraction consistency between review authors and between review versions. We resolved any differences through discussion. We used the risk of bias tool outlined in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> to assess bias in included studies (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). This tool incorporates assessment of randomisation (sequence generation and allocation concealment), blinding (of participants, treatment providers and outcome assessment), completeness of outcome data, selection of outcomes reported and other sources of bias. We assessed three additional sources of bias: major imbalances in baseline characteristics; lack of comparability of care programmes other than the interventions under test; and inadequate duration of follow-up.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2013-09-04 10:20:24 +0100" MODIFIED_BY="Lindsey Elstub">
<P>We calculated risk ratios (RR) and 95% confidence intervals (CIs) for dichotomous outcomes.</P>
<P>If future updates of this review include studies with continuous outcomes, we will calculate mean differences and 95% CIs.</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2013-09-03 14:34:49 +0100" MODIFIED_BY="Lindsey Elstub">
<P>We did not have any unit of analysis issues, in particular those relating to cluster-RCTs, cross-over trials or trials with multiple treatment groups.</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2013-09-03 14:35:21 +0100" MODIFIED_BY="Lindsey Elstub">
<P>As all the studies (except <LINK REF="STD-Euba-2009" TYPE="STUDY">Euba 2009</LINK>) were conducted more than 10 years ago, we therefore chose not request to additional information from the trial authors.</P>
<P>Whenever possible, we performed intention-to-treat analyses to include all randomised participants. However, when we identified drop-outs, we used the actual denominators of participants contributing data at the relevant outcome assessment. Should continuous outcome data be available in future, we will be alert to the potential mislabelling or non-identification of standard errors and standard deviations. Unless missing standard deviations can be derived from CIs or standard errors, we will not assume values in order to present these in the analyses.<BR/>
</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2013-09-03 14:35:25 +0100" MODIFIED_BY="Lindsey Elstub">
<P>We assessed heterogeneity by visual inspection of the forest plot and using the Chi² statistic (with significance set at P &lt; 0.10) in conjunction with the I² statistic, which describes the percentage of the variability in effect estimates that are due to heterogeneity rather than sampling error (chance) (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>). We considered an I² value &gt; 50% as evidence of substantial heterogeneity.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2013-09-03 14:35:37 +0100" MODIFIED_BY="Lindsey Elstub">
<P>As an insufficient number of trials met our inclusion criteria (fewer than 10 trials), we did not generate funnel plots to explore the potential for publication bias.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2013-09-03 14:35:41 +0100" MODIFIED_BY="Lindsey Elstub">
<P>Where appropriate, we pooled data using the fixed-effect model and presented 95% CI values.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2013-09-04 10:20:54 +0100" MODIFIED_BY="Lindsey Elstub">
<P>In future updates, if appropriate, we will investigate possible causes of heterogeneity by subgrouping according to different bacteria groups (gram-negative, gram-positive or polymicrobial infection), severity of the disease (medullary, superficial, localised or diffuse) (<LINK REF="REF-Cierny-2003" TYPE="REFERENCE">Cierny 2003</LINK>), treatment duration (more or less than six weeks) and classification (post-traumatic, post-surgical).</P>
<P>We will investigate whether the results of subgroups are significantly different by inspecting the overlap of confidence intervals and performing the test for subgroup differences available in <LINK REF="REF-Review-Manager-_x0028_RevMan_x0029_" TYPE="REFERENCE">Review Manager (RevMan)</LINK>RevMan.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2013-09-03 15:01:00 +0100" MODIFIED_BY="Lindsey Elstub">
<P>In future updates, if appropriate, we will perform sensitivity analyses to examine various aspects of trial and review methodology, including the effects of missing data, the selection of statistical model (fixed-effect versus random-effects) for pooling, and the effects of excluding trials at high or unclear risk of bias, such as high risk of selection bias arising from the lack of allocation concealment.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2013-09-06 11:08:33 +0100" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2013-09-06 11:08:33 +0100" MODIFIED_BY="[Empty name]">
<SEARCH_RESULTS MODIFIED="2013-09-06 11:08:33 +0100" MODIFIED_BY="[Empty name]">
<P>In the previous search conducted up to October 2008, we screened 519 studies. For this review update (search completed October 2012), we screened a total of 471 records from the following databases: Cochrane Bone, Joint and Muscle Trauma Group Specialised Register (5 records); Cochrane Central Register of Controlled Trials (31), MEDLINE (96), EMBASE (227), LILACS (45) and WHO International Clinical Trials Registry Platform (67). We also identified two potentially eligible studies from other sources (reference lists of included studies and reviews on the subject). For details, see the PRISMA study flowchart (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>)</P>
<P>From the search update, we identified 10 citations of potentially eligible records, for which we obtained full reports where possible. We included one additional trial (two references) in this update (<LINK REF="STD-Euba-2009" TYPE="STUDY">Euba 2009</LINK>), we excluded four trials (<LINK REF="STD-Ingianni-2007" TYPE="STUDY">Ingianni 2007</LINK>; <LINK REF="STD-Marriott-2008" TYPE="STUDY">Marriott 2008</LINK>; <LINK REF="STD-Nguyen--2009" TYPE="STUDY">Nguyen 2009</LINK>; <LINK REF="STD-Tascini-2009" TYPE="STUDY">Tascini 2009</LINK>), and three trials are ongoing (<LINK REF="STD-CTRI_x002f_2008_x002f_091_x002f_000060" TYPE="STUDY">CTRI/2008/091/000060</LINK>; <LINK REF="STD-EUCTR2009_x002d_015744_x002d_42_x002d_GB" TYPE="STUDY">EUCTR2009-015744-42-GB</LINK>; <LINK REF="STD-NCT00324922" TYPE="STUDY">NCT00324922</LINK>). A further study (<LINK REF="STD-Barber_x00e1_n-2000" TYPE="STUDY">Barberán 2000</LINK>) is awaiting classification.</P>
<P>We excluded one of the studies included in the previous version (<LINK REF="STD-Greenberg-1987" TYPE="STUDY">Greenberg 1987</LINK>) from this update.</P>
<P>Overall, we have included eight trials, excluded 15 studies, and identified three ongoing trials and one study awaiting classification.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2013-09-04 10:22:16 +0100" MODIFIED_BY="Lindsey Elstub">
<P>We have listed the details of the individual trials in the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>.</P>
<SUBSECTION>
<HEADING LEVEL="4">Design</HEADING>
<P>Of the eight included trials, seven RCTs and one quasi-RCT (<LINK REF="STD-Mader-1990" TYPE="STUDY">Mader 1990</LINK>). Three trials (<LINK REF="STD-Gentry-1990" TYPE="STUDY">Gentry 1990</LINK>; <LINK REF="STD-Gentry-1991" TYPE="STUDY">Gentry 1991</LINK>; <LINK REF="STD-Norden-1986" TYPE="STUDY">Norden 1986</LINK>) were multicentre trials and five trials were likely to have been conducted at a single site (<LINK REF="STD-Euba-2009" TYPE="STUDY">Euba 2009</LINK>; <LINK REF="STD-Gomis-1999" TYPE="STUDY">Gomis 1999</LINK>; <LINK REF="STD-Greenberg-2000" TYPE="STUDY">Greenberg 2000</LINK>; <LINK REF="STD-Mader-1990" TYPE="STUDY">Mader 1990</LINK>; <LINK REF="STD-Sheftel-1986" TYPE="STUDY">Sheftel 1986</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Sample sizes</HEADING>
<P>The eight included trials comprised a total of 282 participants, with data available from 248. The number of participants enrolled in the individual studies ranged from 12 (<LINK REF="STD-Greenberg-2000" TYPE="STUDY">Greenberg 2000</LINK>) to 67 (<LINK REF="STD-Gentry-1990" TYPE="STUDY">Gentry 1990</LINK>), and in individual intervention groups ranged from five (<LINK REF="STD-Greenberg-2000" TYPE="STUDY">Greenberg 2000</LINK>) to 31 (<LINK REF="STD-Gentry-1990" TYPE="STUDY">Gentry 1990</LINK>). Only one trial reported a sample-size calculation, but even in this trial the trial authors did not achieve the desired sample size (<LINK REF="STD-Norden-1986" TYPE="STUDY">Norden 1986</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Setting</HEADING>
<P>All eight trials were conducted in the tertiary care (hospital) setting. Six trials were conducted in the USA; two of these (<LINK REF="STD-Gentry-1990" TYPE="STUDY">Gentry 1990</LINK>; <LINK REF="STD-Gentry-1991" TYPE="STUDY">Gentry 1991</LINK>) were also carried out in Costa Rica. Two trials were conducted in Spain (<LINK REF="STD-Euba-2009" TYPE="STUDY">Euba 2009</LINK>; <LINK REF="STD-Gomis-1999" TYPE="STUDY">Gomis 1999</LINK>). Three trials were funded by the pharmaceutical industry (<LINK REF="STD-Gentry-1991" TYPE="STUDY">Gentry 1991</LINK>; <LINK REF="STD-Mader-1990" TYPE="STUDY">Mader 1990</LINK>; <LINK REF="STD-Norden-1986" TYPE="STUDY">Norden 1986</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Participants </HEADING>
<P>All trials had at least twice as many male as female participants. Whenever reported, the mean age of participants ranged from 33 years (<LINK REF="STD-Mader-1990" TYPE="STUDY">Mader 1990</LINK>) to 59 years (<LINK REF="STD-Gomis-1999" TYPE="STUDY">Gomis 1999</LINK>).</P>
<P>According to the trial reports, all participants had a diagnosis of chronic osteomyelitis, but with variable duration of symptoms pretreatment. Three trials reported the duration of chronic osteomyelitis (<LINK REF="STD-Euba-2009" TYPE="STUDY">Euba 2009</LINK>; <LINK REF="STD-Mader-1990" TYPE="STUDY">Mader 1990</LINK>; <LINK REF="STD-Norden-1986" TYPE="STUDY">Norden 1986</LINK>) and ranged from one month (<LINK REF="STD-Euba-2009" TYPE="STUDY">Euba 2009</LINK>) to 28 years (<LINK REF="STD-Norden-1986" TYPE="STUDY">Norden 1986</LINK>).</P>
<P>Two studies described the classification of osteomyelitis using the Cierny-Mader System (<LINK REF="STD-Mader-1990" TYPE="STUDY">Mader 1990</LINK>; <LINK REF="STD-Sheftel-1986" TYPE="STUDY">Sheftel 1986</LINK>) and <LINK REF="STD-Gomis-1999" TYPE="STUDY">Gomis 1999</LINK> used the classification based on aetiology. Post-traumatic osteomyelitis was the most frequent type. Where reported, the location of the infection was mainly the tibia and femur.</P>
<P>In all trials, trial authors obtained the bacteria sample for microbiological diagnosis by open biopsy or aspiration from infected bone, and the isolated bacteria were sensitive to the antibiotic used.</P>
<P>In four trials, <I>S. aureus</I> was the most frequent bacterial species isolated (<LINK REF="STD-Gentry-1990" TYPE="STUDY">Gentry 1990</LINK>; <LINK REF="STD-Gentry-1991" TYPE="STUDY">Gentry 1991</LINK>; <LINK REF="STD-Gomis-1999" TYPE="STUDY">Gomis 1999</LINK>; <LINK REF="STD-Mader-1990" TYPE="STUDY">Mader 1990</LINK>), but polymicrobial infections and infections caused by <I>Pseudomonas aeruginosa</I> were common among the trials. Two trials included only chronic osteomyelitis caused by <I>S. aureus</I> (<LINK REF="STD-Euba-2009" TYPE="STUDY">Euba 2009</LINK>; <LINK REF="STD-Norden-1986" TYPE="STUDY">Norden 1986</LINK>) and another trial reported only infection caused by gram-negative bacteria (<LINK REF="STD-Sheftel-1986" TYPE="STUDY">Sheftel 1986</LINK>).</P>
<P>All trials mentioned debridement as part of treatment. Only three trials gave details about the surgical proceedings (<LINK REF="STD-Euba-2009" TYPE="STUDY">Euba 2009</LINK>; <LINK REF="STD-Mader-1990" TYPE="STUDY">Mader 1990</LINK>; <LINK REF="STD-Norden-1986" TYPE="STUDY">Norden 1986</LINK>). <LINK REF="STD-Gentry-1991" TYPE="STUDY">Gentry 1991</LINK> and <LINK REF="STD-Gomis-1999" TYPE="STUDY">Gomis 1999</LINK> reported that the surgical debridement was performed as indicated; <LINK REF="STD-Mader-1990" TYPE="STUDY">Mader 1990</LINK> and <LINK REF="STD-Greenberg-2000" TYPE="STUDY">Greenberg 2000</LINK> did not report whether the surgical debridement was done in all participants; and <LINK REF="STD-Norden-1986" TYPE="STUDY">Norden 1986</LINK> reported that all participants but two had surgical debridement.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Interventions</HEADING>
<P>The included trials evaluated five different comparisons:</P>
<UL>
<LI>Oral antibiotics versus parenteral antibiotics (<LINK REF="STD-Gentry-1990" TYPE="STUDY">Gentry 1990</LINK>; <LINK REF="STD-Gentry-1991" TYPE="STUDY">Gentry 1991</LINK>; <LINK REF="STD-Gomis-1999" TYPE="STUDY">Gomis 1999</LINK>; <LINK REF="STD-Mader-1990" TYPE="STUDY">Mader 1990</LINK>)</LI>
<LI>Oral antibiotics versus parental plus oral antibiotics (<LINK REF="STD-Euba-2009" TYPE="STUDY">Euba 2009</LINK>)</LI>
<LI>Parenteral antibiotics plus oral antibiotics versus parenteral antibiotic (<LINK REF="STD-Norden-1986" TYPE="STUDY">Norden 1986</LINK>)</LI>
<LI>Parenteral antibiotics versus another parenteral antibiotics (<LINK REF="STD-Sheftel-1986" TYPE="STUDY">Sheftel 1986</LINK>)</LI>
<LI>Oral antibiotics versus another oral antibiotics (<LINK REF="STD-Greenberg-2000" TYPE="STUDY">Greenberg 2000</LINK>)</LI>
</UL>
<P>No trial specifically compared different durations of antibiotic treatment for chronic osteomyelitis. </P>
<P>Regarding oral antibiotics used, five trials used quinolones (<LINK REF="STD-Gentry-1990" TYPE="STUDY">Gentry 1990</LINK>; <LINK REF="STD-Gentry-1991" TYPE="STUDY">Gentry 1991</LINK>; <LINK REF="STD-Gomis-1999" TYPE="STUDY">Gomis 1999</LINK>; <LINK REF="STD-Greenberg-2000" TYPE="STUDY">Greenberg 2000</LINK>; <LINK REF="STD-Mader-1990" TYPE="STUDY">Mader 1990</LINK>), two trials used rifampin (<LINK REF="STD-Euba-2009" TYPE="STUDY">Euba 2009</LINK>; <LINK REF="STD-Norden-1986" TYPE="STUDY">Norden 1986</LINK>), one trial used cloxacillin (<LINK REF="STD-Euba-2009" TYPE="STUDY">Euba 2009</LINK>) and one trial used cotrimoxazole (<LINK REF="STD-Euba-2009" TYPE="STUDY">Euba 2009</LINK>).</P>
<P>Trials used several different parenteral antibiotics. Four trials used ceftazidime or cefazolin (<LINK REF="STD-Gentry-1990" TYPE="STUDY">Gentry 1990</LINK>; <LINK REF="STD-Gentry-1991" TYPE="STUDY">Gentry 1991</LINK>; <LINK REF="STD-Norden-1986" TYPE="STUDY">Norden 1986</LINK>; <LINK REF="STD-Sheftel-1986" TYPE="STUDY">Sheftel 1986</LINK>), three trials used nafcillin (<LINK REF="STD-Gentry-1990" TYPE="STUDY">Gentry 1990</LINK>; <LINK REF="STD-Mader-1990" TYPE="STUDY">Mader 1990</LINK>; <LINK REF="STD-Norden-1986" TYPE="STUDY">Norden 1986</LINK>), one trial used imipenem (<LINK REF="STD-Gomis-1999" TYPE="STUDY">Gomis 1999</LINK>), three trials used aminoglycoside (<LINK REF="STD-Gentry-1990" TYPE="STUDY">Gentry 1990</LINK>; <LINK REF="STD-Mader-1990" TYPE="STUDY">Mader 1990</LINK>; <LINK REF="STD-Sheftel-1986" TYPE="STUDY">Sheftel 1986</LINK>), one trial used cloxacillin (<LINK REF="STD-Euba-2009" TYPE="STUDY">Euba 2009</LINK>) and one trial used ticarcillin (<LINK REF="STD-Sheftel-1986" TYPE="STUDY">Sheftel 1986</LINK>).</P>
<P>The antibiotic regimens varied among the trials in terms of drugs used; even within the same trial, there were many different combinations of antibiotics. We could not make comparisons between the included trials to determine the best antibiotic for treating chronic osteomyelitis in adults.</P>
<P>The duration of treatment in the included studies varied within and between trials and ranged from less than seven days (<LINK REF="STD-Gomis-1999" TYPE="STUDY">Gomis 1999</LINK>) to 110 days (<LINK REF="STD-Greenberg-2000" TYPE="STUDY">Greenberg 2000</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Outcomes</HEADING>
<P>Across the trials, authors did not uniformly report the definitions of the outcome measures. Also, the reported definition of the outcomes varied between trials but we considered these definitions to be clinically consistent enough to permit pooling in some cases.</P>
<P>The outcomes were clinically and microbiologically based in two trials (<LINK REF="STD-Gentry-1990" TYPE="STUDY">Gentry 1990</LINK>; <LINK REF="STD-Sheftel-1986" TYPE="STUDY">Sheftel 1986</LINK>) and clinically based in the remaining six trials.</P>
<P>Eight trials reported the complete resolution of disease symptoms at the end of treatment, and seven trials after follow-up of at least 12 months (<LINK REF="STD-Euba-2009" TYPE="STUDY">Euba 2009</LINK>; <LINK REF="STD-Gentry-1990" TYPE="STUDY">Gentry 1990</LINK>; <LINK REF="STD-Gentry-1990" TYPE="STUDY">Gentry 1990</LINK>; <LINK REF="STD-Greenberg-2000" TYPE="STUDY">Greenberg 2000</LINK>; <LINK REF="STD-Mader-1990" TYPE="STUDY">Mader 1990</LINK>; <LINK REF="STD-Norden-1986" TYPE="STUDY">Norden 1986</LINK>; <LINK REF="STD-Sheftel-1986" TYPE="STUDY">Sheftel 1986</LINK>). The length of follow-up for individual trial participants, which varied between and within trials, ranged from less than one month (<LINK REF="STD-Greenberg-2000" TYPE="STUDY">Greenberg 2000</LINK>) to more than 13 years (<LINK REF="STD-Euba-2009" TYPE="STUDY">Euba 2009</LINK>).</P>
<P>All eight trials reported adverse events related to antibiotic therapy. Five trials reported the adverse events as severe. Four trials reported the occurrence of superinfection during the treatment (<LINK REF="STD-Gentry-1990" TYPE="STUDY">Gentry 1990</LINK>; <LINK REF="STD-Gentry-1991" TYPE="STUDY">Gentry 1991</LINK>; <LINK REF="STD-Gomis-1999" TYPE="STUDY">Gomis 1999</LINK>; <LINK REF="STD-Sheftel-1986" TYPE="STUDY">Sheftel 1986</LINK>).</P>
<P>Only one trial (<LINK REF="STD-Euba-2009" TYPE="STUDY">Euba 2009</LINK>) reported data on the length of hospital stay. No trial reported on the costs related to treatment.</P>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2013-09-03 15:49:25 +0100" MODIFIED_BY="Lindsey Elstub">
<P>We excluded 15 studies (see the <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> for details). The main reasons for exclusion were lack of separate data for participants with chronic osteomyelitis (seven studies), lack of details of the antibiotic used and the diagnosis criteria (three studies), lack of surgical debridement (three studies) and retrospective study design (two studies). We excluded a previously included trial (<LINK REF="STD-Greenberg-1987" TYPE="STUDY">Greenberg 1987</LINK>) from this update because the trial authors did not perform surgical debridement.</P>
<SUBSECTION>
<HEADING LEVEL="3">Ongoing studies</HEADING>
<P>Three RCTs are ongoing but each have uncertain recruitment status. One study (<LINK REF="STD-CTRI_x002f_2008_x002f_091_x002f_000060" TYPE="STUDY">CTRI/2008/091/000060</LINK>), which includes adults with mild or severe infection, including bone and joint infections, compares treatment with vancomycin plus ceftriaxone versus vancomycin alone. <LINK REF="STD-EUCTR2009_x002d_015744_x002d_42_x002d_GB" TYPE="STUDY">EUCTR2009-015744-42-GB</LINK>, which includes adults with bone and joint infection, compares treatment with oral antibiotics versus parenteral antibiotics. <LINK REF="STD-NCT00324922" TYPE="STUDY">NCT00324922</LINK>, which includes adults with bone and joint infection by methicillin-resistant <I>S. aureus, </I>compares treatment with trimethoprim-sulphamethoxazole versus vancomycin.</P>
</SUBSECTION>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2013-09-03 15:56:53 +0100" MODIFIED_BY="Helen HG Handoll">
<P>We have summarised the risk of bias judgements for the individual trials in <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK> and <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>. We described them in the 'Risk of bias' tables in the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>.</P>
<ALLOCATION MODIFIED="2013-09-03 14:48:56 +0100" MODIFIED_BY="Helen HG Handoll">
<P>We judged the two studies that provided details of random sequence generation (computer-generated randomisation list and random numbers table, respectively) to be at low risk of selection bias related to sequence generation (<LINK REF="STD-Euba-2009" TYPE="STUDY">Euba 2009</LINK>; <LINK REF="STD-Norden-1986" TYPE="STUDY">Norden 1986</LINK>). Both of these studies and five other studies failed to provide sufficient information to permit judgement regarding allocation concealment and had unclear risk of bias. In <LINK REF="STD-Mader-1990" TYPE="STUDY">Mader 1990</LINK>, the trial authors "sequentially assigned" participants to the two treatment groups and this trial was therefore considered at high risk of selection bias.</P>
</ALLOCATION>
<BLINDING MODIFIED="2013-09-03 15:50:09 +0100" MODIFIED_BY="Helen HG Handoll">
<P>Seven studies did not blind the participants, personnel or assessors to the treatment (<LINK REF="STD-Euba-2009" TYPE="STUDY">Euba 2009</LINK>; <LINK REF="STD-Gentry-1990" TYPE="STUDY">Gentry 1990</LINK>; <LINK REF="STD-Gentry-1991" TYPE="STUDY">Gentry 1991</LINK>; <LINK REF="STD-Gomis-1999" TYPE="STUDY">Gomis 1999</LINK>; <LINK REF="STD-Greenberg-2000" TYPE="STUDY">Greenberg 2000</LINK>; <LINK REF="STD-Norden-1986" TYPE="STUDY">Norden 1986</LINK>; <LINK REF="STD-Sheftel-1986" TYPE="STUDY">Sheftel 1986</LINK>). However, we classified these studies as low risk of bias because we judged that the outcomes (remission after the treatment) were not influenced by lack of blinding. We considered <LINK REF="STD-Gentry-1990" TYPE="STUDY">Gentry 1990</LINK> at high risk of detection bias because participants reported the return of the symptoms either via the telephone or a letter.</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2013-09-03 15:50:14 +0100" MODIFIED_BY="Helen HG Handoll">
<P>Three studies reported the number of withdrawals and they undertook intention-to-treat analysis whenever possible (<LINK REF="STD-Gomis-1999" TYPE="STUDY">Gomis 1999</LINK>; <LINK REF="STD-Greenberg-2000" TYPE="STUDY">Greenberg 2000</LINK>; <LINK REF="STD-Sheftel-1986" TYPE="STUDY">Sheftel 1986</LINK>). Five studies stated the numbers and reasons for withdrawal but they were unable to undertake intention-to-treat analysis (<LINK REF="STD-Euba-2009" TYPE="STUDY">Euba 2009</LINK>; <LINK REF="STD-Gentry-1990" TYPE="STUDY">Gentry 1990</LINK>; <LINK REF="STD-Gentry-1991" TYPE="STUDY">Gentry 1991</LINK>; <LINK REF="STD-Mader-1990" TYPE="STUDY">Mader 1990</LINK>; <LINK REF="STD-Norden-1986" TYPE="STUDY">Norden 1986</LINK>). We judged these five studies at high risk of attrition bias.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2013-09-03 15:08:20 +0100" MODIFIED_BY="Helen HG Handoll">
<P>All studies reported the outcomes described in the methods section, including adverse events, and had no evidence of selective reporting.</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2013-09-03 15:56:53 +0100" MODIFIED_BY="Helen HG Handoll">
<P>In general, studies described the baseline characteristics of participant age, gender and site of infection. Three trials mentioned duration of disease (<LINK REF="STD-Euba-2009" TYPE="STUDY">Euba 2009</LINK>; <LINK REF="STD-Mader-1990" TYPE="STUDY">Mader 1990</LINK>; <LINK REF="STD-Norden-1986" TYPE="STUDY">Norden 1986</LINK>), and only two trials gave the classification of disease using the Cierny-Mader System (<LINK REF="STD-Mader-1990" TYPE="STUDY">Mader 1990</LINK>; <LINK REF="STD-Sheftel-1986" TYPE="STUDY">Sheftel 1986</LINK>). We considered there was baseline comparability in four trials (<LINK REF="STD-Euba-2009" TYPE="STUDY">Euba 2009</LINK>; <LINK REF="STD-Gomis-1999" TYPE="STUDY">Gomis 1999</LINK>; <LINK REF="STD-Mader-1990" TYPE="STUDY">Mader 1990</LINK>; <LINK REF="STD-Norden-1986" TYPE="STUDY">Norden 1986</LINK>).</P>
<P>In all trials, participants received apparently identical care programmes. However, no study gave details for individual treatment groups of medical history, physical examination or laboratory investigations carried out during the study.</P>
<P>There was some variation between trials in the definition of inclusion criteria, outcome measures and outcome assessment, but all trials gave sufficient information and were clinically consistent.</P>
<P>Trials reported active follow-up. However, the length of follow-up was different for each participant within the trials and was not long enough in four trials, where some participants were followed up for nine months (<LINK REF="STD-Norden-1986" TYPE="STUDY">Norden 1986</LINK>), six months (<LINK REF="STD-Gomis-1999" TYPE="STUDY">Gomis 1999</LINK>), two months (<LINK REF="STD-Sheftel-1986" TYPE="STUDY">Sheftel 1986</LINK>) or less than one month (<LINK REF="STD-Greenberg-2000" TYPE="STUDY">Greenberg 2000</LINK>).</P>
<P>Overall, we judged two trials (<LINK REF="STD-Euba-2009" TYPE="STUDY">Euba 2009</LINK>; <LINK REF="STD-Mader-1990" TYPE="STUDY">Mader 1990</LINK>) at low risk of other bias; two trials (<LINK REF="STD-Gentry-1990" TYPE="STUDY">Gentry 1990</LINK>; <LINK REF="STD-Gentry-1991" TYPE="STUDY">Gentry 1991</LINK>) at unclear risk; and the other four trials at high risk.</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2013-09-04 10:26:33 +0100" MODIFIED_BY="Lindsey Elstub">
<P>We report the results for the five comparisons made by the included trials below. None addressed the impact of different bacteria species (e.g. <I>S. aureus</I>, <I>Enterobacteriaceae</I>, <I>Pseudomonas spp</I>) on the rate of remission, or the impact of different duration of antibiotic use on the rate of remission. Only <LINK REF="STD-Euba-2009" TYPE="STUDY">Euba 2009</LINK> reported on length of hospital stay. None of the included trials reported on cost.</P>
<SUBSECTION>
<HEADING LEVEL="3">Oral versus parenteral route of administration of antibiotics</HEADING>
<P>Four trials, presenting data from a total of 150 participants, compared oral quinolones with various parenteral antibiotics regimens (<LINK REF="STD-Gentry-1990" TYPE="STUDY">Gentry 1990</LINK>; <LINK REF="STD-Gentry-1991" TYPE="STUDY">Gentry 1991</LINK>; <LINK REF="STD-Gomis-1999" TYPE="STUDY">Gomis 1999</LINK>; <LINK REF="STD-Mader-1990" TYPE="STUDY">Mader 1990</LINK>).</P>
<P>The remission rates at the end of treatment with oral versus parenteral antibiotic were 88% (70/80) with oral antibiotic and 83% (58/70) with parenteral antibiotic, with no statistically significant difference between the two groups (RR 1.04, 95% CI 0.92 to 1.18; four trials, 150 participants; <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>). We did not observe any statistical heterogeneity between trials.</P>
<P>Remission rates at 12 or more months after the end of treatment were 77% (49/64) with oral antibiotic and 81% (44/54) with parenteral antibiotics (<LINK REF="STD-Gentry-1990" TYPE="STUDY">Gentry 1990</LINK>; <LINK REF="STD-Gentry-1991" TYPE="STUDY">Gentry 1991</LINK>; <LINK REF="STD-Mader-1990" TYPE="STUDY">Mader 1990</LINK>). We did not detect any statistically significant difference between groups (RR 0.94, 95% CI 0.78 to 1.13; three trials, 118 participants; <LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>) or any statistical heterogeneity between trials.</P>
<P>Three trials reported a variety of mild adverse events relating to the antibiotic used (<LINK REF="STD-Gentry-1990" TYPE="STUDY">Gentry 1990</LINK>; <LINK REF="STD-Gentry-1991" TYPE="STUDY">Gentry 1991</LINK>; <LINK REF="STD-Mader-1990" TYPE="STUDY">Mader 1990</LINK>); 17% (11/64) in the oral antibiotic groups and 15% (8/54) in the parenteral groups. We did not observe any statistically significant difference between the two groups in the pooled results (RR 1.08, 95% CI 0.49 to 2.42; three trials, 118 participants; <LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>). Moderate or severe adverse events, such as those requiring termination of treatment, occurred in 6.1% (3/49) of participants in the oral antibiotic group and 9.5% (4/42) in the parenteral groups but this was nota statistically significant difference (RR 0.69, 95% CI 0.19 to 2.57; three trials, 91 participants; <LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>).</P>
<P>Superinfection occurred in participants of both groups (7.6% (5/66) in the oral group versus 6.9% (4/58) in the parenteral group) (RR 1.08, 95% CI 0.33 to 3.60; three trials, 124 participants; <LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Oral antibiotics versus parenteral plus oral antibiotics</HEADING>
<P>One trial (<LINK REF="STD-Euba-2009" TYPE="STUDY">Euba 2009</LINK>) included 55 participants with chronic osteomyelitis by <I>S. aureus </I>and<I> </I>compared oral antibiotics (cotrimoxazole and rifampicin) versus parenteral (cloxacillin) plus oral antibiotic (cloxacillin). The remission rates at 12 months after the end of treatment were 80% (24/30) in the group that received oral antibiotics and 76% (19/25) in the group that received parenteral plus oral antibiotic. We did not observe any statistically significant difference between the two groups (RR 1.05, 95% CI 0.79 to 1.40; one trial, 55 participants; <LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>).</P>
<P>In total there were eight adverse events: three cases of rash, one case of bronchospasm and one case of nausea in the oral antibiotic group; and three cases of phlebitis in the parenteral plus oral antibiotic group (RR 1.39, 95% CI 0.37 to 5.25; one trial, 55 participants; <LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>).</P>
<P>The median number of days in hospital stay (interquartile range) was significantly shorter in the group who received oral antibiotics only compared with the group who received parental plus oral antibiotic: 31 days (21 to 49 days) versus 51 days (43 to 67), P = 0.002.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Parenteral plus oral antibiotics versus parenteral antibiotics</HEADING>
<P>Remission rate at least 12 months after the end of treatment was reported in only one trial with 19 participants (data available from 18) with chronic osteomyelitis caused by <I>Staphylococcus aureus</I> (<LINK REF="STD-Norden-1986" TYPE="STUDY">Norden 1986</LINK>). The remission rates were 80% (8/10) in the parenteral plus oral antibiotic group and 50% (4/8) in the parenteral antibiotic group. We did not observe any statistically significant difference (RR 1.60, 95% CI 0.75 to 3.42; one trial, 18 participants; <LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>).</P>
<P>Trial authors reported significant neutropenia in one participant of the parenteral plus oral antibiotic group and three participants of the parenteral antibiotic group, all with spontaneous recovery (RR 0.27, 95% CI 0.03 to 2.10; one trial, 18 participants; <LINK REF="CMP-003.02" TYPE="ANALYSIS">Analysis 3.2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Parenteral antibiotics</HEADING>
<P>
<LINK REF="STD-Sheftel-1986" TYPE="STUDY">Sheftel 1986</LINK> compared regimens of parenteral antibiotics (ceftazidime versus ticarcillin plus tobramycin) in 18 participants with chronic osteomyelitis caused by gram-negative bacilli. <I>P. aeruginosa</I> and <I>Enterobacter cloacae</I> were the most common organisms isolated. The remission rates at 12 months after the end of treatment were 67% (6/9) in the group that received ceftazidime and 89% (8/9) in the group that received ticarcillin (RR 0.75, 95% 0.45 to 1.26; one trial, 18 participants; <LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>).</P>
<P>The trial author reported one adverse event, a case of mild increase in serum hepatic enzyme level in the ceftazidime group, and none in the other group (RR 3.00, 95% 0.14 to 65.16; one trial, 18 participants; <LINK REF="CMP-004.02" TYPE="ANALYSIS">Analysis 4.2</LINK>).</P>
<P>Trial authors reported superinfection in two participants of the ceftazidime group and none in the ticarcillin plus tobramycin group (RR 5.00, 95% CI 0.27 to 91.52; one trial, 18 participants; <LINK REF="CMP-004.03" TYPE="ANALYSIS">Analysis 4.3</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Oral antibiotics</HEADING>
<P>One trial (<LINK REF="STD-Greenberg-2000" TYPE="STUDY">Greenberg 2000</LINK>) compared two different oral quinolones (ciprofloxacin and lomefloxacin) and included five and seven participants with chronic osteomyelitis respectively in the two groups. We did not observe any statistically significant difference in the remission rates after 12 months follow-up between the groups (two in each group; RR 1.40, 95% CI 0.29 to 6.86; one trial, 12 participants; <LINK REF="CMP-005.01" TYPE="ANALYSIS">Analysis 5.1</LINK>).</P>
<P>Trial authors reported adverse events in three participants of the lomefloxacin group and in none of the ciprofloxacin group but this difference was not statistically significant (RR 0.19, 95% CI 0.01 to 3.03; one trial, 12 participants; <LINK REF="CMP-005.02" TYPE="ANALYSIS">Analysis 5.2</LINK>).</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2013-09-04 10:48:05 +0100" MODIFIED_BY="Lindsey Elstub">
<SUMMARY_OF_RESULTS MODIFIED="2013-09-03 16:06:10 +0100" MODIFIED_BY="[Empty name]">
<P>In this review update, we included eight small and heterogeneous studies that involved 282 adults with biopsy-proven chronic osteomyelitis caused by bacteria with confirmed sensitivity to the antibiotics used. Results data were available for 248 participants. The main finding of this review is the lack of evidence to guide practice. The route of antibiotic administration was the only outcome that was evaluated by more than one trial.</P>
<P>We found no evidence of a difference between oral antibiotics (all quinolones in four trials) compared with parenteral antibiotic in the rate of remission at the end of therapy (RR 1.04, 95% CI 0.92 to 1.18; four trials, 150 participants) and after 12 months or more follow-up (RR 0.94, 95% CI 0.78 to 1.13; three trials, 118 participants). These results were statistically homogeneous. Separately pooled results for mild and more serious adverse events again showed no statistical differences between the two routes of administration. We did not observe any difference between the two groups in the incidence of superinfection.</P>
<P>Single trials with few participants found no statistical significant differences for remission or adverse events for the following four comparisons: oral antibiotic versus parenteral plus oral (one trial, 55 participants); parenteral plus oral versus parenteral only administration (one trial, 18 participants); two parenteral antibiotic regimens (one trial, 18 participants); two oral antibiotic regimens (one trial, 12 participants).</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2013-09-04 10:48:05 +0100" MODIFIED_BY="Lindsey Elstub">
<P>Due to the lack of data, we were unable to draw robust conclusions. In the comparison of oral versus parenteral antibiotics, the data suggest that provided the infective bacteria show sensitivity to the antibiotic used, the method of administration does not affect rate of disease remission. However, the number of participants in the included trials and pooled results may be insufficient to detect a difference between different routes of antibiotic administration to treat chronic osteomyelitis.</P>
<P>Other considerations include length of follow-up, the relative importance of surgical debridement and currency of the trial evidence.</P>
<P>Chronic osteomyelitis in adults generally occurs secondary to an open injury to the bone or after surgery for reconstruction of the bone (<LINK REF="REF-Holtom-1999" TYPE="REFERENCE">Holtom 1999</LINK>; <LINK REF="REF-Lazzarini-2002" TYPE="REFERENCE">Lazzarini 2002</LINK>; <LINK REF="REF-Mader-1999b" TYPE="REFERENCE">Mader 1999b</LINK>; <LINK REF="REF-Trampuz-2006" TYPE="REFERENCE">Trampuz 2006</LINK>). It may present as a recurrent or intermittent disease, with periods of quiescence of variable duration. Because of this aspect, the term 'remission' is preferable to 'cure' and the time of post-treatment follow-up should be at least 12 months to assume a sustained remission of disease. While we have applied the 12-month definition here, some authors suggest a follow-up of five years as ideal (<LINK REF="STD-Mader-1990" TYPE="STUDY">Mader 1990</LINK>). Others recommend survival analysis to provide information about the length of time free of relapse (<LINK REF="REF-Simpson-2001" TYPE="REFERENCE">Simpson 2001</LINK>; <LINK REF="REF-Walenkamp-1997" TYPE="REFERENCE">Walenkamp 1997</LINK>). In one trial, the authors planned a survival analysis but this was not presented (<LINK REF="STD-Euba-2009" TYPE="STUDY">Euba 2009</LINK>).</P>
<P>The current practice for treating chronic osteomyelitis includes complete surgical debridement of necrotic bone and antibiotic therapy. The contribution of each component to clinical success in the treatment of osteomyelitis is not known. Some researchers argue that the surgical intervention is the most important and that insufficient debridement is correlated with a high recurrence rate (<LINK REF="REF-Eckardt-1994" TYPE="REFERENCE">Eckardt 1994</LINK>; <LINK REF="STD-Gentry-1990" TYPE="STUDY">Gentry 1990</LINK>; <LINK REF="REF-Haidar-2010" TYPE="REFERENCE">Haidar 2010</LINK>; <LINK REF="REF-Simpson-2001" TYPE="REFERENCE">Simpson 2001</LINK>; <LINK REF="REF-Stengel-2001" TYPE="REFERENCE">Stengel 2001</LINK>). The requirement of surgical debridement is unquestionable, but we do not know whether surgical debridement is enough for the sustained remission of chronic osteomyelitis. Given that antibiotics could contribute to the control of chronic bone infection, it remains important to know if the class of antimicrobial used, the route of drug administration and the duration of therapy could influence the rate of sustained remission of infection.</P>
<P>The only aspect of the antibiotic regimen that was evaluated by more than one trial included in this review was the route of administration. The trial participants were treated with many different antibiotics and surgical debridement. Since the trials did not give details about the surgical intervention, we do not know if this aspect of treatment was adequate and comparable among the trials. However, some trials did attribute some treatment failures to inadequate debridement (e.g. <LINK REF="STD-Gentry-1990" TYPE="STUDY">Gentry 1990</LINK>). Nonetheless, the available data preclude any conclusion about the exact contribution of surgery to the rate of remission.</P>
<P>If oral antibiotics have the same success rates as parenteral antibiotics, with similar risks of adverse adverse effects, then these have the attraction of being easier to administer, being less expensive and avoiding the inconvenience of prolonged hospital stays and medical treatment associated with parenteral administration. However, we were not able to demonstrate this in this review due to the variability in the trial characteristics and lack of evidence for aspects of administration such as duration of treatment.</P>
<P>Currently, chronic osteomyelitis is increasing and is often associated with trauma, such as car accidents and orthopedic surgeries, and affects patients with diabetes mellitus or decubitus ulcers. This heterogeneous population is not adequately represented in this review because we excluded people with diabetic foot osteomyelitis, implant-associated osteomyelitis, sternal or vertebral osteomyelitis.</P>
<P>Finally, the majority of the included trials are over 20 years old. Nowadays there are higher prevalences of bacteria resistant to one or more available antibiotics, particularly when the infections are associated with healthcare procedures (<LINK REF="REF-Murphy-2011" TYPE="REFERENCE">Murphy 2011</LINK>; <LINK REF="REF-Sheehy-2010" TYPE="REFERENCE">Sheehy 2010</LINK>). For example, methicillin-resistant <I>S. aureus</I> prevalence is much higher now compared to the past two decades. We have a very limited number of antibiotics to treat this bacterial infection (<LINK REF="REF-Liu-2011" TYPE="REFERENCE">Liu 2011</LINK>). Continuously evolving bacterial resistance represents another challenge to the choice of antibiotics to treat chronic osteomyelitis.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2013-09-03 16:16:59 +0100" MODIFIED_BY="[Empty name]">
<P>We judged almost all of the included trials to be at moderate to high risk of bias due to trial design and reporting. These factors included failure to conceal allocation, lack of blinding, poor or unknown comparability of baseline characteristics, inadequate follow-up and post-randomisation exclusions in some trials. Overall, we did not detect statistically significant differences for the pooled results of trials comparing oral versus parenteral antibiotics. Exaggerated effects that may be associated with these biases were therefore not apparent.</P>
<P>Overall, we consider the quality of the evidence for the main comparison (oral versus parenteral antibiotics) to below. This reflects, in particular, the high likelihood of bias, the questions over applicability of the evidence and the small sample size. Further research may change the results and conclusions for this comparison.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2013-09-03 16:17:43 +0100" MODIFIED_BY="[Empty name]">
<P>The key potential bias in our review is that we may have not included all the evidence from randomised trials. Although our database search was comprehensive, we may have missed trials reported in conference proceedings. However, such reports are likely to be unavailable if these were contemporaneous with most of the studies in this review. As most of the trials and trial reports were over 10 years old, we decided not to request information from trial authors, including separate data for patients with chronic osteomyelitis in several excluded trials with mixed populations.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2013-09-03 14:51:31 +0100" MODIFIED_BY="[Empty name]">
<P>We located five published systematic reviews on the clinical efficacy of antibiotics for treating bone and joint infection including chronic osteomyelitis (<LINK REF="REF-Haidar-2010" TYPE="REFERENCE">Haidar 2010</LINK>; <LINK REF="REF-Karamanis-2008" TYPE="REFERENCE">Karamanis 2008</LINK>; <LINK REF="REF-Lazarini-2005" TYPE="REFERENCE">Lazarini 2005</LINK>; <LINK REF="REF-Spellberg-2012" TYPE="REFERENCE">Spellberg 2012</LINK>; <LINK REF="REF-Stengel-2001" TYPE="REFERENCE">Stengel 2001</LINK>). These differ from our review in terms of participants' characteristics, types of infections and study designs included. In this review, we included RCTs and quasi-RCTs of adult patients with chronic osteomyelitis treated with systemic antibiotics.</P>
<P>
<LINK REF="REF-Stengel-2001" TYPE="REFERENCE">Stengel 2001</LINK> included RCTs and quasi-RCTs only and covered local antibiotic therapy and joint infection. They concluded that no reliable inferences could be made from the available data on antibiotic therapy for osteomyelitis and septic arthritis.</P>
<P>
<LINK REF="REF-Lazarini-2005" TYPE="REFERENCE">Lazarini 2005</LINK> evaluated antibiotic treatment for acute and chronic osteomyelitis in children and adults and included uncontrolled studies. The authors concluded that the optimal duration of antibiotic therapy remains undefined and they could not determine the best agent, route or duration of antibiotic therapy from the available data.</P>
<P>
<LINK REF="REF-Karamanis-2008" TYPE="REFERENCE">Karamanis 2008</LINK> included seven RCTs and compared fluoroquinolones versus B-lactamic antibiotic to treat osteomyelitis. We did not include three studies described in <LINK REF="REF-Karamanis-2008" TYPE="REFERENCE">Karamanis 2008</LINK> in our review: one trial (<LINK REF="REF-Lipsky-1997" TYPE="REFERENCE">Lipsky 1997</LINK>) included participants with osteomyelitis secondary to diabetic foot infection and two trials (<LINK REF="STD-Giamarellou-1989" TYPE="STUDY">Giamarellou 1989</LINK>; <LINK REF="STD-Greenberg-1987" TYPE="STUDY">Greenberg 1987</LINK>) did not report whether bone debridement was done.</P>
<P>
<LINK REF="REF-Haidar-2010" TYPE="REFERENCE">Haidar 2010</LINK> searched the medical literature for evidence in animal and human studies to support the use of short courses of antibiotics for treating chronic osteomyelitis. The review authors only included studies that used short courses of antibiotics (three to 14 days). <LINK REF="REF-Haidar-2010" TYPE="REFERENCE">Haidar 2010</LINK> did not report their criteria for study inclusion nor the length of follow-up. The authors suggested that shortened duration of antimicrobial treatment with emphasis on debridement, and well-vascularised flap coverage might be a possible alternative for treating chronic osteomyelitis in the lower extremities. They concluded that properly designed studies are needed to determine the optimal duration of antibiotics.</P>
<P>The most recent review included 13 RCTs and 63 non-RCTs (<LINK REF="REF-Spellberg-2012" TYPE="REFERENCE">Spellberg 2012</LINK>). The authors concluded that oral and parenteral therapies achieve similar cure rates and that there is no evidence that antibiotic therapy for greater than four to six weeks improves outcomes compared with shorter regimens. However, the review included RCTs and non-RCTs and heterogeneous populations in terms of the type of osteomyelitis (osteomyelitis secondary to diabetes foot infection and orthopaedic implants).</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2013-09-03 12:31:51 +0100" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2013-09-03 12:31:51 +0100" MODIFIED_BY="[Empty name]">
<P>There remains insufficient evidence or no evidence from RCTs to determine the adequate duration of treatment, the regimen of antibiotic or the route of administration for treating chronic osteomyelitis in adults. There is insufficient evidence to confirm the lack of statistically significant differences in remission and adverse events between oral versus parenteral administration of systemic antibiotics for treating chronic osteomyelitis in adults.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2013-09-03 12:31:45 +0100" MODIFIED_BY="[Empty name]">
<P>There is a need for well-designed and adequately powered RCTs comparing antibiotic treatments for chronic osteomyelitis, mainly in terms of therapy duration, adjusted for groups of bacteria (gram-positive, gram-negative, polymicrobial), antibiotic resistance profile, antibiotic activity against microorganisms in the biofilm, and the severity of disease. Such trials are likely to be multicentre, should ensure adequate surgical debridement prior to starting the trial interventions and actively record remission and adverse affects of treatment. They should abide by the CONSORT statement when reporting their results. Considering that people with chronic osteomyelitis can have frequent relapses, even years after clinical remission, trial authors should use a follow-up period of longer than 12 months to enable assessment of survival rates in terms of long relapse-free periods.</P>
<P>While the route of administration remains important, findings of the ongoing <LINK REF="STD-EUCTR2009_x002d_015744_x002d_42_x002d_GB" TYPE="STUDY">EUCTR2009-015744-42-GB</LINK> trial may influence the direction of further research. Thus it seems prudent to wait for the publication of this trial before embarking on further research on this aspect.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2013-09-03 12:30:22 +0100" MODIFIED_BY="Lindsey Elstub">
<P>We are grateful to Prof Carlos Rodrigues da Silva Filho for his contribution to the first version of the review.</P>
<P>We are very grateful to Dr Karla Soares Weiser for her suggestions on the protocol and the Iberoamerican Cochrane Centre for assistance during the review. We are very grateful to Lesley Gillespie for searching for the studies and help during the editorial process, Joanne Elliott for updating the search, and Lindsey Elstub, Helen Handoll, Lesley Gillespie, Vicki Livingstone, Janet Wale and Geert Walenkamp for valuable comments and guidance during this review.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2013-09-03 16:51:07 +0100" MODIFIED_BY="[Empty name]">
<P>Lucieni O Conterno - none known<BR/>Marilia D Turchi - none known<BR/>
</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2013-09-03 16:51:38 +0100" MODIFIED_BY="[Empty name]">
<P>Prof Lucieni Oliveira Conterno screened studies for inclusion, performed data extraction and analyses, interpreted results and wrote the review. Prof Conterno is the guarantor of the review.<BR/>
</P>
<P>Prof Marilia Dalva Turchi screened studies for inclusion, performed data extraction and analyses, interpreted results and wrote the review update.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2013-09-03 12:28:14 +0100" MODIFIED_BY="Lindsey Elstub">
<OL>
<LI>In line with Collaboration recommendations, we assessed the risk of bias in included studies.</LI>
<LI>We have made several amendments to the types of outcome measures since the protocol was published.</LI>
<OL>
<LI>We clarified that treatment failure also includes early termination of treatment, such as for adverse effects or disease complications such as amputation.</LI>
<LI>We added superinfection as a secondary outcome.</LI>
<LI>We removed squamous cell carcinoma as a potential adverse event of treatment.</LI>
<LI>We deleted length of hospital stay and cost from 'Adverse events' and placed them under 'Resource use'.</LI>
</OL>
</OL>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2013-09-06 11:16:23 +0100" MODIFIED_BY="Lindsey Elstub">
<STUDIES MODIFIED="2013-09-06 11:14:33 +0100" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2013-09-06 11:11:14 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Euba-2009" MODIFIED="2013-09-06 11:11:14 +0100" MODIFIED_BY="[Empty name]" NAME="Euba 2009" YEAR="2009">
<REFERENCE MODIFIED="2013-09-03 16:53:16 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Cardenal JA</AU>
<TI>Oral rifampin-cotrimoxazole combination versus intravenous cloxacillin in chronic staphylococcal osteomyelitis: a long-term follow-up trial</TI>
<SO>http://isrctn.org/ISRCTN27058472 (accessed 20 April 2013)</SO>
<YR>2008</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-09-06 11:11:14 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;table cols=&quot;0&quot; rows=&quot;0&quot;&gt;&lt;tr&gt;&lt;td&gt;&lt;p&gt;Long-term&lt;/p&gt;&lt;p&gt;follow-up&lt;/p&gt;&lt;p&gt;trial&lt;/p&gt;&lt;p&gt;of&lt;/p&gt;&lt;p&gt;oral&lt;/p&gt;&lt;p&gt;rifampin-cotrimoxazole&lt;/p&gt;&lt;p&gt;combination&lt;/p&gt;&lt;p&gt;versus&lt;/p&gt;&lt;p&gt;intravenous cloxacillin in treatment of chronic Staphylococcal osteomyelitis.&lt;/p&gt;&lt;p&gt;Euba G., Murillo O., Fernandez-Sabe N., Mascaro J., Cabo J., Perez A., Tubau F., Verdaguer R., Gudiol F., Ariza J. EmbaseAntimicrobial Agents and Chemotherapy. 53 (6) (pp 2672-2676), 2009. Date of Publication: June 2009. [Journal: Article]&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" NOTES_MODIFIED="2013-09-06 11:11:14 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Euba G, Murillo O, Fernandez-Sabé N, Mascaró J, Cabo J, Perez A et al</AU>
<TI>Long-term follow-up trial of oral rifampin-cotrimoxazole combination versus intravenous cloxacillin in treatment of chronic staphylococcal osteomyelitis</TI>
<SO>Antimicrobial Agents and Chemotherapy</SO>
<YR>2009</YR>
<VL>53</VL>
<NO>6</NO>
<PG>2672-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-08-29 13:07:21 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-08-29 13:07:21 +0100" MODIFIED_BY="[Empty name]" TYPE="ISRCTN" VALUE="ISRCTN27058472 "/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gentry-1990" MODIFIED="2013-09-03 16:53:09 +0100" MODIFIED_BY="[Empty name]" NAME="Gentry 1990" YEAR="1990">
<REFERENCE MODIFIED="2013-09-03 16:53:09 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Gentry LO. Rodriguez GG. Oral ciprofloxacin compared with parenteral antibiotics in the treatment of osteomyelitis. [Clinical Trial. Journal Article. Randomized Controlled Trial] Antimicrobial Agents &amp;amp; Chemotherapy. 34(1):40-3, 1990 Jan. &lt;br&gt;UI: 2183710&lt;/p&gt;" NOTES_MODIFIED="2013-09-03 16:53:09 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gentry LO, Rodriguez GG</AU>
<TI>Oral ciprofloxacin compared with parenteral antibiotics in the treatment of osteomyelitis</TI>
<SO>Antimicrobial Agents and Chemotherapy</SO>
<YR>1990</YR>
<VL>34</VL>
<NO>1</NO>
<PG>40-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gentry-1991" MODIFIED="2013-08-29 13:09:21 +0100" MODIFIED_BY="[Empty name]" NAME="Gentry 1991" YEAR="1991">
<REFERENCE MODIFIED="2013-08-29 13:09:21 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Gentry LO, Rodriguez-Gomez G. Related Articles, Links &lt;br&gt; Ofloxacin versus parenteral therapy for chronic osteomyelitis.&lt;br&gt;Antimicrob Agents Chemother. 1991 Mar;35(3):538-41. JE&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2013-08-29 13:09:21 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gentry LO, Rodriguez-Gomez G</AU>
<TI>Ofloxacin versus parenteral therapy for chronic osteomyelitis</TI>
<SO>Antimicrobial Agents and Chemotherapy</SO>
<YR>1991</YR>
<VL>35</VL>
<NO>3</NO>
<PG>538-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gomis-1999" MODIFIED="2009-02-13 14:07:16 +0000" MODIFIED_BY="[Empty name]" NAME="Gomis 1999" YEAR="1999">
<REFERENCE MODIFIED="2009-02-13 14:07:16 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Gomis M, Barberan J, Sanchez B, Khorrami S, Borja J, Garcia BJ. Oral ofloxacin versus parenteral imipenem-cilastatin in the treatment of osteomyelitis. Revista Espanola de Quimioterapia 1999; 12(3):244-249.&lt;/p&gt;" NOTES_MODIFIED="2009-02-13 14:07:16 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gomis M, Barberan J, Sanchez B, Khorrami S, Borja J, Garcia BJ</AU>
<TI>Oral ofloxacin versus parenteral imipenem-cilastatin in the treatment of osteomyelitis</TI>
<TO>Ofloxacino oral versus imipenem-cilastatina intravenoso en el tratamiento de la osteomielitis</TO>
<SO>Revista Espanola de Quimioterapia</SO>
<YR>1999</YR>
<VL>12</VL>
<NO>3</NO>
<PG>244-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Greenberg-2000" MODIFIED="2013-09-03 16:53:22 +0100" MODIFIED_BY="[Empty name]" NAME="Greenberg 2000" YEAR="2000">
<REFERENCE MODIFIED="2013-09-03 16:53:22 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Greenberg RN, Newman MT, Shariaty S, Pectol RW. Ciprofloxacin, lomefloxacin, or levofloxacin as treatment for chronic osteomyelitis. Antimicrobial Agents &amp;amp; Chemotherapy 2000; 44(1):164-166.&lt;/p&gt;" NOTES_MODIFIED="2013-09-03 16:53:22 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Greenberg RN, Newman MT, Shariaty S, Pectol RW</AU>
<TI>Ciprofloxacin, lomefloxacin, or levofloxacin as treatment for chronic osteomyelitis</TI>
<SO>Antimicrobial Agents and Chemotherapy</SO>
<YR>2000</YR>
<VL>44</VL>
<NO>1</NO>
<PG>164-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mader-1990" MODIFIED="2013-08-29 13:10:36 +0100" MODIFIED_BY="[Empty name]" NAME="Mader 1990" YEAR="1990">
<REFERENCE MODIFIED="2013-08-29 13:10:36 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mader JT, Cantrell JS, Calhoun J</AU>
<TI>Oral ciprofloxacin compared with standard parenteral antibiotic therapy for chronic osteomyelitis in adults</TI>
<SO>Journal of Bone Joint Surgery - American Volume</SO>
<YR>1990</YR>
<VL>72</VL>
<NO>1</NO>
<PG>104-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Norden-1986" MODIFIED="2013-09-03 16:53:29 +0100" MODIFIED_BY="[Empty name]" NAME="Norden 1986" YEAR="1986">
<REFERENCE NOTES="&lt;p&gt;Norden CW, Bryant R, Palmer D, Montgomerie JZ, Wheat J. Chronic osteomyelitis caused by Staphylococcus aureus: controlled clinical trial of nafcillin therapy and nafcillin-rifampin therapy. Southern Medical Journal 1986; 79(8):947-951.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Norden CW, Bryant R, Palmer D, Montgomerie JZ, Wheat J</AU>
<TI>Chronic osteomyelitis caused by Staphylococcus aureus: controlled clinical trial of nafcillin therapy and nafcillin-rifampin therapy</TI>
<SO>Southern Medical Journal</SO>
<YR>1986</YR>
<VL>79</VL>
<NO>8</NO>
<PG>947-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-09-03 16:53:29 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Norden CW. Fierer J. Bryant RE. Chronic staphylococcal osteomyelitis: treatment with regimens containing rifampin. [Clinical Trial. Journal Article. Randomized Controlled Trial] Reviews of Infectious Diseases. 5 Suppl 3:S495-501, 1983 Jul-Aug. JE&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2013-09-03 16:53:29 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Norden CW, Fierer J, Bryant RE</AU>
<TI>Chronic Staphylococcus osteomyelitis: treatment with regimens containing rifampin</TI>
<SO>Reviews of Infectious Diseases</SO>
<YR>1983</YR>
<VL>5</VL>
<NO>Suppl 3</NO>
<PG>S495-501</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sheftel-1986" MODIFIED="2013-09-03 16:53:36 +0100" MODIFIED_BY="[Empty name]" NAME="Sheftel 1986" YEAR="1986">
<REFERENCE MODIFIED="2013-09-03 16:53:36 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Sheftel TG. Mader JT. Randomized evaluation of ceftazidime or ticarcillin and tobramycin for the treatment of osteomyelitis caused by gram-negative bacilli. [Clinical Trial. Journal Article. Randomized Controlled Trial] Antimicrobial Agents &amp;amp; Chemotherapy. 29(1):112-5, 1986 Jan. &lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2013-09-03 16:53:36 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sheftel TG, Mader JT</AU>
<TI>Randomized evaluation of ceftazidime or ticarcillin and tobramycin for the treatment of osteomyelitis caused by gram-negative bacilli</TI>
<SO>Antimicrobial Agents and Chemotherapy</SO>
<YR>1986</YR>
<VL>29</VL>
<NO>1</NO>
<PG>112-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2013-09-06 11:14:33 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Baumgartner-1983" MODIFIED="2013-09-03 16:53:42 +0100" MODIFIED_BY="[Empty name]" NAME="Baumgartner 1983" YEAR="1983">
<REFERENCE MODIFIED="2013-09-03 16:53:42 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Baumgartner JD. Glauser MP. Comparative study of imipenem in severe infections. [Clinical Trial. Journal Article. Randomized Controlled Trial] Journal of Antimicrobial Chemotherapy. 12 Suppl D:141-8, 1983 Dec. JE&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2013-09-03 16:53:42 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Baumgartner JD, Glauser MP</AU>
<TI>Comparative study of imipenem in severe infections</TI>
<SO>Journal of Antimicrobial Chemotherapy</SO>
<YR>1983</YR>
<VL>12</VL>
<NO>Suppl D</NO>
<PG>141-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Giamarellou-1989" MODIFIED="2013-09-03 16:53:47 +0100" MODIFIED_BY="[Empty name]" NAME="Giamarellou 1989" YEAR="1989">
<REFERENCE MODIFIED="2013-09-03 16:53:47 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Giamarellou H, Perdikaris G, Galanakis N, Davoulos G, Mandragos K, Sfikakis P. Pefloxacin versus ceftazidime in the treatment of a variety of gram-negative-bacterial infections. Antimicrobial Agents &amp;amp; Chemotherapy 1989; 33(8):1362-1367.&lt;/p&gt;" NOTES_MODIFIED="2013-09-03 16:53:47 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Giamarellou H, Perdikaris G, Galanakis N, Davoulos G, Mandragos K, Sfikakis P</AU>
<TI>Pefloxacin versus ceftazidime in the treatment of a variety of gram-negative-bacterial infections</TI>
<SO>Antimicrobial Agents and Chemotherapy</SO>
<YR>1989</YR>
<VL>33</VL>
<NO>8</NO>
<PG>1362-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Greenberg-1987" MODIFIED="2013-09-06 11:11:55 +0100" MODIFIED_BY="[Empty name]" NAME="Greenberg 1987" YEAR="1987">
<REFERENCE MODIFIED="2013-09-06 11:11:55 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Greenberg RN. Tice AD. Marsh PK. Craven PC. Reilly PM. Bollinger M. Weinandt WJ. Randomized trial of ciprofloxacin compared with other antimicrobial therapy in the treatment of osteomyelitis. [Clinical Trial. Journal Article. Randomized Controlled Trial] American Journal of Medicine. 82(4A):266-9, 1987 Apr 27. JE&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2013-09-06 11:11:55 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Greenberg RN, Tice AD, Marsh PK, Craven PC, Reilly PM, Bollinger M et al</AU>
<TI>Randomized trial of ciprofloxacin compared with other antimicrobial therapy in the treatment of osteomyelitis</TI>
<SO>American Journal of Medicine</SO>
<YR>1987</YR>
<VL>82</VL>
<NO>4A</NO>
<PG>266-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hedstrom-1975" NAME="Hedstrom 1975" YEAR="1975">
<REFERENCE NOTES="&lt;p&gt;Hedstrom SA. Treatment of chronic staphylococcal osteomyelitis with cloxacillin and dicloxacillin--a comparative study in 12 patients. Scandinavian Journal of Infectious Diseases 1975; 7(1):55-57.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hedstrom SA</AU>
<TI>Treatment of chronic staphylococcal osteomyelitis with cloxacillin and dicloxacillin - a comparative study in 12 patients</TI>
<SO>Scandinavian Journal of Infectious Diseases</SO>
<YR>1975</YR>
<VL>7</VL>
<NO>1</NO>
<PG>55-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ingianni-2007" MODIFIED="2012-10-08 15:31:53 +0100" MODIFIED_BY="[Empty name]" NAME="Ingianni 2007" YEAR="2007">
<REFERENCE MODIFIED="2012-10-08 15:31:53 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;table cols=&quot;0&quot; rows=&quot;0&quot;&gt;&lt;tr&gt;&lt;td&gt;&lt;p&gt;Standard&lt;/p&gt;&lt;p&gt;versus&lt;/p&gt;&lt;p&gt;specific&lt;/p&gt;&lt;p&gt;therapy&lt;/p&gt;&lt;p&gt;for&lt;/p&gt;&lt;p&gt;chronic&lt;/p&gt;&lt;p&gt;osteomyelitis&lt;/p&gt;&lt;p&gt;treatment&lt;/p&gt;&lt;p&gt;.&lt;/p&gt;&lt;p&gt;Ingianni A., Lampis G., Laconi S., Cariello D., Pompei R. EmbaseAmerican Journal of Infectious Diseases. 3 (3) (pp 128-133), 2007. Date of Publication: 2007. [Journal: Article] AN: 2009474923&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" NOTES_MODIFIED="2012-10-08 15:31:53 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ingianni A, Lampis G, Laconi S, Cariello D, Pompei R</AU>
<TI>Standard versus specific therapy for chronic osteomyelitis treatment</TI>
<SO>American Journal of Infectious Diseases</SO>
<YR>2007</YR>
<VL>3</VL>
<NO>3</NO>
<PG>128-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Loffler-1986" MODIFIED="2013-09-03 16:53:52 +0100" MODIFIED_BY="[Empty name]" NAME="Loffler 1986" YEAR="1986">
<REFERENCE MODIFIED="2013-09-03 16:53:52 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Loffler L, Bauernfeind A, Keyl W, Hoffstedt B, Piergies A, Lenz W. An open, comparative study of sulbactam plus ampicillin vs. cefotaxime as initial therapy for serious soft tissue and bone and joint infections. Reviews of Infectious Diseases 1986; 8 Suppl 5:S593-S598.&lt;/p&gt;" NOTES_MODIFIED="2013-09-03 16:53:52 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Loffler L, Bauernfeind A, Keyl W, Hoffstedt B, Piergies A, Lenz W</AU>
<TI>An open, comparative study of sulbactam plus ampicillin vs. cefotaxime as initial therapy for serious soft tissue and bone and joint infections</TI>
<SO>Reviews of Infectious Diseases</SO>
<YR>1986</YR>
<VL>8</VL>
<NO>Suppl 5</NO>
<PG>S593-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Loffler L, Bauernfeind A, Keyl W. Sulbactam/ampicillin versus cefotaxime as initial therapy in serious soft tissue, joint and bone infections. Drugs 1988;35 Suppl 7:46-52.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Loffler L, Bauernfeind A, Keyl W</AU>
<TI>Sulbactam/ampicillin versus cefotaxime as initial therapy in serious soft tissue, joint and bone infections</TI>
<SO>Drugs</SO>
<YR>1988</YR>
<VL>35</VL>
<NO>Suppl 7</NO>
<PG>46-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mandell-1989" MODIFIED="2013-09-03 16:54:09 +0100" MODIFIED_BY="[Empty name]" NAME="Mandell 1989" YEAR="1989">
<REFERENCE MODIFIED="2013-09-03 16:54:09 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Mandell LA. Bergeron MG. Ronald AR. Vega C. Harding G. Saginur R. Feld R. Duperval R. Landis SJ. Miedzinski LJ. et al. Once-daily therapy with ceftriaxone compared with daily multiple-dose therapy with cefotaxime for serious bacterial infections: a randomized, double-blind study. [Clinical Trial. Journal Article. Multicenter Study. Randomized Controlled Trial] Journal of Infectious Diseases. 160(3):433-41, 1989 Sep. JE&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2013-09-03 16:54:09 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mandell LA, Bergeron MG, Ronald AR, Vega C, Harding G, Saginur R, et al</AU>
<TI>Once-day therapy with ceftriaxone compared with daily multiple-dose therapy with cefotaxime for serious bacterial infections: a randomised, double-blind study</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>1989</YR>
<VL>160</VL>
<NO>3</NO>
<PG>433-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Marier-1983" MODIFIED="2013-09-03 16:54:04 +0100" MODIFIED_BY="[Empty name]" NAME="Marier 1983" YEAR="1983">
<REFERENCE MODIFIED="2013-09-03 16:54:04 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Marier RL. McCloskey RV. Dickenson G. Sanders CV. Aldridge KE. Hoffman T. Gutterman D. Janney A. Comparative clinical trial of imipenem-cilastatin (N-formimidoyl-thienamycin-dehydropeptidase inhibitor) and cefazolin. [Clinical Trial. Journal Article. Randomized Controlled Trial] Journal of Antimicrobial Chemotherapy. 12 Suppl D:133-9, 1983 JE&lt;/p&gt;" NOTES_MODIFIED="2013-09-03 16:54:04 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Marier RL, McCloskey RV, Dickenson G, Sanders CV, Aldridge KE, Hoffman T, et al</AU>
<TI>Comparative clinical trial of imipenem-cilastatin (N-formimidoyl-thienamycin-dehydropeptidase inhibitor) and cefazolin</TI>
<SO>Journal of Antimicrobial Chemotherapy</SO>
<YR>1983</YR>
<VL>12</VL>
<NO>Suppl D</NO>
<PG>133-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Marriott-2008" MODIFIED="2012-10-08 15:33:29 +0100" MODIFIED_BY="[Empty name]" NAME="Marriott 2008" YEAR="2008">
<REFERENCE MODIFIED="2012-10-08 15:33:12 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;table cols=&quot;0&quot; rows=&quot;0&quot;&gt;&lt;tr&gt;&lt;td&gt;&lt;p&gt;ssful&lt;/p&gt;&lt;p&gt;truncated&lt;/p&gt;&lt;p&gt;osteomyelitis&lt;/p&gt;&lt;p&gt;treatment&lt;/p&gt;&lt;p&gt;for&lt;/p&gt;&lt;p&gt;chronic&lt;/p&gt;&lt;p&gt;osteomyelitis&lt;/p&gt;&lt;p&gt;secondary&lt;/p&gt;&lt;p&gt;to&lt;/p&gt;&lt;p&gt;pressure&lt;/p&gt;&lt;p&gt;ulcers&lt;/p&gt;&lt;p&gt;in&lt;/p&gt;&lt;p&gt;spinal&lt;/p&gt;&lt;p&gt;cord&lt;/p&gt;&lt;p&gt;injury&lt;/p&gt;&lt;p&gt;patients&lt;/p&gt;&lt;p&gt;.&lt;/p&gt;&lt;p&gt;Marriott R. Rubayi S. Ovid MEDLINE(R)Annals of Plastic Surgery. 61(4):425-9, 2008 Oct. [Journal Article] UI: 18812715&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" NOTES_MODIFIED="2012-10-08 15:33:12 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Marriott R, Rubayi S</AU>
<TI>Successful truncated osteomyelitis treatment for chronic osteomyelitis secondary to pressure ulcers in spinal cord injury patients</TI>
<SO>Annals of Plastic Surgery</SO>
<YR>2008</YR>
<VL>61</VL>
<NO>4</NO>
<PG>425-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nguyen--2009" MODIFIED="2013-09-03 16:53:58 +0100" MODIFIED_BY="[Empty name]" NAME="Nguyen  2009" YEAR="2009">
<REFERENCE MODIFIED="2013-09-03 16:53:58 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nguyen S, Pasquet A, Legout L, Beltrand E, Dubreuil L, Migaud H, et al</AU>
<TI>Efficacy and tolerance of rifampicin&#8211;linezolid compared with rifampicin&#8211;cotrimoxazole combinations in prolonged oral therapy for bone and joint infections</TI>
<SO>Clinical Microbiology and Infection</SO>
<YR>2009</YR>
<VL>15</VL>
<NO>12</NO>
<PG>1163-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-07-12 14:00:26 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Paladino-1991" MODIFIED="2013-08-29 13:17:43 +0100" MODIFIED_BY="[Empty name]" NAME="Paladino 1991" YEAR="1991">
<REFERENCE MODIFIED="2013-08-29 13:17:43 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Paladino JA. Sperry HE. Backes JM. Gelber JA. Serrianne DJ. Cumbo TJ. Schentag JJ. Clinical and economic evaluation of oral ciprofloxacin after an abbreviated course of intravenous antibiotics. [Clinical Trial. Journal Article. Randomized Controlled Trial] American Journal of Medicine. 91(5):462-70, 1991&lt;/p&gt;" NOTES_MODIFIED="2013-08-29 13:17:43 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Paladino JA, Sperry HE, Backes JM, Gelber JA, Serrianne,DJ, Cumbo TJ, et al</AU>
<TI>Clinical and economic evaluation of oral ciprofloxacin after an abbreviated course of intravenous antibiotics</TI>
<SO>American Journal of Medicine</SO>
<YR>1991</YR>
<VL>91</VL>
<NO>5</NO>
<PG>462-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Peacock-1989" MODIFIED="2013-09-06 11:14:33 +0100" MODIFIED_BY="[Empty name]" NAME="Peacock 1989" YEAR="30">
<REFERENCE MODIFIED="2013-09-06 11:14:33 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Peacock, JE. Pegram, PS. Weber, SF. Leone, PA. Prospective, randomized comparison of sequential intravenous followed by oral ciprofloxacin with intravenous ceftazidime in the treatment of serious infections. [Journal article] American Journal of Medicine. 87(Nov 30 Suppl): p 185S-190S. 1989. &lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2013-09-06 11:14:33 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Peacock JE Jr, Pegram PS, Weber SF, Leone PA</AU>
<TI>Prospective, randomised comparison of sequential intravenous followed by oral ciprofloxacin with intravenous ceftazidime in the treatment of serious infections</TI>
<SO>American Journal of Medicine</SO>
<YR>1989</YR>
<VL>87</VL>
<NO>5A</NO>
<PG>185S-90S</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Reinhardt-1986" MODIFIED="2013-08-29 13:19:00 +0100" MODIFIED_BY="[Empty name]" NAME="Reinhardt 1986" YEAR="1986">
<REFERENCE MODIFIED="2013-08-29 13:19:00 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Reinhardt JF. Johnston L. Ruane P. Johnson CC. Ingram-drake L. MacDonald K. Ward KW. Mathisen G. George WL. Finegold SM. et al. A randomized, double-blind comparison of sulbactam/ampicillin and clindamycin for the treatment of aerobic and aerobic-anaerobic infections. [Clinical Trial. Journal Article. Randomized Controlled Trial] Reviews of Infectious Diseases. 8 Suppl 5:S569-75, 1986 Nov-Dec&lt;/p&gt;" NOTES_MODIFIED="2013-08-29 13:19:00 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Reinhardt JF, Jonnston L, Ruane P, Johnson CC, Ingram-drake L, MacDonald K, et al</AU>
<TI>A randomised, double-blind comparison of sulbactam/ampicillin and clindamycin for the treatment of aerobic and aerobic-anaerobic infections</TI>
<SO>Reviews of Infectious Diseases</SO>
<YR>1986</YR>
<VL>8</VL>
<NO>Suppl 5</NO>
<PG>S569-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Siebert-1985" NAME="Siebert 1985" YEAR="1985">
<REFERENCE NOTES="&lt;p&gt;Siebert WT, Kopp PE. Ticarcillin plus clavulanic acid versus moxalactam therapy of osteomyelitis, septic arthritis, and skin and soft tissue infections. American Journal of Medicine 1985; 79(5B):141-145.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Siebert WT, Kopp PE</AU>
<TI>Ticarcillin plus clavulanic acid versus moxalactam therapy of osteomyelitis, septic arthritis, and skin and soft tissue infections</TI>
<SO>American Journal of Medicine</SO>
<YR>1985</YR>
<VL>79</VL>
<NO>5B</NO>
<PG>141-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tascini-2009" MODIFIED="2012-11-18 15:23:23 +0000" MODIFIED_BY="[Empty name]" NAME="Tascini 2009" YEAR="2009">
<REFERENCE MODIFIED="2012-11-18 15:20:53 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;table cols=&quot;0&quot; rows=&quot;0&quot;&gt;&lt;tr&gt;&lt;td&gt;&lt;p&gt;Three-times&lt;/p&gt;&lt;p&gt;weekly&lt;/p&gt;&lt;p&gt;teicoplanin&lt;/p&gt;&lt;p&gt;as&lt;/p&gt;&lt;p&gt;outpatient&lt;/p&gt;&lt;p&gt;treatment&lt;/p&gt;&lt;p&gt;of&lt;/p&gt;&lt;p&gt;chronic&lt;/p&gt;&lt;p&gt;osteoarticular&lt;/p&gt;&lt;p&gt;infections&lt;/p&gt;&lt;p&gt;.&lt;/p&gt;&lt;p&gt;Tascini C. Tagliaferri E. Di Paolo A. Ciofi L. Del Tacca M. Lambelet P. Menichetti F. Ovid MEDLINE(R)Journal of Chemotherapy. 21(4):421-5, 2009 Aug. [Journal Article] UI: 19622461&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" NOTES_MODIFIED="2012-11-18 15:20:53 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tascini C, Tagliaferri E, Di Paolo A, Del Tacca M, Lambelet P, Menichetti F</AU>
<TI>Three-times weekly teicoplanin as outpatient treatment of chronic osteoarticular infections</TI>
<SO>Journal of Chemotherapy</SO>
<YR>2009</YR>
<VL>21</VL>
<NO>4</NO>
<PG>421-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2013-09-03 16:54:40 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Barber_x00e1_n-2000" MODIFIED="2013-09-03 16:54:40 +0100" MODIFIED_BY="[Empty name]" NAME="Barberán 2000" YEAR="2000">
<REFERENCE MODIFIED="2013-09-03 16:54:40 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Barberán J, Gomis M, Sánchez B, Hernández-Salván J, García Del Salto L, Carroquino G, et al</AU>
<TI>Cefepime in the treatment of osteomyelitis caused by Gram negative bacilli</TI>
<TO>Cefepima en el tratamiento de la osteomielitis por bacilos gramnegativos</TO>
<SO>Revista Espanola de Quimioterapia</SO>
<YR>2000</YR>
<VL>13</VL>
<NO>4</NO>
<PG>366-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES MODIFIED="2013-09-03 16:54:34 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-CTRI_x002f_2008_x002f_091_x002f_000060" MODIFIED="2013-09-03 16:54:34 +0100" MODIFIED_BY="[Empty name]" NAME="CTRI/2008/091/000060" YEAR="2008">
<REFERENCE MODIFIED="2013-09-03 16:54:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Saraf N, Mudgai M</AU>
<TI>A clinical trial to study the safety and efficacy of combination drugs, vancomycin and ceftriaxone compared to vancomycin in mild to severe bacterial infections</TI>
<SO>http://ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=100&amp;EncHid=&amp;userName=ceftriaxone (accessed 12 August 2013)</SO>
<YR>2008</YR>
<IDENTIFIERS MODIFIED="2012-10-08 15:48:09 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-10-08 15:48:05 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-10-08 15:48:05 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="CRTI/2008/091/000060"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-EUCTR2009_x002d_015744_x002d_42_x002d_GB" MODIFIED="2013-09-03 16:54:29 +0100" MODIFIED_BY="[Empty name]" NAME="EUCTR2009-015744-42-GB" YEAR="2009">
<REFERENCE MODIFIED="2013-09-03 16:54:29 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Oxford Radcliffe Hospital Trust (sponsor)</AU>
<TI>Randomised open label study of oral versus intravenous antibiotic treatment for bone and joint infections requiring prolonged antibiotic treatment</TI>
<SO>http://apps.who.int/trialsearch/Trial.aspx?TrialID=EUCTR2009-015744-42-GB (accessed 20 April 2013)</SO>
<YR>2009</YR>
<IDENTIFIERS MODIFIED="2013-04-20 22:24:10 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-04-20 22:24:10 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="EUCTR2009-015744-42-GB"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-10-08 15:48:30 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-10-08 15:48:30 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="EUCTR2009-015744-42-GB"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00324922" MODIFIED="2013-09-03 16:54:24 +0100" MODIFIED_BY="[Empty name]" NAME="NCT00324922" YEAR="2006">
<REFERENCE MODIFIED="2013-09-03 16:54:24 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Ramers C, Taistman L, Harrington R, Chan J, Henley BM, Hawn TR, et al</AU>
<TI>A prospective randomised trial comparing vancomycin with trimethoprim/sulphamethoxazole for the treatment of MRSA osteomyelitis</TI>
<SO>http://clinicaltrials.gov/show/NCT00324922 (accessed 20 April 2013)</SO>
<YR>2006</YR>
<IDENTIFIERS MODIFIED="2013-04-20 22:50:20 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-04-20 22:50:36 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-04-20 22:50:36 +0100" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT00324922"/>
</IDENTIFIERS>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2013-09-06 11:16:23 +0100" MODIFIED_BY="Lindsey Elstub">
<ADDITIONAL_REFERENCES MODIFIED="2013-09-06 11:16:23 +0100" MODIFIED_BY="Lindsey Elstub">
<REFERENCE ID="REF-Bourguignat-1996" NAME="Bourguignat 1996" NOTES="&lt;p&gt;Bourguignat A. Ferard G. Jenny JY. Gaudias J. Kempf I. Diagnostic value of C-reactive protein and transthyretin in bone infections of the lower limb. [Case Reports. Journal Article] Clinica Chimica Acta. 255(1):27-38, 1996&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Bourguignat A, Ferard G, Jenny JY, Gaudias J, Kempf I</AU>
<TI>Diagnostic value of C-reactive protein and transthyretin in bone infections of lower limb</TI>
<SO>Clinica Chimica Acta</SO>
<YR>1996</YR>
<VL>255</VL>
<NO>1</NO>
<PG>27-38</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Carek-2001" NAME="Carek 2001" NOTES="&lt;p&gt;Carek PJ. Dickerson LM. Sack JL. Diagnosis and management of osteomyelitis.[erratum appears in Am Fam Physician 2002 May 1;65(9):1751]. [Review] [34 refs] [Journal Article. Review. Review, Tutorial] American Family Physician. 63(12):2413-20, 2001 Jun 15. &lt;br&gt;&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Carek PJ, Dickerson LM, Sack JL</AU>
<TI>Diagnosis and management of osteomyelitis</TI>
<SO>American Family Physician</SO>
<YR>2001</YR>
<VL>63</VL>
<NO>12</NO>
<PG>2413-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ciampolini-2000" NAME="Ciampolini 2000" NOTES="&lt;p&gt;Ciampolini J. Harding KG. Pathophysiology of chronic bacterial osteomyelitis. Why do antibiotics fail so often?. [Review] [54 refs] [Journal Article. Review. Review, Tutorial] Postgraduate Medical Journal. 76(898):479-83, 2000 Aug.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Ciampolini J, Harding KG</AU>
<TI>Pathophysiology of chronic bacterial osteomyelitis. Why do antibiotics fail so often?</TI>
<SO>Postgraduate Medical Journal</SO>
<YR>2000</YR>
<VL>76</VL>
<NO>898</NO>
<PG>479-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cierny-1985" MODIFIED="2013-08-29 14:19:16 +0100" MODIFIED_BY="[Empty name]" NAME="Cierny 1985" NOTES="&lt;table cols=&quot;0&quot; rows=&quot;0&quot;&gt;&lt;tr&gt;&lt;td&gt;&lt;p&gt;1.&lt;/p&gt;&lt;/td&gt;&lt;td&gt;A clinical staging system for adult osteomyelitis. Cierny G 3rd. Mader JT. Penninck JJ. Ovid MEDLINE(R)Clinical Orthopaedics &amp;amp; Related Research. (414):7-24, 2003 Sep. [Biography. Classical Article. Historical Article. Journal Article. Portraits] UI: 12966271&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" NOTES_MODIFIED="2013-08-29 14:19:16 +0100" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Cierny G 3rd, Mader JT, Penninck JJ</AU>
<TI>A clinical staging system for adult osteomyelitis</TI>
<SO>Contemporary Orthopaedics</SO>
<YR>1985</YR>
<VL>10</VL>
<PG>17-37</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cierny-2003" NAME="Cierny 2003" TYPE="JOURNAL_ARTICLE">
<AU>Cierny G 3rd, Mader JT, Penninck JJ</AU>
<TI>A clinical staging system for adult osteomyelitis</TI>
<SO>Clinical Orthopaedic and Related Research</SO>
<YR>2003</YR>
<VL>414</VL>
<PG>7-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cunha-2002" NAME="Cunha 2002" NOTES="&lt;p&gt;Cunha BA. Osteomyelitis in elderly patients. [Journal Article] Clinical Infectious Diseases. 35(3):287-93, 2002 Aug 1. &lt;br&gt;UI: 12115094&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Cunha BA</AU>
<TI>Osteomyelitis in elderly patients</TI>
<SO>Clinical Infectious Diseases</SO>
<YR>2002</YR>
<VL>35</VL>
<NO>3</NO>
<PG>287-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Darouiche-2004" MODIFIED="2012-10-08 15:58:23 +0100" MODIFIED_BY="[Empty name]" NAME="Darouiche 2004" NOTES="&lt;table cols=&quot;0&quot; rows=&quot;0&quot;&gt;&lt;tr&gt;&lt;td&gt;&lt;p&gt;Treatment&lt;/p&gt;&lt;p&gt;of&lt;/p&gt;&lt;p&gt;infections&lt;/p&gt;&lt;p&gt;associated&lt;/p&gt;&lt;p&gt;with&lt;/p&gt;&lt;p&gt;surgical&lt;/p&gt;&lt;p&gt;implants&lt;/p&gt;&lt;p&gt;. [Review] [49 refs]&lt;/p&gt;&lt;p&gt;Darouiche RO. Ovid MEDLINE(R)New England Journal of Medicine. 350(14):1422-9, 2004 Apr 1. [Journal Article. Review] UI: 15070792&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" NOTES_MODIFIED="2012-10-08 15:58:23 +0100" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Darouiche RO</AU>
<TI>Treatment of infections associated with surgical implants</TI>
<SO>New England Journal of Medicine</SO>
<YR>2004</YR>
<VL>350</VL>
<NO>14</NO>
<PG>1422-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Eckardt-1994" MODIFIED="2013-08-29 14:22:40 +0100" MODIFIED_BY="[Empty name]" NAME="Eckardt 1994" NOTES="&lt;p&gt;Eckardt JJ. Wirganowicz PZ. Mar T. An aggressive surgical approach to the management of chronic osteomyelitis. [Journal Article] Clinical Orthopaedics &amp;amp; Related Research. (298):229-39, 1994 Jan. &lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2013-08-29 14:22:40 +0100" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Eckardt JJ, Wirganowicz PZ, Mar T</AU>
<TI>An aggressive surgical approach to the management of chronic osteomyelitis</TI>
<SO>Clinical Orthopaedics and Related Research</SO>
<YR>1994</YR>
<VL>(298)</VL>
<PG>229-39</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ferard-2002" NAME="Ferard 2002" NOTES="&lt;p&gt;Ferard G. Gaudias J. Bourguignat A. Ingenbleek Y. C-reactive protein to transthyretin ratio for the early diagnosis and follow-up of postoperative infection. [Journal Article] Clinical Chemistry &amp;amp; Laboratory Medicine. 40(12):1334-8, 2002 Dec&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Ferard G, Gaudias J, Bourguignat A, Ingenbleek Y</AU>
<TI>C-reactive protein to transthyretin ratio for the early diagnosis and follow-up of postoperative infection</TI>
<SO>Clinical Chemistry and Laboratory Medicine</SO>
<YR>2002</YR>
<VL>40</VL>
<NO>12</NO>
<PG>1334-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gristina-1990" NAME="Gristina 1990" NOTES="&lt;p&gt;Gristina AG. Naylor PT. Myrvik QN. Musculoskeletal infection, microbial adhesion, and antibiotic resistance. [Review] [52 refs] [Journal Article. Review. Review, Tutorial] Infectious Disease Clinics of North America. 4(3):391-408, 1990 Sep. &lt;br&gt;&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Gristina AG, Naylor PT, Myrvik QN</AU>
<TI>Musculoskeletal infection, microbial adhesion, and antibiotic resistance</TI>
<SO>Infectious Disease Clinics of North America</SO>
<YR>1990</YR>
<VL>4</VL>
<NO>3</NO>
<PG>391-408</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Haas-1996" NAME="Haas 1996" NOTES="&lt;p&gt;Haas DW. McAndrew MP. Bacterial osteomyelitis in adults: evolving considerations in diagnosis and treatment. [Review] [117 refs] [Journal Article. Review. Review, Tutorial] American Journal of Medicine. 101(5):550-61, 1996 Nov. &lt;br&gt;&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Haas DW, McAndrew MP</AU>
<TI>Bacterial osteomyelitis in adults: evolving considerations in diagnosis and treatment</TI>
<SO>American Journal of Medicine</SO>
<YR>1996</YR>
<VL>101</VL>
<NO>5</NO>
<PG>550-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Haidar-2010" MODIFIED="2012-10-08 16:01:49 +0100" MODIFIED_BY="[Empty name]" NAME="Haidar 2010" TYPE="JOURNAL_ARTICLE">
<AU>Haidar R, Der Boghossian A, Atiyeh B</AU>
<TI>Duration of post-surgical antibiotics in chronic osteomyelitis: empiric or evidence-based?</TI>
<SO>International Journal of Infectious Diseases</SO>
<YR>2010</YR>
<VL>14</VL>
<NO>9</NO>
<PG>e752-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" NAME="Higgins 2003" NOTES="&lt;p&gt;Higgins JP. Thompson SG. Deeks JJ. Altman DG. Measuring inconsistency in meta-analyses. [Review] [24 refs] [Journal Article. Review] BMJ. 327(7414):557-60, 2003 Sep 6. &lt;br&gt;&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JP, Tompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analyses</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<NO>7414</NO>
<PG>557-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2006" MODIFIED="2013-09-03 16:54:53 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2006" NOTES="&lt;p&gt;Higgins JPT, Green S, editors. Highly sensitive search strategies for identifying reports of randomized controlled trials in MEDLINE. Cochrane Handbook for Systematic Reviews of Interventions 4.2.6 [updated September 2006]; Appendix 5b. www.cochrane.org/resources/handbook/hbook.htm (accessed 01 May 2007).&lt;/p&gt;" NOTES_MODIFIED="2013-09-03 16:54:53 +0100" NOTES_MODIFIED_BY="[Empty name]" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Highly sensitive search strategies for identifying reports of randomised controlled trials in MEDLINE. Cochrane Handbook for Systematic Reviews of Interventions 4.2.6 [updated September 2006]; Appendix 5b</TI>
<SO>www.cochrane.org/resources/handbook/hbook.htm (accessed 01 May 2007)</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2011-08-25 13:23:34 +0100" MODIFIED_BY="Lindsey Elstub" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions</TI>
<SO>Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Holtom-1999" MODIFIED="2009-05-11 16:24:55 +0100" MODIFIED_BY="[Empty name]" NAME="Holtom 1999" NOTES="&lt;p&gt;Holtom PD. Smith AM. Introduction to adult posttraumatic osteomyelitis of the tibia. [Journal Article] Clinical Orthopaedics &amp;amp; Related Research. (360):6-13, 1999&lt;/p&gt;" NOTES_MODIFIED="2009-05-11 16:24:55 +0100" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Holtom PD, Smith AM</AU>
<TI>Introduction to adult posttraumatic osteomyelitis of the tibia</TI>
<SO>Clinical Orthopaedics and Related Research</SO>
<YR>1999</YR>
<VL>(360)</VL>
<PG>6-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Huber-2002" MODIFIED="2013-09-06 11:14:14 +0100" MODIFIED_BY="[Empty name]" NAME="Huber 2002" NOTES="&lt;p&gt;Huber AM. Lam PY. Duffy CM. Yeung RS. Ditchfield M. Laxer D. Cole WG. Kerr Graham H. Allen RC. Laxer RM. Chronic recurrent multifocal osteomyelitis: clinical outcomes after more than five years of follow-up. [Evaluation Studies. Journal Article] Journal of Pediatrics. 141(2):198-203, 2002&lt;/p&gt;" NOTES_MODIFIED="2013-09-06 11:14:14 +0100" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Huber AM, Lam PY, Duffy CM, Yeung RS, Ditchfield M, Laxer D et al</AU>
<TI>Chronic recurrent multifocal osteomyelitis: clinical outcomes after more than five years of follow-up</TI>
<SO>Journal of Pediatrics</SO>
<YR>2002</YR>
<VL>141</VL>
<NO>2</NO>
<PG>198-203</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Johnston-2007" MODIFIED="2012-10-08 16:04:10 +0100" MODIFIED_BY="[Empty name]" NAME="Johnston 2007" NOTES="&lt;table cols=&quot;0&quot; rows=&quot;0&quot;&gt;&lt;tr&gt;&lt;td&gt;&lt;p&gt;Osteomyelitis&lt;/p&gt;&lt;p&gt;management&lt;/p&gt;&lt;p&gt;: More art than science?.&lt;/p&gt;&lt;p&gt;Johnston B.L., Conly J.M. EmbaseCanadian Journal of Infectious Diseases and Medical Microbiology. 18 (2) (pp 115-118), 2007. Date of Publication: March/April 2007.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" NOTES_MODIFIED="2012-10-08 16:04:10 +0100" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Johnston BL, Conly JM</AU>
<TI>Osteomyelitis management: More art than science?</TI>
<SO>Canadian Journal of Infectious Diseases &amp; Medical Microbiology</SO>
<YR>2007</YR>
<VL>18</VL>
<NO>2</NO>
<PG>115-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Karamanis-2008" MODIFIED="2013-09-03 16:54:57 +0100" MODIFIED_BY="[Empty name]" NAME="Karamanis 2008" NOTES="&lt;table cols=&quot;0&quot; rows=&quot;0&quot;&gt;&lt;tr&gt;&lt;td&gt;&lt;p&gt;Fluoroquinolones versus beta-lactam based regimens for the treatment of osteomyelitis: a meta-analysis of randomized controlled trials.&lt;/p&gt;&lt;p&gt;Karamanis EM. Matthaiou DK. Moraitis LI. Falagas ME. Ovid MEDLINE(R)Spine. 33(10):E297-304, 2008 May 1.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" NOTES_MODIFIED="2013-09-03 16:54:57 +0100" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Karamanis EM, Matthaiou DK, Moraitis LI, Falagas ME</AU>
<TI>Fluoroquinolones versus<I> </I>ß-lactam based regimens for the treatment of osteomyelitis: a meta-analysis of randomized controlled trials</TI>
<SO>Spine</SO>
<YR>2008</YR>
<VL>33</VL>
<NO>10</NO>
<PG>e297-e304</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lazarini-2005" NAME="Lazarini 2005" NOTES="&lt;p&gt;Lazzarini L. Lipsky BA. Mader JT. Antibiotic treatment of osteomyelitis: what have we learned from 30 years of clinical trials?. [Review] [107 refs] [Journal Article. Review] International Journal of Infectious Diseases. 9(3):127-38, 2005 May. JE&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Lazzarini L, Lipsky BA, Mader JT</AU>
<TI>Antibiotic treatment of osteomyelitis: what have we learned from 30 years of clinical trials?</TI>
<SO>International Journal of Infectious Diseases</SO>
<YR>2005</YR>
<VL>9</VL>
<NO>3</NO>
<PG>127-38</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lazzarini-2002" NAME="Lazzarini 2002" TYPE="JOURNAL_ARTICLE">
<AU>Lazzarini L, De Lalla F, Mader JT</AU>
<TI>Long bone osteomyelitis</TI>
<SO>Current Infectious Disease Reports</SO>
<YR>2002</YR>
<VL>4</VL>
<NO>5</NO>
<PG>439-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lew-2004" MODIFIED="2012-10-08 16:07:28 +0100" MODIFIED_BY="[Empty name]" NAME="Lew 2004" NOTES="&lt;table cols=&quot;0&quot; rows=&quot;0&quot;&gt;&lt;tr&gt;&lt;td&gt;&lt;p&gt;Osteomyelitis. [Review] [104 refs]&lt;/p&gt;&lt;p&gt;Lew DP&lt;/p&gt;&lt;p&gt;. Waldvogel FA. Ovid MEDLINE(R)Lancet. 364(9431):369-79, 2004 Jul 24-30.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" NOTES_MODIFIED="2012-10-08 16:07:28 +0100" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Lew DP, Waldvogel FA</AU>
<TI>Osteomyelitis</TI>
<SO>Lancet</SO>
<YR>2004</YR>
<VL>364</VL>
<NO>9431</NO>
<PG>369-79</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lipsky-1997" MODIFIED="2012-10-08 16:08:36 +0100" MODIFIED_BY="[Empty name]" NAME="Lipsky 1997" NOTES="&lt;table cols=&quot;0&quot; rows=&quot;0&quot;&gt;&lt;tr&gt;&lt;td&gt;&lt;p&gt;Antibiotic&lt;/p&gt;&lt;p&gt;therapy&lt;/p&gt;&lt;p&gt;for&lt;/p&gt;&lt;p&gt;diabetic&lt;/p&gt;&lt;p&gt;foot&lt;/p&gt;&lt;p&gt;infections&lt;/p&gt;&lt;p&gt;: comparison of two parenteral-to-oral regimens.&lt;/p&gt;&lt;p&gt;Lipsky BA. Baker PD. Landon GC. Fernau R. Ovid MEDLINE(R)Clinical Infectious Diseases. 24(4):643-8, 1997 Apr.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" NOTES_MODIFIED="2012-10-08 16:08:36 +0100" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Lipsky BA, Baker PD, Landon GC, Fernau R</AU>
<TI>Antibiotic therapy for diabetic foot infections: comparison of two parenteral-to-oral regimens</TI>
<SO>Clinical Infectious Diseases</SO>
<YR>1997</YR>
<VL>24</VL>
<NO>4</NO>
<PG>643-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Liu-2011" MODIFIED="2013-09-03 16:55:04 +0100" MODIFIED_BY="[Empty name]" NAME="Liu 2011" NOTES="&lt;table cols=&quot;0&quot; rows=&quot;0&quot;&gt;&lt;tr&gt;&lt;td&gt;&lt;p&gt;Clinical&lt;/p&gt;&lt;p&gt;practice&lt;/p&gt;&lt;p&gt;guidelines&lt;/p&gt;&lt;p&gt;by&lt;/p&gt;&lt;p&gt;the&lt;/p&gt;&lt;p&gt;infectious&lt;/p&gt;&lt;p&gt;diseases&lt;/p&gt;&lt;p&gt;society&lt;/p&gt;&lt;p&gt;of&lt;/p&gt;&lt;p&gt;america&lt;/p&gt;&lt;p&gt;for&lt;/p&gt;&lt;p&gt;the&lt;/p&gt;&lt;p&gt;treatment&lt;/p&gt;&lt;p&gt;of&lt;/p&gt;&lt;p&gt;methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary.&lt;/p&gt;&lt;p&gt;Liu C. Bayer A. Cosgrove SE. Daum RS. Fridkin SK. Gorwitz RJ. Kaplan SL. Karchmer AW. Levine DP. Murray BE. J Rybak M. Talan DA. Chambers HF.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" NOTES_MODIFIED="2013-09-03 16:55:04 +0100" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, et al</AU>
<TI>Clinical practice guidelines by the infectious diseases society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary</TI>
<SO>Clinical Infectious Diseases</SO>
<YR>2011</YR>
<VL>52</VL>
<NO>3</NO>
<PG>285-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mader-1992" NAME="Mader 1992" NOTES="&lt;p&gt;Mader JT. Norden C. Nelson JD. Calandra GB. Evaluation of new anti-infective drugs for the treatment of osteomyelitis in adults. Infectious Diseases Society of America and the Food and Drug Administration. [Guideline. Journal Article. Practice Guideline] Clinical Infectious Diseases. 15 Suppl 1:S155-61, 1992 Nov&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Mader JT, Norden C, Nelson JD, Calandra GB</AU>
<TI>Evaluation of new anti-infective drugs for the treatment of osteomyelitis in adults. Infectious Diseases Society of America and the Food and Drug Administration</TI>
<SO>Clinical Infectious Diseases</SO>
<YR>1992</YR>
<VL>15</VL>
<NO>Suppl 1</NO>
<PG>S155-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mader-1993" MODIFIED="2009-05-11 16:25:35 +0100" MODIFIED_BY="[Empty name]" NAME="Mader 1993" NOTES="&lt;p&gt;Mader JT. Landon GC. Calhoun J. Antimicrobial treatment of osteomyelitis. [Journal Article] Clinical Orthopaedics &amp;amp; Related Research. (295):87-95, 1993 Oct. &lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2009-05-11 16:25:35 +0100" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Mader JT, Landon GC, Calhoun J</AU>
<TI>Antimicrobial treatment of osteomyelitis</TI>
<SO>Clinical Orthopaedics and Related Research</SO>
<YR>1993</YR>
<VL>(295)</VL>
<PG>87-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mader-1997a" NAME="Mader 1997a" NOTES="&lt;p&gt;Mader JT. Shirtliff M. Calhoun JH. Staging and staging application in osteomyelitis. [Review] [51 refs] [Journal Article. Review. Review, Tutorial] Clinical Infectious Diseases. 25(6):1303-9, 1997 Dec. &lt;br&gt;&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Mader JT, Shirtliff M, Calhoun JH</AU>
<TI>Staging and staging application in osteomyelitis</TI>
<SO>Clinical Infectious Diseases</SO>
<YR>1997</YR>
<VL>25</VL>
<NO>6</NO>
<PG>1303-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mader-1999a" MODIFIED="2009-05-11 16:25:16 +0100" MODIFIED_BY="[Empty name]" NAME="Mader 1999a" NOTES="&lt;p&gt;Mader JT. Shirtliff ME. Bergquist SC. Calhoun J. Antimicrobial treatment of chronic osteomyelitis. [Review] [105 refs] [Journal Article. Review] Clinical Orthopaedics &amp;amp; Related Research. (360):47-65, 1999 Mar. &lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2009-05-11 16:25:16 +0100" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Mader JT, Shirtliff ME, Bergquist SC, Calhoun J</AU>
<TI>Antimicrobial treatment of chronic osteomyelitis</TI>
<SO>Clinical Orthopaedics and Related Research</SO>
<YR>1999</YR>
<VL>(360)</VL>
<PG>47-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mader-1999b" MODIFIED="2009-05-11 16:26:14 +0100" MODIFIED_BY="[Empty name]" NAME="Mader 1999b" NOTES="&lt;p&gt;Mader JT. Cripps MW. Calhoun JH. Adult posttraumatic osteomyelitis of the tibia. [Review] [53 refs] [Journal Article. Review] Clinical Orthopaedics &amp;amp; Related Research. (360):14-21, 1999 Mar. &lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2009-05-11 16:26:14 +0100" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Mader JT, Cripps MW, Calhoun JH</AU>
<TI>Adult posttraumatic osteomyelitis of the tibia</TI>
<SO>Clinical Orthopaedics and Related Research</SO>
<YR>1999</YR>
<VL>(360)</VL>
<PG>14-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mader-2001" MODIFIED="2013-09-03 16:55:10 +0100" MODIFIED_BY="[Empty name]" NAME="Mader 2001" NOTES="&lt;p&gt;Mader JT. Wang J. Calhoun JH. Antibiotic therapy for musculoskeletal infections. [Journal: Conference Paper] Journal of Bone &amp;amp; Joint Surgery - American Volume. Vol. 83(12)(pp 1878-1890), 2001. &lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2013-09-03 16:55:10 +0100" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Mader JT, Wang J, Calhoun JH</AU>
<TI>Antibiotic therapy for musculoskeletal infections</TI>
<SO>Journal of Bone and Joint Surgery - American Volume</SO>
<YR>2001</YR>
<VL>83</VL>
<NO>12</NO>
<PG>1878-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Murphy-2011" MODIFIED="2013-09-03 16:55:16 +0100" MODIFIED_BY="[Empty name]" NAME="Murphy 2011" NOTES="&lt;table cols=&quot;0&quot; rows=&quot;0&quot;&gt;&lt;tr&gt;&lt;td&gt;&lt;p&gt;Multidrug-resistant&lt;/p&gt;&lt;p&gt;chronic&lt;/p&gt;&lt;p&gt;osteomyelitis&lt;/p&gt;&lt;p&gt;complicating&lt;/p&gt;&lt;p&gt;war&lt;/p&gt;&lt;p&gt;injury&lt;/p&gt;&lt;p&gt;in&lt;/p&gt;&lt;p&gt;Iraqi&lt;/p&gt;&lt;p&gt;civilians.&lt;/p&gt;&lt;p&gt;Murphy RA. Ronat JB. Fakhri RM. Herard P. Blackwell N. Abgrall S. Anderson DJ. Ovid MEDLINE(R)Journal of Trauma-Injury Infection &amp;amp; Critical Care. 71(1):252-4, 2011 Jul. [Comparative Study. Journal Article] UI: 21818032&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" NOTES_MODIFIED="2013-09-03 16:55:16 +0100" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Murphy RA, Ronat JB, Fakhri RM, Herard P, Blackwell N, Abgrall S, et al</AU>
<TI>Multidrug-resistant chronic osteomyelitis complicating war injury in Iraqi civilians</TI>
<SO>Journal of Trauma-Injury Infection and Critical Care</SO>
<YR>2011</YR>
<VL>71</VL>
<NO>1</NO>
<PG>252-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Parsons-2004" MODIFIED="2012-10-08 16:12:11 +0100" MODIFIED_BY="[Empty name]" NAME="Parsons 2004" NOTES="&lt;table cols=&quot;0&quot; rows=&quot;0&quot;&gt;&lt;tr&gt;&lt;td&gt;&lt;p&gt;Surgical&lt;/p&gt;&lt;p&gt;management&lt;/p&gt;&lt;p&gt;of&lt;/p&gt;&lt;p&gt;chronic&lt;/p&gt;&lt;p&gt;osteomyelitis&lt;/p&gt;&lt;p&gt;. [Review] [60 refs]&lt;/p&gt;&lt;p&gt;Parsons B. Strauss E. Ovid MEDLINE(R)American Journal of Surgery. 188(1A Suppl):57-66, 2004 Jul. [Journal Article. Review]&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" NOTES_MODIFIED="2012-10-08 16:12:11 +0100" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Parson B, Strauss E</AU>
<TI>Surgical management of chronic osteomyelitis</TI>
<SO>American Journal of Surgery</SO>
<YR>2004</YR>
<VL>188</VL>
<NO>1A Suppl</NO>
<PG>57-66</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pollard-2006" MODIFIED="2012-10-08 16:13:22 +0100" MODIFIED_BY="[Empty name]" NAME="Pollard 2006" NOTES="&lt;table cols=&quot;0&quot; rows=&quot;0&quot;&gt;&lt;tr&gt;&lt;td&gt;&lt;p&gt;Deep&lt;/p&gt;&lt;p&gt;wound&lt;/p&gt;&lt;p&gt;infection&lt;/p&gt;&lt;p&gt;after&lt;/p&gt;&lt;p&gt;proximal&lt;/p&gt;&lt;p&gt;femoral&lt;/p&gt;&lt;p&gt;fracture&lt;/p&gt;&lt;p&gt;: consequences and costs.&lt;/p&gt;&lt;p&gt;Pollard TC. Newman JE. Barlow NJ. Price JD. Willett KM. Ovid MEDLINE(R)Journal of Hospital Infection. 63(2):133-9, 2006 Jun. [Journal Article]&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" NOTES_MODIFIED="2012-10-08 16:13:22 +0100" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Pollard TC, Newman JE, Barlow NJ, Price JD, Willett KM</AU>
<TI>Deep wound infection after proximal femoral fracture: consequences and costs</TI>
<SO>Journal of Hospital Infection</SO>
<YR>2006</YR>
<VL>63</VL>
<NO>2</NO>
<PG>133-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Review-Manager-_x0028_RevMan_x0029_" MODIFIED="2013-09-03 16:55:22 +0100" MODIFIED_BY="[Empty name]" NAME="Review Manager (RevMan)" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2012</YR>
<EN>5.2</EN>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rissing-1997" NAME="Rissing 1997" NOTES="&lt;p&gt;Rissing JP. Antimicrobial therapy for chronic osteomyelitis in adults: role of the quinolones. [Review] [53 refs] [Journal Article. Review] Clinical Infectious Diseases. 25(6):1327-33, 1997 Dec. &lt;br&gt;&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Rissing JP</AU>
<TI>Antimicrobial therapy for chronic osteomyelitis in adults: role of the quinolones</TI>
<SO>Clinical Infectious Diseases</SO>
<YR>1997</YR>
<VL>25</VL>
<NO>6</NO>
<PG>1327-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Saginur-2006" MODIFIED="2013-09-03 16:55:29 +0100" MODIFIED_BY="[Empty name]" NAME="Saginur 2006" TYPE="JOURNAL_ARTICLE">
<AU>Saginur R, St Denis M, Ferris W, Aron SD, Chang F, Lee C, et al</AU>
<TI>Multiple combination bactericidal testing of Staphylococcal biofilms from implant-associated infections</TI>
<SO>Antimicrobial Agents and Chemotherapy</SO>
<YR>2006</YR>
<VL>50</VL>
<NO>1</NO>
<PG>55-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Senneville-2006" MODIFIED="2012-10-08 16:14:55 +0100" MODIFIED_BY="[Empty name]" NAME="Senneville 2006" NOTES="&lt;table cols=&quot;0&quot; rows=&quot;0&quot;&gt;&lt;tr&gt;&lt;td&gt;&lt;p&gt;Culture&lt;/p&gt;&lt;p&gt;of&lt;/p&gt;&lt;p&gt;percutaneous&lt;/p&gt;&lt;p&gt;bone&lt;/p&gt;&lt;p&gt;biopsy&lt;/p&gt;&lt;p&gt;specimens&lt;/p&gt;&lt;p&gt;for&lt;/p&gt;&lt;p&gt;diagnosis&lt;/p&gt;&lt;p&gt;of&lt;/p&gt;&lt;p&gt;diabetic&lt;/p&gt;&lt;p&gt;foot&lt;/p&gt;&lt;p&gt;osteomyelitis&lt;/p&gt;&lt;p&gt;: concordance with ulcer swab cultures.&lt;/p&gt;&lt;p&gt;Senneville E. Melliez H. Beltrand E. Legout L. Valette M. Cazaubiel M. Cordonnier M. Caillaux M. Yazdanpanah Y. Mouton Y. Ovid MEDLINE(R)Clinical Infectious Diseases. 42(1):57-62, 2006 Jan 1. [Comparative Study. Journal Article] UI: 16323092&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" NOTES_MODIFIED="2012-10-08 16:14:55 +0100" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Senneville E, Melliez H, Beltrand E, Legout L, Valette M, Cazaubiel M</AU>
<TI>Culture of percutaneous bone biopsy specimens for diagnosis of diabetic foot osteomyelitis: concordance with ulcer swab cultures</TI>
<SO>Clinical of Infectious Diseases</SO>
<YR>2006</YR>
<VL>42</VL>
<NO>1</NO>
<PG>57-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sheehy-2010" MODIFIED="2013-09-06 11:16:23 +0100" MODIFIED_BY="[Empty name]" NAME="Sheehy 2010" TYPE="JOURNAL_ARTICLE">
<AU>Sheehy SH, Atkins BA, Bejon P, Byren I, Wyllie D, Athanasou NA et al</AU>
<TI>The microbiology of chronic osteomyelitis: prevalence of resistance to common empirical anti-microbial regimens</TI>
<SO>Journal of Infection</SO>
<YR>2010</YR>
<VL>60</VL>
<NO>5</NO>
<PG>338-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Simpson-2001" MODIFIED="2013-09-03 16:55:34 +0100" MODIFIED_BY="[Empty name]" NAME="Simpson 2001" NOTES="&lt;table cols=&quot;0&quot; rows=&quot;0&quot;&gt;&lt;tr&gt;&lt;td&gt;&lt;p&gt;Chronic osteomyelitis. The effect of the extent of surgical resection on infection-free survival.&lt;/p&gt;&lt;p&gt;Simpson AH&lt;/p&gt;&lt;p&gt;. Deakin M. Latham JM. Ovid MEDLINE(R) Journal of Bone &amp;amp; Joint Surgery - British Volume. 83(3):403-7, 2001 Apr. [Comparative Study. Journal Article] UI: 11341428&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" NOTES_MODIFIED="2013-09-03 16:55:34 +0100" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Simpson AH, Deakin M, Latham JM</AU>
<TI>Chronic osteomyelitis. The effect of the extent of surgical resection on infection-free survival</TI>
<SO>Journal of Bone and Joint Surgery - British Volume</SO>
<YR>2001</YR>
<VL>83</VL>
<NO>3</NO>
<PG>403-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Spellberg-2012" MODIFIED="2012-10-08 16:17:27 +0100" MODIFIED_BY="[Empty name]" NAME="Spellberg 2012" NOTES="&lt;table cols=&quot;0&quot; rows=&quot;0&quot;&gt;&lt;tr&gt;&lt;td&gt;&lt;p&gt;Systemic&lt;/p&gt;&lt;p&gt;antibiotic&lt;/p&gt;&lt;p&gt;therapy&lt;/p&gt;&lt;p&gt;for&lt;/p&gt;&lt;p&gt;chronic&lt;/p&gt;&lt;p&gt;osteomyelitis&lt;/p&gt;&lt;p&gt;in&lt;/p&gt;&lt;p&gt;adults&lt;/p&gt;&lt;p&gt;. [Review]&lt;/p&gt;&lt;p&gt;Spellberg B. Lipsky BA. Ovid MEDLINE(R)Clinical Infectious Diseases. 54(3):393-407, 2012 Feb 1.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" NOTES_MODIFIED="2012-10-08 16:17:27 +0100" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Spellberg B, Lipsky BA</AU>
<TI>Systemic antibiotic therapy for chronic osteomyelitis in adults</TI>
<SO>Clinical Infectious Diseases</SO>
<YR>2012</YR>
<VL>54</VL>
<NO>3</NO>
<PG>393-407</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stengel-2001" MODIFIED="2013-09-03 16:55:40 +0100" MODIFIED_BY="[Empty name]" NAME="Stengel 2001" NOTES="&lt;p&gt;Stengel D. Bauwens K. Sehouli J. Ekkernkamp A. Porzsolt F. Systematic review and meta-analysis of antibiotic therapy for bone and joint infections.[erratum appears in Lancet Infect Dis 2002 Feb;2(2):125]. [Review] [84 refs] [Journal Article. Review. Review, Tutorial] The Lancet Infectious Diseases. 1(3):175-88, 2001&lt;/p&gt;" NOTES_MODIFIED="2013-09-03 16:55:40 +0100" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Stengel D, Bauwens K, Sehouli J, Ekkernkamp A, Porzsolt F</AU>
<TI>Systematic review and meta-analysis of antibiotic therapy for bone and joint infections</TI>
<SO>Lancet Infectious Diseases</SO>
<YR>2001</YR>
<VL>1</VL>
<NO>3</NO>
<PG>175-88</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Swiontkowski-1999" NAME="Swiontkowski 1999" NOTES="&lt;p&gt;Swiontkowski MF. Hanel DP. Vedder NB. Schwappach JR. A comparison of short- and long-term intravenous antibiotic therapy in the postoperative management of adult osteomyelitis. [Journal Article] Journal of Bone &amp;amp; Joint Surgery - British Volume. 81(6):1046-50, 1999 Nov. &lt;br&gt;&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Swiontkowski MF, Hanel DP, Vedder NB, Schwappach JR</AU>
<TI>A comparison of short- and long-term intravenous antibiotic therapy in the postoperative management of adult osteomyelitis</TI>
<SO>Journal of Bone and Joint Surgery - British Volume</SO>
<YR>1999</YR>
<VL>81</VL>
<NO>6</NO>
<PG>1046-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Trampuz-2006" MODIFIED="2012-10-08 16:18:42 +0100" MODIFIED_BY="[Empty name]" NAME="Trampuz 2006" TYPE="JOURNAL_ARTICLE">
<AU>Trampuz A, Zimmerli W</AU>
<TI>Diagnosis and treatment of infections associated with fracture-fixation devices</TI>
<SO>Injury</SO>
<YR>2006</YR>
<VL>37</VL>
<NO>Suppl 2</NO>
<PG>S59-66</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Waldvogel-1970" NAME="Waldvogel 1970" NOTES="&lt;p&gt;Waldvogel FA. Medoff G. Swartz MN. Treatment of osteomyelitis. [Journal Article] New England Journal of Medicine. 283(15):822, 1970 Oct 8. &lt;br&gt;&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Waldvogel FA, Medoff G, Swartz MN</AU>
<TI>Treatment of osteomyelitis</TI>
<SO>New England Journal of Medicine</SO>
<YR>1970</YR>
<VL>283</VL>
<NO>15</NO>
<PG>822</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Waldvogel-1980" NAME="Waldvogel 1980" NOTES="&lt;p&gt;Waldvogel FA. Papageorgiou PS. Osteomyelitis: the past decade. [Review] [125 refs] [Journal Article. Review] New England Journal of Medicine. 303(7):360-70, 1980 Aug 14. &lt;br&gt;&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Waldvogel FA, Papageorgiou PS</AU>
<TI>Osteomyelitis: the past decade</TI>
<SO>New England Journal of Medicine</SO>
<YR>1980</YR>
<VL>303</VL>
<NO>7</NO>
<PG>360-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Walenkamp-1997" MODIFIED="2009-05-11 15:39:48 +0100" MODIFIED_BY="[Empty name]" NAME="Walenkamp 1997" NOTES="&lt;table cols=&quot;0&quot; rows=&quot;0&quot;&gt;&lt;tr&gt;&lt;td&gt;&lt;p&gt;Chronic&lt;/p&gt;&lt;p&gt;osteomyelitis&lt;/p&gt;&lt;p&gt;.&lt;/p&gt;&lt;p&gt;Walenkamp G.H.I.M. EMBASE Acta Orthopaedica Scandinavica. 68(5)(pp 497-506), 1997. Date of Publication: 1997. [Journal: Article] AN: 1997349639&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" NOTES_MODIFIED="2009-05-11 15:39:48 +0100" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Walenkamp GHIM</AU>
<TI>Chronic osteomyelitis</TI>
<SO>Acta Orthopaedica Scandinavica</SO>
<YR>1997</YR>
<VL>68</VL>
<NO>5</NO>
<PG>497-506</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Walter-2012" MODIFIED="2012-10-08 16:19:17 +0100" MODIFIED_BY="[Empty name]" NAME="Walter 2012" NOTES="&lt;table cols=&quot;0&quot; rows=&quot;0&quot;&gt;&lt;tr&gt;&lt;td&gt;&lt;p&gt;Treatment&lt;/p&gt;&lt;p&gt;algorithms&lt;/p&gt;&lt;p&gt;for&lt;/p&gt;&lt;p&gt;chronic&lt;/p&gt;&lt;p&gt;osteomyelitis&lt;/p&gt;&lt;p&gt;. [Review]&lt;/p&gt;&lt;p&gt;Walter G. Kemmerer M. Kappler C. Hoffmann R. Ovid MEDLINE(R)Deutsches Arzteblatt International. 109(14):257-64, 2012 Apr. [Journal Article. Review]&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" NOTES_MODIFIED="2012-10-08 16:19:17 +0100" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Walter G, Kemmerer M, Kappler C, Hoffmann R</AU>
<TI>Treatment algorithms for chronic osteomyelitis</TI>
<SO>Deutsches Ärzteblatt International</SO>
<YR>2012</YR>
<VL>109</VL>
<NO>14</NO>
<PG>257-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Zuluaga-2002" MODIFIED="2012-10-08 16:20:43 +0100" MODIFIED_BY="[Empty name]" NAME="Zuluaga 2002" TYPE="JOURNAL_ARTICLE">
<AU>Zuluaga AF, Galvis W, Jaimes F, Vesga O</AU>
<TI>Lack of microbiological concordance between bone and non-bone specimens in chronic osteomyelitis: an observational study</TI>
<SO>BMC Infectious Diseases</SO>
<YR>2002</YR>
<VL>2</VL>
<NO>8</NO>
<PG>1-7</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2012-10-08 16:23:55 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Conterno-2009" MODIFIED="2012-10-08 16:23:55 +0100" MODIFIED_BY="[Empty name]" NAME="Conterno 2009" TYPE="COCHRANE_REVIEW">
<AU>Conterno LO, da Silva Filho CR</AU>
<TI>Antibiotics for treating chronic osteomyelitis in adults</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2009</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2012-10-08 16:23:55 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-10-08 16:23:55 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD004439.pub2"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES MODIFIED="2012-10-08 16:22:16 +0100" MODIFIED_BY="[Empty name]"/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2013-09-03 16:53:00 +0100" MODIFIED_BY="Lindsey Elstub">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2013-09-03 16:53:00 +0100" MODIFIED_BY="Lindsey Elstub" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2013-09-03 12:27:53 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Euba-2009">
<CHAR_METHODS MODIFIED="2013-09-03 12:27:53 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Design:</B> RCT. Participants, treatment providers and outcome assessor not blinded.</P>
<P>
<B>Follow-up: </B>at least 12 months after the end of treatment (range 3.8 to 13 years).</P>
<P>
<B>Setting:</B> one site trial conducted in Spain (1991 to 1996).</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-09-03 12:27:53 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Enrolled: </B>55 adults with chronic osteomyelitis caused by <I>S. aureus.</I>
</P>
<P>Data available for 50 participants: 38 male, 12 female; mean age 44 years.</P>
<P>
<B>Location of infection:</B> femur (17), tibia (16), humerus (5), small bones (12). Osteomyelitis classification: post surgical (34), hematogenous (9), post trauma (4), secondary to continuous focus (3).<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-08-08 12:19:35 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Surgery:</B> debridement of bone and soft tissues and removal of foreign material when possible.</P>
<P>
<B>Comparison: </B>oral antibiotics versus parenteral plus oral antibiotics.</P>
<P>
<B>Antibiotics:</B> oral rifampin plus cotrimoxazole (8 weeks) versus parenteral cloxacillin (6 weeks) plus oral cloxacillin (2 weeks).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-08-08 12:19:43 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Clinical outcomes:</B> remission of symptoms and the absence of failure during follow-up; clinical relapse appearance or recurrence of local inflammatory signs or sinus tract drainage, with or without microbiological confirmation of <I>S. aureus</I> in local samples; treatment tolerability.</P>
<P>
<B>Resource use:</B> length of hospital stay.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-08-08 12:19:53 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Microbiologic diagnosis:</B> obtained by surgical sample culture.</P>
<P>
<B>Support:</B> not reported.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-09-03 12:27:43 +0100" MODIFIED_BY="Lindsey Elstub" STUDY_ID="STD-Gentry-1990">
<CHAR_METHODS MODIFIED="2013-09-03 12:27:43 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Design:</B> RCT. Participants, treatment providers, outcome assessors not blinded.</P>
<P>
<B>Follow-up:</B> 12 months after the end of treatment.</P>
<P>
<B>Setting:</B> two-site trial conducted in USA and Costa Rica (1980 to 1987).<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-09-03 12:27:40 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Enrolled:</B> 67 adults with chronic osteomyelitis.</P>
<P>Data available for 59 participants: 51 male, 8 female; mean age 37 years.</P>
<P>
<B>Location of infection </B>(listed only for treatment failures): femur (6), ischium (1), tibia (6).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-08-08 12:22:50 +0100" MODIFIED_BY="Lindsey Elstub">
<P>
<B>Surgery</B>: debridement and removal of all foreign material.</P>
<P>
<B>Comparison: </B>oral antibiotics versus parenteral antibiotics.</P>
<P>
<B>Antibiotics: </B>oral ciprofloxacin (28 to 96 days) versus ceftazidime or nafcillin and aminoglycoside (parenteral administration) (8 to 77 days).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-08-08 12:22:57 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Clinical outcomes</B>: all signs and symptoms related to infection absent on completion of therapy and at 12 months follow-up; relapse of infection (same pathogen) or reinfection (different pathogen) within 12 months of completion of therapy. Adverse outcomes, superinfection.</P>
<P>
<B>Resource use:</B> not reported.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-09-03 12:27:36 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Microbiologic diagnosis:</B> obtained by open biopsy and were repeated during and after therapy completion. Excluded MRSA infection. <I>S. aureus</I> accounted for 25% of isolates and <I>P. aeruginosa</I> for 21%.</P>
<P>
<B>Support</B>: not reported.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-09-03 12:27:26 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gentry-1991">
<CHAR_METHODS MODIFIED="2013-09-03 12:27:26 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Design:</B> RCT. Participants, treatment providers, outcome assessors not blinded.</P>
<P>
<B>Follow-up:</B> 18 months.</P>
<P>
<B>Setting: </B>two-site trial conducted in USA and Costa Rica.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-09-03 12:27:24 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Enrolled:</B> 42 adults with chronic osteomyelitis.</P>
<P>Data available from 33 participants: 23 male, 10 female.</P>
<P>
<B>Location of infection:</B> not mentioned.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-08-08 12:24:00 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Surgery:</B> debridement if necessary.</P>
<P>
<B>Comparison: </B>oral antibiotics versus parenteral antibiotics.</P>
<P>
<B>Antibiotics:</B> oral ofloxacin (21 to 86 days) versus cefazolin or ceftazidime (15 to 55 days) plus cloxacillin.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-08-08 12:24:04 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Clinical outcomes</B>: all signs and symptoms related to infection absent on completion of therapy and at 18 months of follow-up; relapse of infection (same pathogen) or reinfection (different pathogen) within 18 months of completion of therapy. Adverse events, superinfection.</P>
<P>
<B>Resource use:</B> not reported.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-08-30 18:30:47 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Microbiologic diagnosis</B>: obtained by open biopsy or aspirate.</P>
<P>
<I>S. aureus</I> accounted for 40% of isolates.</P>
<P>
<B>Support</B>: R. W. Johnson Research Institute, Ortho Pharmaceutical Corporation, Raritan, N.J.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-08-08 12:25:32 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gomis-1999">
<CHAR_METHODS MODIFIED="2013-08-08 12:25:13 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Design:</B> randomised open-label controlled trial. Participants, treatment providers, outcome assessors not blinded.</P>
<P>
<B>Follow-up: </B>6 months.</P>
<P>
<B>Setting:</B> trial conducted in Spain (1993 to 1996).</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-04-21 15:03:44 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Enrolled: </B>32 adults with chronic osteomyelitis (22 male and 10 female); mean age 59 years. Types of chronic osteomyelitis: contiguous (14); post traumatic (8); post surgical (4); associated with foot in diabetes patients (4); associated with a prosthetic device (1). </P>
<P>
<B>Location of infection: </B>tibia (9); foot (7); ankle (4); femur (4); hand (3); radius (2); sacrum (1); femur and tibia (1); femur and sacrum (1).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-08-08 12:25:25 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Surgery:</B> debridement as indicated.</P>
<P>
<B>Comparison: </B>oral antibiotics versus parenteral antibiotics.</P>
<P>
<B>Antibiotics:</B> oral ofloxacin (7 to 50 days) versus imipenem-cilastin (1 to 42 days). Clindamycin added if anaerobic organism isolated or suspected.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-08-08 12:25:29 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Clinical outcomes:</B> cure (resolution of all signs and symptoms of active infection at the end of therapy and follow up); failure (lack of apparent response to therapy or recurrence of signs and symptoms plus isolation of the same pathogen four to six weeks after discontinuation of antibacterial therapy).</P>
<P>
<B>Microbiologic response</B>: eradication, presumptive eradication, eradication with relapse, persistence, superinfection, undetermined. Adverse events.</P>
<P>
<B>Resource use:</B> not reported.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-08-08 12:25:32 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Microbiologic diagnosis: </B>obtained by open biopsy.</P>
<P>
<I>S. aureus </I>accounted for 32% of isolates; <I>Pseudomonas aeruginosa</I> accounted for 17% of isolates.</P>
<P>
<B>Support</B>: not reported.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-09-03 12:26:59 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Greenberg-2000">
<CHAR_METHODS MODIFIED="2013-09-03 12:26:59 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Design: </B>RCT. Participants, treatment provider, outcome assessor not blinded.</P>
<P>
<B>Follow-up:</B> from 0 to 36 months.</P>
<P>
<B>Setting: </B>trial conducted in USA.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-08-17 12:01:56 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Enrolled: </B>12 adults with chronic osteomyelitis. Together with 15 other participants given levofloxacin in an open trial: 20 male; 7 female; mean age 38 years.</P>
<P>
<B>Location of infection: </B>tibia (4); femur (3); knee (1); finger (1); ulna (1); fibula (1); disc (1).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-08-08 12:26:29 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Surgery:</B> debridement (no details reported).</P>
<P>
<B>Comparison: </B>oral antibiotic1 versus oral antibiotic 2.</P>
<P>
<B>Antibiotics:</B> oral ciprofloxacin (52 to 110 days) versus oral lomefloxacin (2 to 59 days).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-08-08 12:26:31 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Clinical outcomes: </B>cure (healed wound without any drainage or swelling); improved (signs and symptoms markedly reduced at the end of therapy); failure (no response during the therapy). Adverse events.</P>
<P>
<B>Resource use:</B> not reported.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-08-30 18:07:33 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Microbiologic diagnosis: </B>obtained by open biopsy or aspiration from infected bone. <I>S. aureus</I> accounted for 75% of isolates.</P>
<P>
<B>Support</B>: not reported.</P>
<P>Patients from open trial were not included in the review.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-09-03 12:26:52 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mader-1990">
<CHAR_METHODS MODIFIED="2013-09-03 12:26:52 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Design:</B> quasi-RCT. Participants were sequentially assigned. Participants, treatment provider, outcome assessor not blinded.</P>
<P>
<B>Follow-up:</B> 24 to 39 months after the end of treatment.</P>
<P>
<B>Setting: </B>trial conducted in USA.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-09-03 12:26:50 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Enrolled:</B> 37 adults with post-traumatic chronic osteomyelitis. Data available from 26 participants: 19 male, 7 female; mean age 33 years.</P>
<P>
<B>Location of infection:</B> tibia (18); femur (4); ulna (1); hip (2) humerus (1). Classification using the Cierny-Mader system: type1 (2); type 2 (1); type 3 (11); type 4 (12) and the physiologic class of the host: A (16); B (10).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-09-03 12:26:45 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Surgery:</B> debridement (no details reported).</P>
<P>
<B>Comparison: </B>oral antibiotics versus parenteral antibiotics.</P>
<P>
<B>Antibiotics:</B> oral ciprofloxacin (28 to 64 days) versus parenteral nafcillin and gentamicin and clindamycin or parenteral nafcillin and clindamycin (29 to 60 days).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-08-08 12:27:04 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Clinical outcomes: </B>no evidence of infection at the completion of therapy or at 24 months follow-up; failure and superinfection.</P>
<P>
<B>Resource use:</B> not reported.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-08-30 18:10:21 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Microbiologic diagnosis: </B>obtained by open biopsy or debridement.</P>
<P>
<I>S. aureus</I> accounted for 37% of isolates; two or more organisms were isolated in 22 patients.</P>
<P>
<B>Support</B>: Marine Biomedical Institute and Miles Incorporated, West Haven, Connecticut.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-09-03 12:26:37 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Norden-1986">
<CHAR_METHODS MODIFIED="2013-09-03 12:26:37 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Design: </B>RCT using random table numbers. Participants, treatment provider, outcome assessor not blinded.</P>
<P>
<B>Follow-up: </B>9 months to 4 years.</P>
<P>
<B>Setting:</B> multicentre trial conducted in USA (1980 to 1982)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-09-03 12:26:33 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Enrolled: </B>19 adults with chronic post-traumatic osteomyelitis caused by <I>S. aureus. </I>
</P>
<P>Data available from 18 participants: 15 male, 3 female.</P>
<P>
<B>Location of infection: </B>femur (10); tibia (4); humerus (3); fibula (1).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-08-08 12:27:53 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Surgery: </B>debridement (no details reported).</P>
<P>
<B>Comparison: </B>parenteral plus oral antibiotics versus parenteral antibiotics.</P>
<P>
<B>Antibiotics: </B>nafcillin or cephalothin or cephapirin versus nafcillin-rifampin (42 days).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-08-08 12:27:56 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Clinical outcomes:</B> remission (no sign of clinical or x-ray activity of the disease for less than two years after completion of treatment); probable cure (no relapse and no evidence of activity at two or more years after the treatment course was completed); persistent infection (no or minimal clinical response to therapy); probable relapse (positive clinical or roentgenographic findings developing after an initial period of remission); definitive relapse (presence of clinical and/or x-ray findings, in conjunction with culture of infected material). Adverse events.</P>
<P>
<B>Resource use:</B> not reported.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-08-17 12:04:25 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Microbiologic diagnosis: </B>obtained from bone or from a needle biopsy.</P>
<P>Two participants did not have debridement surgery.</P>
<P>
<B>Support</B>: Merrell Dow Pharaceuticals, Cicinnati, Ohio.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-09-03 16:53:00 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sheftel-1986">
<CHAR_METHODS MODIFIED="2013-09-03 12:26:20 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Design</B>: RCT. Participants, treatment providers, outcome assessors not blinded.</P>
<P>
<B>Follow-up: </B>2 to 38 months.</P>
<P>
<B>Setting: </B>trial conducted in USA.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-04-21 15:14:55 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Enrolled: </B>18 adults with chronic osteomyelitis caused by gram-negative bacilli (17 male and 1 female); mean age 34 years. </P>
<P>
<B>Location of infection:</B> tibia (9); femur (3); metatarsal phalangeal joint (2); spine (1); radius/ulna (1); hip prothesis (1); sternum (1).</P>
<P>Classification using the Cierny-Mader system: type1 (2); type 2 (2); type 3 (8); type 4 (6), and the physiologic class of the host: A (12); B (6).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-09-03 16:53:00 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Surgery:</B> debridement (no details reported).</P>
<P>
<B>Comparison: </B>parenteral antibiotic1 versus parenteral antibiotic 2.</P>
<P>
<B>Antibiotics:</B> ceftazidime versus ticarcillin plus tobramycin (26 to 63 days).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-08-08 12:28:42 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Clinical outcomes:</B> response (no evidence of infection at the completion of therapy or on follow-up); failure (presence of pain swelling, erythema, or draining sinus tracts). Adverse events.</P>
<P>
<B>Resource use: </B>not reported.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-08-08 12:28:50 +0100" MODIFIED_BY="Helen HG Handoll">
<P>
<B>Microbiologic diagnosis:</B> obtained by open biopsy.</P>
<P>
<I>P. aeruginosa</I> were the most common organisms isolated.</P>
<P>
<B>Support:</B> not reported.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2013-09-03 12:26:05 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2013-09-03 12:26:05 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Baumgartner-1983">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-03 12:26:05 +0100" MODIFIED_BY="[Empty name]">
<P>RCT including participants with severe bacterial infections (bone and soft tissue infections) that compared parenteral antibiotics. No separate data for chronic osteomyelitis.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-03 12:26:01 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Giamarellou-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-03 12:26:01 +0100" MODIFIED_BY="[Empty name]">
<P>RCT of 53 participants with gram-negative-bacterial infections (15 with chronic osteomyelitis exacerbation). No mention of surgical debridement.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-03 12:25:59 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Greenberg-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-03 12:25:59 +0100" MODIFIED_BY="[Empty name]">
<P>RCT of 30 participants with chronic osteomyelitis. No mention of surgical debridement.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-03 12:25:56 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hedstrom-1975">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-03 12:25:56 +0100" MODIFIED_BY="[Empty name]">
<P>RCT of 12 participants with chronic osteomyelitis. No clear data available about the population included, clinical diagnosis, microbiological diagnosis criteria or surgical intervention.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-03 12:25:54 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ingianni-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-03 12:25:54 +0100" MODIFIED_BY="[Empty name]">
<P>RCT of 58 participants with chronic osteomyelitis, treated either with a standard therapy or with a specific targeted therapy based on antibiogram (largely varied). No data about the specific antibiotics used.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-03 12:25:51 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Loffler-1986">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-03 12:25:51 +0100" MODIFIED_BY="[Empty name]">
<P>RCT of 23 participants with bone, joint or soft tissue infections, treated with parenteral antibiotics. No clear definition of clinical and microbiological diagnosis criteria.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-03 12:25:48 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mandell-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-03 12:25:48 +0100" MODIFIED_BY="[Empty name]">
<P>RCT of 325 participants with severe bacterial infections (23 patients with bone and joint infections), treated with parenteral antibiotics. No separate data for chronic osteomyelitis.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-03 12:25:46 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Marier-1983">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-03 12:25:46 +0100" MODIFIED_BY="[Empty name]">
<P>RCT of 186 participants with infections in various sites (8 bone and joint infections), treated with parenteral antibiotics. No separate data for chronic osteomyelitis.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-08-30 18:14:03 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Marriott-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-08-30 18:14:03 +0100" MODIFIED_BY="[Empty name]">
<P>Retrospective study including 55 participants with pressure ulcer and acute osteomyelitis, chronic osteomyelitis and negative osteomyelitis.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-08-08 12:29:38 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nguyen--2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-08-08 12:29:38 +0100" MODIFIED_BY="[Empty name]">
<P>Retrospective cohort study including 56 participants with bone and joint infections, treated with rifampicin and linezolid combination or rifampicin and cotrimoxazole combination.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-03 12:25:43 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Paladino-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-03 12:25:43 +0100" MODIFIED_BY="[Empty name]">
<P>RCT of 105 participants with serious infections (9 bone and joint infections) treated with parenteral antibiotics. No separate data for chronic osteomyelitis.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-03 12:25:39 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Peacock-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-03 12:25:39 +0100" MODIFIED_BY="[Empty name]">
<P>RCT of 47 participants with severe infections (with bone and soft tissue infections) all treated with parenteral and oral antibiotics. No separate data for chronic osteomyelitis.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-03 12:25:38 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Reinhardt-1986">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-03 12:25:38 +0100" MODIFIED_BY="[Empty name]">
<P>RCT of 30 patients with aerobic and aerobic-anaerobic infections (14 bone infections) treated with parenteral antibiotics. No separate data for chronic osteomyelitis.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-03 12:25:35 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Siebert-1985">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-03 12:25:35 +0100" MODIFIED_BY="[Empty name]">
<P>RCT of 25 participants,13 with osteomyelitis, treated with parenteral antibiotics. No separate data for chronic osteomyelitis.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-08-17 12:05:50 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tascini-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-08-17 12:05:50 +0100" MODIFIED_BY="[Empty name]">
<P>Controlled trial with a mixed population including just 7 participants with osteomyelitis. No information about microbiological diagnosis.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2013-09-03 12:25:23 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR MODIFIED="2013-09-03 12:25:23 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Barber_x00e1_n-2000">
<CHAR_METHODS MODIFIED="2013-08-08 12:30:50 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised open label trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-08-17 12:05:43 +0100" MODIFIED_BY="[Empty name]">
<P>45 participants with diagnosis of osteomyelitis due to gram-negative bacilli.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-08-08 12:30:52 +0100" MODIFIED_BY="[Empty name]">
<P>Cefepime or other parenteral beta-lactam.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-03-01 20:40:24 +0000" MODIFIED_BY="[Empty name]">
<P>Cure</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-09-03 12:25:23 +0100" MODIFIED_BY="[Empty name]">
<P>We were unable to obtain the full text article. We are awaiting a response from from the authors regarding our request for a full report and further information.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2013-09-03 12:25:10 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR MODIFIED="2013-09-03 12:24:29 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-CTRI_x002f_2008_x002f_091_x002f_000060">
<CHAR_STUDY_NAME MODIFIED="2013-08-08 12:30:43 +0100" MODIFIED_BY="[Empty name]">
<P>A clinical trial to study the safety and efficacy of combination drugs, vancomycin and ceftriaxone compared to vancomycin in mild to severe bacterial infections.</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2013-09-03 12:24:29 +0100" MODIFIED_BY="[Empty name]">
<P>RCT with parallel group. Not blinded.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-09-03 12:24:26 +0100" MODIFIED_BY="[Empty name]">
<P>Adults with lower respiratory infection, skin and skin structure infections, endocarditis, bacterial meningitis and bone infection.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-08-08 12:30:36 +0100" MODIFIED_BY="[Empty name]">
<P>Vancomycin and ceftriaxone 6 g intravenous in two divided slowly doses versus vancomycin 2 g divided either as 500 mg every 6 hours or 1 g every 12 hours.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-08-08 12:30:29 +0100" MODIFIED_BY="[Empty name]">
<P>Efficacy and safety.</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2013-04-21 12:05:31 +0100" MODIFIED_BY="[Empty name]">
<P>08/04/2008</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2013-04-20 23:14:09 +0100" MODIFIED_BY="[Empty name]">
<P>Dr Namit Saraf, New Delhi, India<BR/>Email: drnamitsara@rediffmail.com</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2013-09-03 12:24:22 +0100" MODIFIED_BY="[Empty name]">
<P>Sponsor: Venus Remedies Limited. Target recruitment: 200 participants (5 centres). Mixed population.</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2013-09-03 12:25:10 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-EUCTR2009_x002d_015744_x002d_42_x002d_GB">
<CHAR_STUDY_NAME MODIFIED="2013-08-08 12:30:24 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised open label study of oral versus intravenous antibiotic treatment for bone and joint infections requiring prolonged antibiotic treatment.</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2013-09-03 12:24:32 +0100" MODIFIED_BY="[Empty name]">
<P>RCT; not blinded.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-09-03 12:25:10 +0100" MODIFIED_BY="[Empty name]">
<P>Adults with bone and joint infection including: osteomyelitis, septic arthritis, prosthetic joint associated infection, orthopaedic device associated infection and discitis/epidural abscess.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-08-08 12:30:19 +0100" MODIFIED_BY="[Empty name]">
<P>Oral versus intravenous antibiotic.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-08-17 12:05:16 +0100" MODIFIED_BY="[Empty name]">
<P>Failure of infection treatment.</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2012-07-12 13:57:50 +0100" MODIFIED_BY="[Empty name]">
<P>03/12/2009</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2013-04-20 22:55:23 +0100" MODIFIED_BY="[Empty name]">
<P>Oxford Radcliffe Hospitals Trust (sponsor), UK. No contact address given.</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2013-04-22 12:07:46 +0100" MODIFIED_BY="[Empty name]">
<P>Recruitment may be ongoing or finished. Target of 200 participants. Mixed population.</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2013-09-03 12:24:57 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT00324922">
<CHAR_STUDY_NAME MODIFIED="2013-09-03 12:24:50 +0100" MODIFIED_BY="[Empty name]">
<P>A prospective RCT comparing vancomycin with trimethoprim/sulphamethoxazole for the treatment of MRSA osteomyelitis.</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2013-09-03 12:24:53 +0100" MODIFIED_BY="[Empty name]">
<P>RCT, parallel assignment.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-09-03 12:24:57 +0100" MODIFIED_BY="[Empty name]">
<P>18 years of age or more, with osteomyelitis (culture-proved MRSA from bone or a deep soft-tissue site that is contiguous with bone).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-08-08 12:30:10 +0100" MODIFIED_BY="[Empty name]">
<P>Trimethoprim/sulphamethoxazole versus vancomycin.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-08-08 12:30:09 +0100" MODIFIED_BY="[Empty name]">
<P>Clinical cure at 12 months.</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2012-07-06 19:22:51 +0100" MODIFIED_BY="[Empty name]">
<P>May 2006</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2013-04-20 22:54:43 +0100" MODIFIED_BY="[Empty name]">
<P>Christian Ramers<BR/>University of Washington, USA</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2013-04-20 22:53:42 +0100" MODIFIED_BY="[Empty name]">
<P>No longer recruiting; meant to have completed in May 2011. Target was 300 participants.</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2013-09-03 12:32:50 +0100" MODIFIED_BY="Lindsey Elstub">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2013-09-03 12:32:50 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-17 11:59:49 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Euba-2009">
<DESCRIPTION>
<P>Participants were randomised by a computer-generated randomisation list.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-08 12:23:42 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gentry-1990">
<DESCRIPTION>
<P>No information about the sequence generation process.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-03 12:32:50 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gentry-1991">
<DESCRIPTION>
<P>No information about the sequence generation process.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-03 12:32:50 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gomis-1999">
<DESCRIPTION>
<P>Randomised open-label study.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-03 12:26:56 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Greenberg-2000">
<DESCRIPTION>
<P>Participants were enrolled in a prospective, RCT.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-17 12:03:51 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Mader-1990">
<DESCRIPTION>
<P>The participants were sequentially assigned to two groups.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-03 12:32:50 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Norden-1986">
<DESCRIPTION>
<P>Participants were assigned to treatment group according to a random numbers table.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-08 12:28:55 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sheftel-1986">
<DESCRIPTION>
<P>Unclear.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2013-09-03 12:32:50 +0100" MODIFIED_BY="Lindsey Elstub" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-08 12:20:04 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Euba-2009">
<DESCRIPTION>
<P>Insufficient information to permit judgement.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-08 12:23:40 +0100" MODIFIED_BY="Lindsey Elstub" RESULT="UNKNOWN" STUDY_ID="STD-Gentry-1990">
<DESCRIPTION>
<P>Not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-03 12:32:50 +0100" MODIFIED_BY="Lindsey Elstub" RESULT="UNKNOWN" STUDY_ID="STD-Gentry-1991">
<DESCRIPTION>
<P>Not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-03 12:32:50 +0100" MODIFIED_BY="Lindsey Elstub" RESULT="UNKNOWN" STUDY_ID="STD-Gomis-1999">
<DESCRIPTION>
<P>Unclear.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-03 12:32:50 +0100" MODIFIED_BY="Lindsey Elstub" RESULT="UNKNOWN" STUDY_ID="STD-Greenberg-2000">
<DESCRIPTION>
<P>Unclear.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-03 12:26:41 +0100" MODIFIED_BY="Lindsey Elstub" RESULT="NO" STUDY_ID="STD-Mader-1990">
<DESCRIPTION>
<P>Inadequate: quasi-RCT.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-03 12:32:50 +0100" MODIFIED_BY="Lindsey Elstub" RESULT="UNKNOWN" STUDY_ID="STD-Norden-1986">
<DESCRIPTION>
<P>Unclear.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-08 12:28:56 +0100" MODIFIED_BY="Lindsey Elstub" RESULT="UNKNOWN" STUDY_ID="STD-Sheftel-1986">
<DESCRIPTION>
<P>Unclear.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2013-09-03 12:32:50 +0100" MODIFIED_BY="Helen HG Handoll" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-09-03 12:27:48 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Euba-2009">
<DESCRIPTION>
<P>No blinding, but outcomes were unlikely to have been influenced by lack of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-09-03 12:27:32 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gentry-1990">
<DESCRIPTION>
<P>No blinding, but outcomes were unlikely to have been influenced by lack of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-09-03 12:32:50 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gentry-1991">
<DESCRIPTION>
<P>Outcomes were unlikely to have been influenced by lack of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-09-03 12:32:50 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gomis-1999">
<DESCRIPTION>
<P>Outcomes were unlikely to have been influenced by lack of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-09-03 12:32:50 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Greenberg-2000">
<DESCRIPTION>
<P>Outcomes were unlikely to have been influenced by lack of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-09-03 12:26:41 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mader-1990">
<DESCRIPTION>
<P>Outcomes were unlikely to have been influenced by lack of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-09-03 12:32:50 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Norden-1986">
<DESCRIPTION>
<P>Outcomes were unlikely to have been influenced by lack of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-09-03 12:26:16 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sheftel-1986">
<DESCRIPTION>
<P>Outcomes were unlikely to have been influenced by lack of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2013-09-03 12:32:50 +0100" MODIFIED_BY="Helen HG Handoll" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-09-03 12:32:50 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Euba-2009">
<DESCRIPTION>
<P>No blinding, but the outcomes were unlikely to have been influenced by lack of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-08-17 12:00:56 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Gentry-1990">
<DESCRIPTION>
<P>Participants were contacted by telephone or letter and asked whether there had been a return of the symptoms of their infection.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-09-03 12:32:50 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gentry-1991">
<DESCRIPTION>
<P>Outcomes were unlikely to have been influenced by lack of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-09-03 12:32:50 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gomis-1999">
<DESCRIPTION>
<P>Outcomes were unlikely to have been influenced by lack of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-09-03 12:32:50 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Greenberg-2000">
<DESCRIPTION>
<P>Outcomes were unlikely to have been influenced by lack of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-09-03 12:32:50 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mader-1990">
<DESCRIPTION>
<P>Outcomes were unlikely to have been influenced by lack of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-09-03 12:32:50 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Norden-1986">
<DESCRIPTION>
<P>Outcomes were unlikely to have been influenced by lack of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-09-03 12:26:17 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sheftel-1986">
<DESCRIPTION>
<P>Outcomes were unlikely to have been influenced by lack of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2013-09-03 12:32:50 +0100" MODIFIED_BY="Helen HG Handoll" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-09-03 12:32:50 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Euba-2009">
<DESCRIPTION>
<P>Five participants were excluded after randomisation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-04-21 14:56:15 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Gentry-1990">
<DESCRIPTION>
<P>Eight courses of treatment were deemed invalid (12%).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-09-03 12:32:50 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Gentry-1991">
<DESCRIPTION>
<P>Loss of follow-up of 21.4% of participants.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-09-03 12:32:50 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gomis-1999">
<DESCRIPTION>
<P>Intention-to-treat analysis was done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-09-03 12:32:50 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Greenberg-2000">
<DESCRIPTION>
<P>No incomplete data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-09-03 12:32:50 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Mader-1990">
<DESCRIPTION>
<P>29% of the participants were lost to follow-up.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-09-03 12:32:50 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Norden-1986">
<DESCRIPTION>
<P>One participant lost to follow-up.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-09-03 12:26:17 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sheftel-1986">
<DESCRIPTION>
<P>Intention-to-treat analysis was done.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2013-09-03 12:32:50 +0100" MODIFIED_BY="Helen HG Handoll" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-03 12:32:50 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Euba-2009">
<DESCRIPTION>
<P>All relevant outcomes in the methods section were reported in the results section.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-08 12:23:35 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gentry-1990">
<DESCRIPTION>
<P>No evidence of selective reporting.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-03 12:32:50 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gentry-1991">
<DESCRIPTION>
<P>No evidence of selective reporting.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-03 12:32:50 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gomis-1999">
<DESCRIPTION>
<P>No evidence of selective reporting.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-03 12:32:50 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Greenberg-2000">
<DESCRIPTION>
<P>No evidence of selective reporting.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-03 12:32:50 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mader-1990">
<DESCRIPTION>
<P>No evidence of selective reporting.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-03 12:32:50 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Norden-1986">
<DESCRIPTION>
<P>No selective reporting.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-08 12:29:01 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sheftel-1986">
<DESCRIPTION>
<P>No evidence of selective reporting.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2013-09-03 12:32:50 +0100" MODIFIED_BY="Helen HG Handoll" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-03 12:32:50 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Euba-2009">
<DESCRIPTION>
<P>The reported baseline characteristics, surgical treatment and the care programme were apparently similar between groups; the length of active follow-up was adequate.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-17 12:01:04 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gentry-1990">
<DESCRIPTION>
<P>Unclear if baseline characteristics, surgical treatment and the care programme groups were similar between the groups; the time of active follow-up was adequate.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-03 12:32:50 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gentry-1991">
<DESCRIPTION>
<P>Unclear if the baseline characteristics, surgical treatment and the care programme were similar between groups; the time of active follow-up was adequate.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-03 12:32:50 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Gomis-1999">
<DESCRIPTION>
<P>The reported baseline characteristics, surgical treatment and the care programme were apparently similar between groups. Time of follow-up was 6 months.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-03 12:32:50 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Greenberg-2000">
<DESCRIPTION>
<P>Unclear if the baseline characteristics, surgical treatment and the care programme were similar between groups. Time of follow-up was inadequate for four participants.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-03 12:32:50 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mader-1990">
<DESCRIPTION>
<P>The reported baseline characteristics, surgical treatment and the care programme were apparently similar between groups. The time of follow-up was adequate.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-03 12:32:50 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Norden-1986">
<DESCRIPTION>
<P>The reported baseline characteristics, surgical treatment and the care programme were apparently similar between groups. Time of follow-up was inadequate for one participant.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-03 12:26:17 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sheftel-1986">
<DESCRIPTION>
<P>No baseline characteristics were reported. Inadequate follow-up in one participant.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2013-04-22 11:22:41 +0100" MODIFIED_BY="[Empty name]"/>
<ADDITIONAL_TABLES MODIFIED="2012-06-09 12:27:36 +0100" MODIFIED_BY="Lindsey Elstub"/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2013-08-17 14:23:03 +0100" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2013-08-08 13:03:23 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Oral antibiotic versus parenteral antibiotic (AB)</NAME>
<DICH_OUTCOME CHI2="1.8679617836369253" CI_END="1.1813900231032968" CI_START="0.9241939555298119" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.044908378029046" ESTIMABLE="YES" EVENTS_1="70" EVENTS_2="58" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.07239329889904261" LOG_CI_START="-0.03423687620752489" LOG_EFFECT_SIZE="0.019078211345758867" METHOD="MH" MODIFIED="2013-08-07 17:11:33 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6002587108622887" P_Q="1.0" P_Z="0.48308379758361" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="80" TOTAL_2="70" WEIGHT="100.0" Z="0.7013513217953585">
<NAME>Remission at the end of treatment</NAME>
<GROUP_LABEL_1>Oral AB</GROUP_LABEL_1>
<GROUP_LABEL_2>Parenteral AB</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours parenteral</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours oral</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1046808193553594" CI_START="0.9117396517026803" EFFECT_SIZE="1.003584229390681" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="27" LOG_CI_END="0.04323681339071991" LOG_CI_START="-0.0401291572534766" LOG_EFFECT_SIZE="0.0015538280686216335" MODIFIED="2013-08-07 17:11:33 +0100" MODIFIED_BY="[Empty name]" ORDER="25617" O_E="0.0" SE="0.04896958382461114" STUDY_ID="STD-Gentry-1990" TOTAL_1="31" TOTAL_2="28" VAR="0.0023980201399556172" WEIGHT="45.68033320781216"/>
<DICH_DATA CI_END="1.2212463409105947" CI_START="0.8523223945058224" EFFECT_SIZE="1.0202429149797572" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="13" LOG_CI_END="0.08680327549881052" LOG_CI_START="-0.06939610045505375" LOG_EFFECT_SIZE="0.008703587521878399" MODIFIED="2013-08-07 17:11:33 +0100" MODIFIED_BY="[Empty name]" ORDER="25618" O_E="0.0" SE="0.09175228663468087" STUDY_ID="STD-Gentry-1991" TOTAL_1="19" TOTAL_2="14" VAR="0.008418482102692637" WEIGHT="24.101209074162654"/>
<DICH_DATA CI_END="2.482845067856566" CI_START="0.7614752223070334" EFFECT_SIZE="1.375" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="8" LOG_CI_END="0.39494961996766004" LOG_CI_START="-0.1183442236350972" LOG_EFFECT_SIZE="0.13830269816628146" MODIFIED="2013-08-07 17:11:33 +0100" MODIFIED_BY="[Empty name]" ORDER="25619" O_E="0.0" SE="0.30151134457776363" STUDY_ID="STD-Gomis-1999" TOTAL_1="16" TOTAL_2="16" VAR="0.09090909090909091" WEIGHT="12.879998371617289"/>
<DICH_DATA CI_END="1.3686104489371655" CI_START="0.6495490316671905" EFFECT_SIZE="0.9428571428571428" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="10" LOG_CI_END="0.13627985138324258" LOG_CI_START="-0.18738806032801889" LOG_EFFECT_SIZE="-0.025554104472388168" MODIFIED="2013-08-07 17:11:33 +0100" MODIFIED_BY="[Empty name]" ORDER="25621" O_E="0.0" SE="0.19012413352119759" STUDY_ID="STD-Mader-1990" TOTAL_1="14" TOTAL_2="12" VAR="0.036147186147186164" WEIGHT="17.33845934640789"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.37573117652706783" CI_END="1.130397953661962" CI_START="0.7805773975316705" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9393418402501723" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="44" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.05323136264612636" LOG_CI_START="-0.10758402834222826" LOG_EFFECT_SIZE="-0.027176332848050933" METHOD="MH" MODIFIED="2013-08-07 17:11:33 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.8287261422517018" P_Q="1.0" P_Z="0.5076943809366135" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="64" TOTAL_2="54" WEIGHT="100.0" Z="0.6624320382109421">
<NAME>Remission at least 12 months after the end of treatment</NAME>
<GROUP_LABEL_1>Oral AB</GROUP_LABEL_1>
<GROUP_LABEL_2>Parenteral AB</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours parenteral</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours oral</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2923307202077337" CI_START="0.7512701416542309" EFFECT_SIZE="0.9853372434017595" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="22" LOG_CI_END="0.11137366813394235" LOG_CI_START="-0.12420387133924969" LOG_EFFECT_SIZE="-0.006415101602653666" MODIFIED="2013-08-07 17:11:33 +0100" MODIFIED_BY="[Empty name]" ORDER="25622" O_E="0.0" SE="0.1383794128141805" STUDY_ID="STD-Gentry-1990" TOTAL_1="31" TOTAL_2="28" VAR="0.019148861890797383" WEIGHT="48.46060581968516"/>
<DICH_DATA CI_END="1.2119035136301923" CI_START="0.609781724395905" EFFECT_SIZE="0.8596491228070176" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="12" LOG_CI_END="0.08346804461077302" LOG_CI_START="-0.21482559589872846" LOG_EFFECT_SIZE="-0.06567877564397773" MODIFIED="2013-08-07 17:11:33 +0100" MODIFIED_BY="[Empty name]" ORDER="25623" O_E="0.0" SE="0.17521916101261564" STUDY_ID="STD-Gentry-1991" TOTAL_1="19" TOTAL_2="14" VAR="0.030701754385964924" WEIGHT="28.965256797583084"/>
<DICH_DATA CI_END="1.3686104489371655" CI_START="0.6495490316671905" EFFECT_SIZE="0.9428571428571428" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="10" LOG_CI_END="0.13627985138324258" LOG_CI_START="-0.18738806032801889" LOG_EFFECT_SIZE="-0.025554104472388168" MODIFIED="2013-08-07 17:11:33 +0100" MODIFIED_BY="[Empty name]" ORDER="25624" O_E="0.0" SE="0.19012413352119759" STUDY_ID="STD-Mader-1990" TOTAL_1="14" TOTAL_2="12" VAR="0.036147186147186164" WEIGHT="22.574137382731756"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.5783595504784875" CI_END="2.415337157957008" CI_START="0.48730369987465844" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0848975682142497" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="8" I2="44.108467251912515" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.3829777626734356" LOG_CI_START="-0.3122002912063354" LOG_EFFECT_SIZE="0.03538873573355011" METHOD="MH" MODIFIED="2013-08-07 17:11:33 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.1670972298632285" P_Q="1.0" P_Z="0.8418342070266338" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="64" TOTAL_2="54" WEIGHT="99.99999999999999" Z="0.19954786290811072">
<NAME>Mild adverse events</NAME>
<GROUP_LABEL_1>Oral AB</GROUP_LABEL_1>
<GROUP_LABEL_2>Parenteral AB</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oral</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours parenteral</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.9018312734890614" CI_START="0.026810240372411077" EFFECT_SIZE="0.22580645161290322" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.27917198460820564" LOG_CI_START="-1.5716992922482373" LOG_EFFECT_SIZE="-0.6462636538200158" MODIFIED="2013-08-07 17:11:33 +0100" MODIFIED_BY="[Empty name]" ORDER="25625" O_E="0.0" SE="1.0872109499860574" STUDY_ID="STD-Gentry-1990" TOTAL_1="31" TOTAL_2="28" VAR="1.1820276497695852" WEIGHT="44.97930165410109"/>
<DICH_DATA CI_END="3.5622412898839464" CI_START="0.4667686007102675" EFFECT_SIZE="1.2894736842105263" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" LOG_CI_END="0.5517233332395298" LOG_CI_START="-0.3308983664161228" LOG_EFFECT_SIZE="0.11041248341170351" MODIFIED="2013-08-07 17:11:33 +0100" MODIFIED_BY="[Empty name]" ORDER="25626" O_E="0.0" SE="0.5184563554256068" STUDY_ID="STD-Gentry-1991" TOTAL_1="19" TOTAL_2="14" VAR="0.26879699248120303" WEIGHT="49.288169261238835"/>
<DICH_DATA CI_END="106.84853954417758" CI_START="0.3444543519401806" EFFECT_SIZE="6.066666666666666" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.0287685904005146" LOG_CI_START="-0.46286832386968974" LOG_EFFECT_SIZE="0.7829501332654123" MODIFIED="2013-08-07 17:11:33 +0100" MODIFIED_BY="[Empty name]" ORDER="25628" O_E="0.0" SE="1.4635998572439606" STUDY_ID="STD-Mader-1990" TOTAL_1="14" TOTAL_2="12" VAR="2.1421245421245416" WEIGHT="5.732529084660062"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.2578480460903583" CI_END="2.574311905534252" CI_START="0.18604367933961483" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6920509075735448" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" I2="11.420079687685027" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="0.41066116519693113" LOG_CI_START="-0.7303850801415421" LOG_EFFECT_SIZE="-0.15986195747230553" METHOD="MH" MODIFIED="2013-08-07 17:11:33 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.32338135337814067" P_Q="1.0" P_Z="0.582877371550458" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="49" TOTAL_2="42" WEIGHT="100.00000000000001" Z="0.5491866441414041">
<NAME>Moderate or severe adverse events</NAME>
<GROUP_LABEL_1>Oral AB</GROUP_LABEL_1>
<GROUP_LABEL_2>Parenteral AB</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oral</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours parenteral</GRAPH_LABEL_2>
<DICH_DATA CI_END="14.68479124710538" CI_START="0.14789077459869637" EFFECT_SIZE="1.4736842105263157" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.1668677771526832" LOG_CI_START="-0.8300589163739025" LOG_EFFECT_SIZE="0.16840443038939024" MODIFIED="2013-08-07 17:11:33 +0100" MODIFIED_BY="[Empty name]" ORDER="25629" O_E="0.0" SE="1.1730046247240717" STUDY_ID="STD-Gentry-1991" TOTAL_1="19" TOTAL_2="14" VAR="1.3759398496240602" WEIGHT="22.199040267056127"/>
<DICH_DATA CI_END="2.560009619986433" CI_START="0.007971908818613843" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.40824159730371434" LOG_CI_START="-2.098437677332228" LOG_EFFECT_SIZE="-0.8450980400142568" MODIFIED="2013-08-07 17:11:33 +0100" MODIFIED_BY="[Empty name]" ORDER="25630" O_E="0.0" SE="1.47243581418368" STUDY_ID="STD-Gomis-1999" TOTAL_1="16" TOTAL_2="16" VAR="2.1680672268907566" WEIGHT="67.4733987064469"/>
<DICH_DATA CI_END="58.48420474751842" CI_START="0.11558676448082908" EFFECT_SIZE="2.6" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.7670385888642943" LOG_CI_START="-0.9370918929226586" LOG_EFFECT_SIZE="0.414973347970818" MODIFIED="2013-08-07 17:11:33 +0100" MODIFIED_BY="[Empty name]" ORDER="25632" O_E="0.0" SE="1.5884196306634222" STUDY_ID="STD-Mader-1990" TOTAL_1="14" TOTAL_2="12" VAR="2.5230769230769226" WEIGHT="10.327561026496975"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.0076705477490846" CI_END="3.5983985163328267" CI_START="0.325614340576913" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0824463774380029" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="0.5561092590262504" LOG_CI_START="-0.4872964763372825" LOG_EFFECT_SIZE="0.03440639134448391" METHOD="MH" MODIFIED="2013-08-07 17:11:33 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.6042089695443825" P_Q="1.0" P_Z="0.8971519588659955" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="66" TOTAL_2="58" WEIGHT="100.0" Z="0.12925995245691072">
<NAME>Superinfection</NAME>
<GROUP_LABEL_1>Oral AB</GROUP_LABEL_1>
<GROUP_LABEL_2>Parenteral AB</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oral</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours parenteral</GRAPH_LABEL_2>
<DICH_DATA CI_END="9.115716969706655" CI_START="0.3579825306780754" EFFECT_SIZE="1.8064516129032258" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="0.9597908324799467" LOG_CI_START="-0.4461381661360913" LOG_EFFECT_SIZE="0.2568263331719277" MODIFIED="2013-08-07 17:11:33 +0100" MODIFIED_BY="[Empty name]" ORDER="25633" O_E="0.0" SE="0.8258496532478447" STUDY_ID="STD-Gentry-1990" TOTAL_1="31" TOTAL_2="28" VAR="0.6820276497695853" WEIGHT="44.21632719217678"/>
<DICH_DATA CI_END="10.794989714170981" CI_START="0.05029521124748365" EFFECT_SIZE="0.7368421052631579" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.0332222328600678" LOG_CI_START="-1.2984733634092496" LOG_EFFECT_SIZE="-0.13262556527459096" MODIFIED="2013-08-07 17:11:33 +0100" MODIFIED_BY="[Empty name]" ORDER="25634" O_E="0.0" SE="1.3696495353279468" STUDY_ID="STD-Gentry-1991" TOTAL_1="19" TOTAL_2="14" VAR="1.8759398496240602" WEIGHT="24.226052190826085"/>
<DICH_DATA CI_END="7.618637080220918" CI_START="0.014584119172649873" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8818772861059678" LOG_CI_START="-1.8361197955452926" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2013-08-07 17:11:33 +0100" MODIFIED_BY="[Empty name]" ORDER="25635" O_E="0.0" SE="1.5965649400644928" STUDY_ID="STD-Gomis-1999" TOTAL_1="16" TOTAL_2="16" VAR="2.5490196078431375" WEIGHT="31.557620616997134"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2013-08-08 13:18:57 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Oral antibiotic versus parenteral plus oral antibiotic</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="24" EVENTS_2="19" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-08-08 13:18:40 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="209.2" SORT_BY="EFFECT_SIZE" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="30" TOTAL_2="25" WEIGHT="0.0" Z="0.0">
<NAME>Remission at least 12 months after the end of the treatment</NAME>
<GROUP_LABEL_1>Oral</GROUP_LABEL_1>
<GROUP_LABEL_2>Parenteral plus oral</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours parenteral + oral</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours oral</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.3980545721718554" CI_START="0.7925536406464576" EFFECT_SIZE="1.0526315789473684" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="19" LOG_CI_END="0.14552412414967072" LOG_CI_START="-0.10097133472736634" LOG_EFFECT_SIZE="0.022276394711152208" MODIFIED="2013-08-08 13:14:18 +0100" MODIFIED_BY="[Empty name]" ORDER="29" O_E="0.0" SE="0.1447926527165717" STUDY_ID="STD-Euba-2009" TOTAL_1="30" TOTAL_2="25" VAR="0.020964912280701742" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="5" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-08-08 13:18:57 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="30" TOTAL_2="25" WEIGHT="0.0" Z="0.0">
<NAME>Adverse events</NAME>
<GROUP_LABEL_1>Oral</GROUP_LABEL_1>
<GROUP_LABEL_2>Parenteral plus oral</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oral</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours parenteral + oral</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.247838705982822" CI_START="0.3675822474268946" EFFECT_SIZE="1.3888888888888888" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.7199804783915932" LOG_CI_START="-0.4346454712541301" LOG_EFFECT_SIZE="0.14266750356873154" MODIFIED="2013-08-08 13:14:37 +0100" MODIFIED_BY="[Empty name]" ORDER="31" O_E="0.0" SE="0.6782329983125268" STUDY_ID="STD-Euba-2009" TOTAL_1="30" TOTAL_2="25" VAR="0.46" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2013-08-08 13:05:27 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Parenteral plus oral antibiotics versus parenteral antibiotic</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="8" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2009-03-05 21:12:10 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="70.42" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="10" TOTAL_2="8" WEIGHT="0.0" Z="0.0">
<NAME>Remission at least 12 months after the end of treatment</NAME>
<GROUP_LABEL_1>Parenteral plus oral</GROUP_LABEL_1>
<GROUP_LABEL_2>Parenteral</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours parenteral only</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours parenteral + oral</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.4181327292638284" CI_START="0.7489469259291619" EFFECT_SIZE="1.6" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="4" LOG_CI_END="0.5337889227696438" LOG_CI_START="-0.12554895745779415" LOG_EFFECT_SIZE="0.2041199826559248" MODIFIED="2009-02-25 21:18:42 +0000" MODIFIED_BY="[Empty name]" ORDER="25637" O_E="0.0" SE="0.3872983346207417" STUDY_ID="STD-Norden-1986" TOTAL_1="10" TOTAL_2="8" VAR="0.15000000000000002" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2009-03-05 21:12:26 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="10" TOTAL_2="8" WEIGHT="0.0" Z="0.0">
<NAME>Adverse events</NAME>
<GROUP_LABEL_1>Parenteral plus oral</GROUP_LABEL_1>
<GROUP_LABEL_2>Parenteral</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours parenteral + oral</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours parenteral only</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.0993830286066975" CI_START="0.033872385430449826" EFFECT_SIZE="0.26666666666666666" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.3220916820481004" LOG_CI_START="-1.470154217503538" LOG_EFFECT_SIZE="-0.5740312677277188" MODIFIED="2009-03-02 18:02:39 +0000" MODIFIED_BY="[Empty name]" ORDER="24" O_E="0.0" SE="1.052774113156917" STUDY_ID="STD-Norden-1986" TOTAL_1="10" TOTAL_2="8" VAR="1.1083333333333332" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2013-08-17 14:23:03 +0100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Parenteral antibiotic 1 (ceftazidime) versus parenteral antibiotic 2 (ticarcillin plus tobramycin)</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="6" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-04-20 17:49:45 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="9" TOTAL_2="9" WEIGHT="0.0" Z="0.0">
<NAME>Remission at least 12 months after the end of the treatment</NAME>
<GROUP_LABEL_1>Parenteral antibiotic 1</GROUP_LABEL_1>
<GROUP_LABEL_2>Parenteral antibiotic 2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours parenteral 2</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours parenteral 1</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2571079283829467" CI_START="0.4474556140327264" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="8" LOG_CI_END="0.09937256542579909" LOG_CI_START="-0.34925003864239895" LOG_EFFECT_SIZE="-0.12493873660829995" MODIFIED="2009-02-27 20:35:21 +0000" MODIFIED_BY="[Empty name]" ORDER="26" O_E="0.0" SE="0.2635231383473649" STUDY_ID="STD-Sheftel-1986" TOTAL_1="9" TOTAL_2="9" VAR="0.06944444444444442" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-004.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-04-20 17:50:22 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="9" TOTAL_2="9" WEIGHT="0.0" Z="0.0">
<NAME>Adverse events</NAME>
<GROUP_LABEL_1>Parenteral antibiotic 1</GROUP_LABEL_1>
<GROUP_LABEL_2>Parenteral antibiotic 2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours parenteral 1</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours parenteral 2</GRAPH_LABEL_2>
<DICH_DATA CI_END="65.16081469815073" CI_START="0.1381198200435548" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8139865056042341" LOG_CI_START="-0.8597439961649093" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2009-02-17 18:19:39 +0000" MODIFIED_BY="[Empty name]" ORDER="27" O_E="0.0" SE="1.5705625319186327" STUDY_ID="STD-Sheftel-1986" TOTAL_1="9" TOTAL_2="9" VAR="2.4666666666666663" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-004.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-04-20 17:50:58 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="9" TOTAL_2="9" WEIGHT="0.0" Z="0.0">
<NAME>Superinfection</NAME>
<GROUP_LABEL_1>Parenteral antibiotic 1</GROUP_LABEL_1>
<GROUP_LABEL_2>Parenteral antibiotic 2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours parenteral 1</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours parenteral 2</GRAPH_LABEL_2>
<DICH_DATA CI_END="91.51787421498676" CI_START="0.2731706807488985" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9615059237367205" LOG_CI_START="-0.5635659150646829" LOG_EFFECT_SIZE="0.6989700043360189" MODIFIED="2009-02-17 18:21:45 +0000" MODIFIED_BY="[Empty name]" ORDER="28" O_E="0.0" SE="1.4832396974191324" STUDY_ID="STD-Sheftel-1986" TOTAL_1="9" TOTAL_2="9" VAR="2.1999999999999997" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" MODIFIED="2013-08-17 14:21:03 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Oral antibiotic 1 (ciprofloxacin) versus oral antibiotic 2 (lomefloxacin)</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-005.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-08-17 14:20:31 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="373.22" SORT_BY="EFFECT_SIZE" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="5" TOTAL_2="7" WEIGHT="0.0" Z="0.0">
<NAME>Remission at least 12 months after the end of treatment</NAME>
<GROUP_LABEL_1>ciprofloxacin</GROUP_LABEL_1>
<GROUP_LABEL_2>lomefloxacin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours lomefloxacin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours ciprofloxacin</GRAPH_LABEL_2>
<DICH_DATA CI_END="6.8572347879842805" CI_START="0.2858295013369598" EFFECT_SIZE="1.4" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8361490197264687" LOG_CI_START="-0.5438929483699927" LOG_EFFECT_SIZE="0.146128035678238" MODIFIED="2009-02-17 17:44:20 +0000" MODIFIED_BY="[Empty name]" ORDER="23" O_E="0.0" SE="0.8106434833777776" STUDY_ID="STD-Greenberg-2000" TOTAL_1="5" TOTAL_2="7" VAR="0.6571428571428573" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-005.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-08-17 14:21:03 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="5" TOTAL_2="7" WEIGHT="0.0" Z="0.0">
<NAME>Adverse events</NAME>
<GROUP_LABEL_1>ciprofloxacin</GROUP_LABEL_1>
<GROUP_LABEL_2>lomefloxacin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours ciprofloxacin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours lomefloxacin</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.0326953688522402" CI_START="0.011963344393556102" EFFECT_SIZE="0.19047619047619047" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.48182878806504975" LOG_CI_START="-1.9221473948769634" LOG_EFFECT_SIZE="-0.7201593034059569" MODIFIED="2009-02-27 20:37:03 +0000" MODIFIED_BY="[Empty name]" ORDER="25" O_E="0.0" SE="1.4121075097341629" STUDY_ID="STD-Greenberg-2000" TOTAL_1="5" TOTAL_2="7" VAR="1.994047619047619" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2013-09-04 11:17:31 +0100" MODIFIED_BY="Lindsey Elstub">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2013-09-04 11:17:31 +0100" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow diagram.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAoIAAALqCAYAAAChVzUiAAB1hklEQVR42uydD2RdSf//f9RaUWuV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=
</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2013-09-03 12:32:52 +0100" MODIFIED_BY="Lindsey Elstub" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Risk of bias summary: review authors' judgements about each risk of bias item for each included study</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAUUAAAJFCAIAAADF/nKXAAAbRklEQVR42u3dsY4kRdaG4ZaQEMYY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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2013-09-03 12:32:52 +0100" MODIFIED_BY="Lindsey Elstub" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAl4AAAEACAMAAABVk4iuAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK MODIFIED="2012-07-05 00:25:36 +0100" MODIFIED_BY="[Empty name]"/>
<APPENDICES MODIFIED="2013-09-03 16:56:45 +0100" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2013-09-03 16:56:45 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2009-03-10 13:49:16 +0000" MODIFIED_BY="Lindsey Elstub">Search strategies</TITLE>
<APPENDIX_BODY MODIFIED="2013-09-03 16:56:45 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Note: </B>We carried out the MEDLINE, EMBASE and LILACs searches for this update in two stages: Stage 1 = 2008 to August 2011; and Stage 2 = August 2011 to September/October 2012.</P>
<SUBSECTION>
<HEADING LEVEL="3">The Cochrane Library (Wiley online library) </HEADING>
<P>#1 MeSH descriptor: [Osteomyelitis] this term only (107)<BR/>#2 MeSH descriptor: [Osteitis] this term only  (25)<BR/>#3 MeSH descriptor: [Periostitis] this term only (2)<BR/>#4 (infect* near/6 bone*) or (Infect* near/6 fractur*) (678)<BR/>#5 (osteomyelitis or periostitis or osteitis) (539)<BR/>#6  (#1 or #2 or #3 or #4 or #5) (1136)<BR/>#7 MeSH descriptor: [Chronic Disease] this term only (10067)<BR/>#8 (chronic or recurrent) (66263)<BR/>#9  (#7 or #8)  (66263)<BR/>#10 MeSH descriptor: [Anti-Infective Agents] this term only (2087)<BR/>#11 MeSH descriptor: [Anti-Bacterial Agents] this term only (7303)<BR/>#12  (antibiotic* or antimicrobial* or antibacterial*):ti (5889)<BR/>#13 (antibiotic* or antimicrobial* or antibacterial*):ab (11565)<BR/>#14 (#10 or #11 or #12 or #13) (18866)<BR/>#15 (#6 and #9 and #14) (31) [Trials]        </P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">MEDLINE (OVID WEB)</HEADING>
<P>1    Osteomyelitis/ (15943)<BR/>2    Osteitis/ (2408)<BR/>3    Periostitis/ (804)<BR/>4    (osteomyelitis or osteitis or periostitis).tw. (18317)<BR/>5    (infect$ adj3 (bone$ or fracture$)).tw. (5456)<BR/>6    or/1-5 (29039)<BR/>7    Chronic Disease/ (204727)<BR/>8    (chronic or recurrent).tw. (837966)<BR/>9    or/7-8 (896233)<BR/>10  Anti-Infective Agents/ or Anti-Bacterial Agents/ (235541)<BR/>11  (antibiotic$ or antimicrob$).tw. (250113)<BR/>12  or/10-11 (370796)<BR/>13 and/6,9,12 (1472)<BR/>14 Randomized controlled trial.pt. (317139)<BR/>15  Controlled clinical trial.pt. (83496)<BR/>16  Randomized Controlled Trials/ (76477)<BR/>17  Random Allocation/ (72845)<BR/>18  Double Blind Method/ (112770)<BR/>19 Single Blind Method/ (15519)<BR/>20  or/14-19 (533597)<BR/>21 Animals/ not Humans/ (3587303)<BR/>22  20 not 21 (494051)<BR/>23  clinical trial.pt. (468409)<BR/>24 exp Clinical Trials as topic/ (249149)<BR/>25  (clinic$ adj25 trial$).tw. (208224)<BR/>26  ((singl$ or doubl$ or trebl$ or tripl$) adj25 (blind$ or mask$)).tw. (117074)<BR/>27 Placebos/ (30166)<BR/>28  placebo$.tw. (137058)<BR/>29  random$.tw. (570356)<BR/>30 Research Design/ (64294)<BR/>31 or/23-30 (1168062)<BR/>32 31 not 21 (1083118)<BR/>33 32 not 22 (628193)<BR/>34 Comparative Study.pt. (1555085)<BR/>35 Evaluation Studies.pt. (156994)<BR/>36 Follow Up Studies/ (432454)<BR/>37 Prospective Studies/ (305381)<BR/>38  (control$ or prospectiv$ or volunteer$).tw. (2539060)<BR/>39  or/34-38 (4178146)<BR/>40  39 not 21 (3253876)<BR/>41  40 not (22 or 33) (2662658)<BR/>42  22 or 33 or 41 (3784902)<BR/>43  13 and 42 (424)<BR/>
<I>Stage 1 2008 to August 2011</I>
<BR/>44 (2008$ or 2009$ or 2010$ or 2011$).ed. (3406041)<BR/>45 43 and 44 (69) <BR/>
<I>Stage 2 August 2011 to September 2012</I>
<BR/>44  (201108* or 201109* or 201110* or 201111* or 201112* or 2012*).ed. (1274856)<BR/>45  43 and 44 (27)</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">EMBASE (OVID WEB)</HEADING>
<P>1    Chronic Osteomyelitis/ (1236)<BR/>2    Hematogenous Osteomyelitis/ or Osteomyelitis/ (19375)<BR/>3    Osteitis/ or Periostitis/ (3735)<BR/>4    (infect$ adj3 (bone$ or fracture$)).tw. (6047)<BR/>5    (osteomyelitis or osteitis or periostitis).tw. (19319)<BR/>6    or/2-5 (33009)<BR/>7    Chronic Disease/ or Chronicity/ (137837)<BR/>8    (chronic or recurrent).tw. (956290)<BR/>9    or/7-8 (1000579)<BR/>10  and/6,9 (6163)<BR/>11  or/1,10 (6455)<BR/>12  exp Randomized Controlled Trial/ (286346)<BR/>13  exp Double Blind Procedure/ (100172)<BR/>14  exp Single Blind Procedure/ (13979)<BR/>15  exp Crossover Procedure/ (30513)<BR/>16  Controlled Study/ (3579948)<BR/>17  or/12-16 (3647710)<BR/>18  ((clinical or controlled or comparative or placebo or prospective$ or randomi#ed) adj3 (trial or study)).tw. (556234)<BR/>19  (random$ adj7 (allocat$ or allot$ or assign$ or basis$ or divid$ or order$)).tw. (134800)<BR/>20  ((singl$ or doubl$ or trebl$ or tripl$) adj7 (blind$ or mask$)).tw. (131638)<BR/>21  (cross?over$ or (cross adj1 over$)).tw. (56160)<BR/>22  ((allocat$ or allot$ or assign$ or divid$) adj3 (condition$ or experiment$ or intervention$ or treatment$ or therap$ or control$ or group$)).tw. (167775)<BR/>23  or/18-22 (833645)<BR/>24  or/17,23 (4046555)<BR/>25  limit 24 to human (2432453)<BR/>26  11 and 25 (614)<BR/>
<I>Stage 1 2008 to August 2011</I>
<BR/>27 (2008$ or 2009$ or 2010$ or "2011").em. (2888943)<BR/>28 26 and 27 (146)<BR/>
<I>Stage 2 August 2011 to September 2012</I>
<BR/>27  (2011* or 2012*).em. (2071245)<BR/>28  26 and 27 (81)</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">LILACS (Bireme)</HEADING>
<P>((Pt randomized controlled trial OR Pt controlled clinical trial OR Mh randomized controlled trials OR Mh random allocation OR Mh double-blind method OR Mh single-blind method) AND NOT (Ct animal AND NOT (Ct human and Ct animal)) OR (Pt clinical trial OR Ex E05.318.760.535$ OR (Tw clin$ AND (Tw trial$ OR Tw ensa$ OR Tw estud$ OR Tw experim$ OR Tw investiga$)) OR ((Tw singl$ OR Tw simple$ OR Tw doubl$ OR Tw doble$ OR Tw duplo$ OR Tw trebl$ OR Tw trip$) AND (Tw blind$ OR Tw cego$ OR Tw ciego$ OR Tw mask$ OR Tw mascar$)) OR Mh placebos OR Tw placebo$ OR (Tw random$ OR Tw randon$ OR Tw casual$ OR Tw acaso$ OR Tw azar OR Tw aleator$) OR Mh research design) AND NOT (Ct animal AND NOT (Ct human and Ct animal)) OR (Ct comparative study OR Ex E05.337$ OR Mh follow-up studies OR Mh prospective studies OR Tw control$ OR Tw prospectiv$ OR Tw volunt$ OR Tw volunteer$) AND NOT (Ct animal AND NOT (Ct human and Ct animal))) [Words] (16489)<BR/>
<BR/>AND  and ((Mh Osteomyelitis or Mh osteitis or Mh periostitis) or (Tw infect$ and (Tw bone$ or Tw fract$))) and (Tw antibiotic$ or Tw antimicrobial$ or Tw antibacterial$) [Words]  (104) </P>
<P>
<I>Stage 1 2008 to August 2011</I>
<BR/>And  (2008 or 2009 or 2010 or 2011) [Country, year publication]  (35)</P>
<P>
<I>Stage 2 August 2011 to October 2012</I>
<BR/>And  (2011 or 2012) [Country, year publication]  (10)<BR/>
</P>
</SUBSECTION>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS MODIFIED="2012-07-05 00:25:36 +0100" MODIFIED_BY="[Empty name]">
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;4 studies included in quantitative synthesis (meta-analysis)&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;8 studies (10 reports) included in qualitative synthesis&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;30 reports of 27 studies assessed for eligibility, including&lt;/p&gt;&lt;p&gt;1 study awaiting assessment&lt;/p&gt;&lt;p&gt;3 ongoing studies&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;From previous version (&lt;a link_type=&quot;REFERENCE&quot; protected=&quot;true&quot; href=&quot;Conterno 2009&quot;&gt;Conterno 2009&lt;/a&gt;)&lt;/p&gt;&lt;p&gt;519 records screened&lt;/p&gt;&lt;p&gt;20 reports of 18 studies assessed for eligibility&lt;/p&gt;"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;473 records screened&lt;/p&gt;&lt;p&gt;10 reports of 9 studies assessed for eligibility&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;471 records identified through database searching&lt;/p&gt;" WIDTH="120"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;2 additional records identified through reference checking&lt;/p&gt;" WIDTH="120"/>
<OUT TEXT="&lt;p&gt;463 records excluded&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;15 excluded studies (16 reports)&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>